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Abstract 
Parkinson disease (PD) is the second most common neurodegenerative disorder in the world, 
directly affecting 2-3% of the population over the age of 65. People diagnosed with the 
disorder can experience motor, autonomic, cognitive, sensory and neuropsychiatric 
symptoms that can significantly impact quality of life. Uncertainty still exists about the 
pathophysiological mechanisms that underlie a range of clinical features of the disorder, 
linked to structural as well as functional brain changes.  
 
This thesis thus aimed to uncover neuroimaging biomarkers associated with clinical 
dysfunction in PD. A ‘hubs-and-spokes’ neural circuit-based approach can contribute to this 
aim, by analysing the component elements and also the interconnections of important brain 
networks. This thesis focusses on structures within basal ganglia-thalamocortical neuronal 
circuits that are linked to a range functions impacted in the disorder, and that are vulnerable 
to the consequences of PD pathology. This thesis investigated neuronal ‘hubs’ by studying 
the morphology of the caudate nucleus, putamen, thalamus and neocortex. The caudate 
nucleus, putamen and thalamus are all vital subcortical ‘hubs’ that play important roles in a 
number of functional domains that are compromised in PD. The neocortex, on the other hand, 
has a range of ‘hubs’ spread across it, regions of the brain that are crucial for neuronal 
signalling and communication. The interconnections, or ‘spokes’, between these hubs and 
other brain regions were investigated using seed-based resting-state functional connectivity 
analyses. Finally, a morphological analysis was used to investigate possible structural 
changes to the corpus callosum, the major inter-hemispheric white matter tract of the brain, 
crucial to effective higher-order brain processes. 
 
 V 
This thesis demonstrates that the caudate nucleus, putamen, thalamus, corpus callosum and 
neocortex are all atrophied in PD participants with dementia. PD participants also 
demonstrated a significant correlation between volumes of the caudate nuclei and general 
cognitive functioning and speed, while putamina volumes were correlated with general motor 
function. Cognitively unimpaired PD participants demonstrated minimal morphological 
alterations compared to control participants, however they demonstrated significant increases 
in functional connectivity of the caudate nucleus, putamen and thalamus with areas across the 
frontal lobe, and decreases in functional connectivity with parietal and cerebellar regions. PD 
participants with mild cognitive impairment and dementia show decreased functional 
connectivity of the thalamus with paracingulate and posterior cingulate cortices, respectively.  
 
This thesis contributes a deeper understanding of the relationship between structures of basal 
ganglia-thalamocortical neuronal circuits, corpus callosal and neocortical morphology, and 
the clinical dysfunction associated with PD. This thesis suggests that functional connectivity 
changes are more common in early stages of the disorder, while morphological alterations are 
more pronounced in advanced disease stages. 
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1. Introduction 
 2 
1. Introduction 
1.1. Overview 
This thesis asks whether we can find neuroimaging biomarkers associated with 
clinical dysfunction in PD. If so, what do these putative biomarkers tell us about the 
pathophysiology of the disorder? The introduction to this thesis begins with a 
presentation of the research rationale as well as the approach used to address these 
main research questions. The introduction then provides a background on the 
epidemiology, aetiology, neuropathology and symptomology of PD. This introduction 
then provides background on neuroimaging biomarkers in PD and the theoretical 
framework used in this thesis to explore this field of research. The introduction 
finishes by presenting the main aims and hypotheses of the thesis, investigated with 
each of the project chapters. 
 
1.2. Research Rationale 
PD is a complex multi-system neurodegenerative disorder that causes significant 
motor, autonomic, cognitive and neuropsychiatric symptoms. Some of the core motor 
features can be effectively managed with therapeutic interventions, however a number 
of symptoms persist despite treatment, significantly impacting quality of life. There is 
a lack of reliable biomarkers that can detect brain changes related to the disorder 
(Strafella et al., 2018), which in turn make staging of disease and thus monitoring 
treatment response difficult. The lack of such staging/prognosis measures may thus 
contribute to difficulties in developing effective disease-modifying or neuroprotective 
therapies available for PD. It follows that development of reliable biomarkers is 
necessary to advance therapeutics. The development of effective therapeutic 
interventions for neurodegenerative disorders like PD requires a complete 
1. Introduction 
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understanding of the in vivo neurobiology associated with each disorder, and 
accordingly the neural circuit basis of clinical dysfunction (Looi et al., 2014). 
Neuroimaging can be used to investigate neural circuits in PD, with the complete 
investigation of a neural circuit requiring an analysis of brain structures and also their 
interconnections (Sporns et al., 2005). This is particularly pertinent in PD, as a 
number of clinical features are linked to structural changes to the brain, while others 
are thought to arise from aberrant brain activity (Mcgregor and Nelson, 2019). 
Accordingly, this thesis uses a neural circuit-based approach to study structural and 
functional brain changes associated with clinical dysfunction in PD. The investigation 
of structural brain changes was performed via an analysis of the morphology of 
important brain ‘hubs’ while the investigation of functional brain changes was 
performed via an analysis of the functional connectivity of ‘spokes’ connecting brain 
regions. 
 
1.3. Approach 
This thesis seeks to answer the key research questions using four projects, presented 
graphically in Figure 1.1. Project one focusses on morphological and functional 
connectivity changes to the striatum, considered an important input hub within basal 
ganglia-thalamocortical circuits that are impacted in PD. Project two investigates 
morphological and functional connectivity changes to the thalamus, an output hub 
within these circuits. Project three investigates morphological and functional 
connectivity changes to the striatum and thalamus, but distinguishes between PD 
participants based on levels of cognitive impairment. And finally, Project four 
investigates how the structure of the corpus callosum is impacted in PD, due to the 
crucial role played by the structure in facilitating inter-hemispheric cortical activity. 
1. Introduction 
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Figure 1.1: Thesis projects. This figure shows the four projects undertaken in this thesis, the 
main focus for each one, and a brief reason for their analysis. 
 
1.4. Background 
The first formal neurological description of PD was written by the eponymous James 
Parkinson in the monograph ‘An essay on the shaking palsy’ (1817). In this work, 
Parkinson described a cohort of patients with ‘involuntary tremulous motion’, a 
propensity to ‘bend the trunk forward,’ and ‘extreme slowness’ (Parkinson, 1817). 
These core motor features, diagnosed in a modern clinical context as resting tremor, 
postural instability and bradykinesia, are now known to be accompanied by a myriad 
of other manifestations including alterations in gait and balance, eye control, speech, 
swallowing and bladder function (Mcgregor and Nelson, 2019). Some of the core 
motor symptoms respond well to the typical dopamine replacement therapy using the 
dopamine precursor levodopa (L-DOPA) or a dopamine agonist, and a positive 
1. Introduction 
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response to the medication is an important criteria for the clinical diagnosis (Gray et 
al., 2014). People with PD also face significant non-motor symptoms including 
cognitive impairment, psychiatric disturbances, autonomic dysfunction, pain and 
fatigue (Aarsland et al., 2017). These clinical features can arise before or after the 
onset of the classic motor symptoms, and many of these features do not respond fully 
to standard pharmacological treatment (Mcgregor and Nelson, 2019). The 
neurobiology and pathophysiological mechanisms that might underlie these clinical 
manifestations require further investigation. This task is becoming more urgent as the 
number of people diagnosed with the disorder continues to rise due to aging 
populations around the world (Dorsey et al., 2018). 
 
1.5. Epidemiology 
PD is the second most common neurodegenerative disorder in the world, impacting 
0.3% of the global population and 2-3% of people over the age of 65 (Pringsheim et 
al., 2014). The disorder is age- and gender-related, with an incident rate in females of 
3.26 per 100,000 person-years within the 40-49 age-bracket, increasing to 103.48 at 
80 years and over. The rate is higher in males, rising from 3.57 per 100,000 person-
years within the 40-49 age-bracket, to 258.47 at age 80 years and over (Hirsch et al., 
2016). Significant variation in incidence rates exists in the epidemiological data 
(Dorsey et al., 2018), highlighting the importance of genetic contributions to the 
aetiology, neuropathology and molecular mechanisms underlying PD. 
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1.6. Aetiology, neuropathology and molecular mechanisms 
1.6.1. Aetiology 
The number of genes found to be associated with PD and its various phenotypes 
continues to increase. A small proportion of cases result from direct gene mutations, 
with leucine-rich repeat kinase 2 genes the most common cause of autosomal 
dominant forms of the disorder, followed by mutations in the alpha-synuclein gene 
(Singleton et al., 2013). Autosomal recessive forms of PD are associated with 
mutations to PRKN, PINK1 and DJ-1 genes, while rare forms of recessive 
parkinsonism are tied to mutations in ATP13A2, PLA2G6 and FBX07 genes 
(Singleton et al., 2013). Several genes have been linked to an increased risk for 
sporadic PD, where the most important are heterozygous mutations in the GBA and 
LRRK2 genes (Poewe et al., 2017). Genome-wide association studies have identified 
over 35 risk loci for PD (Chang et al., 2017), while meta-analyses have identified 
numerous low-risk susceptibility variants that account for additional heritability, each 
variant potentially acting in a small but none-the-less additive manner (Lill, 2016). 
While more is yet to be uncovered in terms of the contribution of genes to the 
aetiology of PD, the neuropathological signature of the disorder is well characterised. 
 
1.6.2. Neuropathology 
PD research has made significant advances in identifying and characterising the 
neuropathology associated with the disorder. Early reports on the neurobiological 
underpinnings of PD argued that the brains of people with the disorder showed no 
observable or consistent abnormalities (Przedborski, 2017). PD is now associated 
with a clear neuropathological signature, with a definitive diagnosis requiring the loss 
of neuromelanin laden cells of the ventrolateral substantia nigra (pars compacta), as 
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well as the abnormal build-up of intraneuronal alpha-synuclein (a-synuclein) in the 
cytoplasm within particular cells in the brain (known as a Lewy pathology) (Hughes 
et al., 1992). Lewy pathology is the neurotoxic outcome of a process whereby the 
once soluble a-synuclein converts from monomers to oligomers, then progressively 
into insoluble a-synuclein fibrils (Kim and Lee, 2008). Lewy pathology presents at 
neuroanatomical sites along an ascending trajectory in the brain, codified in a series 
of stages by Braak et al. (2003). The earliest signs of Lewy pathology are said to be 
the glossopharyngeal-vagus complex and anterior olfactory nucleus (Stage 1). From 
there Lewy pathology can be found at sites in the medulla oblangata and pontine 
tegmentum (Stage 2), the ventrolateral substantia nigra pars compacta of the midbrain 
(Stage 3), the basal prosencephalon including meso- and allocortices (Stage 4), the 
higher association and prefrontal cortices (Stage 5) and finally the motor and primary 
sensory cortices (Stage 6) (Braak et al., 2003). When a patient is diagnosed with PD, 
Stage 3 of the Braak model, it is estimated that between 30-50% of substantia nigra 
pars compacta cells have already been lost (Politis, 2014). 
 
1.6.3. Molecular mechanisms 
PD Lewy pathology and the death of vulnerable cells associated with the disorder has 
been tied to a number of interrelated molecular mechanisms, including mitochondrial 
dysfunction, oxidative stress and neuroinflammation. Mitochondrial dysfunction has 
been proposed to be central to the pathogenesis of both familial and sporadic PD 
(Rocha et al., 2018). Two of the most important functions in cells are performed by 
mitochondria, including the production of ATP by oxidative phosphorylation and the 
mediation of signals for apoptotic cell death. a-synuclein is found in low levels in 
mitochondria, and the oligomerisation and accumulation of the protein within 
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mitochondria has been linked to neuronal degeneration (Schapira, 2007), while the 
clearance of defective mitochondria has been shown to be affected by the presence of 
a-synuclein (Rocha et al., 2018). Oxidative stress is also a consequence of 
mitochondrial dysfunction, and is often increased in the brain tissue of patients with 
PD (Dias et al., 2013). Neurons of the substantia nigra are particularly vulnerable to 
oxidative damage as they possess long, unmyelinated axons with large synapse 
numbers, requiring large amounts of energy to be sustained (Bolam and Pissadaki, 
2012). A complex interplay also takes place between mitochondria and other cellular 
machinery, including impacting the production of free radicals, calcium homeostasis, 
and in the regulation and instigation of the cell-death pathway (Henchcliffe and Beal, 
2008). Further support for this crucial role played by the mitochondria in PD can be 
seen by the fact that a number of PD-associated genes are involved in these pathways, 
and mutations have been linked to the maintenance of dynamic networks of 
mitochondrial structures (Henchcliffe and Beal, 2008). The outcome of these changes 
to mitochondria and other cellular components may be the activation of the 
neuroimmune response in PD, causing further damage to the brain. 
Neuroinflammation has been demonstrated in post-mortem, neuroimaging and 
cerebrospinal fluid biomarker studies, indicating that this is a salient feature of the 
disorder (Moehle and West, 2015). As stated, the oligomerized a-synuclein can be 
present in mitochondria, and there is substantial evidence that this can cause the 
generation of reactive oxygen species causing oxidative stress (Wang et al., 2016). 
One pathway for the generation of oxidative stress due to the build-up of 
oligomerized a-synuclein relates to the activation of microglia in the brain, which are 
highly sensitive to cellular damage signals (Rocha et al., 2018). This activation of 
microglia is tied to important brain homeostasis mechanisms, but research has shown 
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that a-synuclein-induced activation of microglia leads to a number of 
proinflammatory changes that are ultimately neurotoxic (Hoenen et al., 2016). 
Support for the important role of neuroinflammation also comes from genome studies 
that indicate close links between a number of genes, a-synuclein protein aggregates 
and neuroinflammation (Gao et al., 2008). Regardless of the mechanism linked to the 
pathogenesis of PD, all of these molecular mechanisms contribute to a disorder that 
manifests in observable motor dysfunction once midbrain cells of the substantia nigra 
pars compacta are lost. 
 
1.7. Clinical dysfunction 
1.7.1. Motor dysfunction 
The clinical diagnosis of probable PD requires the presence of bradykinesia in 
combination with one of either rigidity or resting tremor. Clinical diagnosis also 
requires two or more supportive criteria including a responsiveness to L-DOPA, the 
presence of L-DOPA-induced dyskinesias or olfactory loss (Postuma et al., 2015). 
Bradykinesia can manifest in reductions in the amplitude of movement, velocity or 
initiation, and can impact a range of muscle groups. Tremor is a variable motor 
symptom, presenting at ~5Hz in most patients, is likely to be present at rest, 
diminishes with voluntary movement and responds well to therapy with L-DOPA or 
dopamine agonists (Mcgregor and Nelson, 2019). With disease progression additional 
motor symptoms can develop that do not respond well to dopaminergic treatment. 
These include impairments of gait, balance and postural reflexes. Speech becomes 
impaired, while swallowing is typically impacted in advanced disease stages, leading 
to significant increases in mortality due to dysphagia and aspiration pneumonia 
(Martinez-Ramirez et al., 2015). While these motor features of PD are crucial to 
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quality of life, there is increasing awareness of the extensive and damaging impact 
non-motor features have on people with PD, many of which show variable responses 
to standard pharmacological treatment.  
 
1.7.2. Non-motor dysfunction 
Some of the earliest non-motor features of PD include autonomic disturbances 
relating to sleep and wakefulness (Fénelon et al., 2010) or constipation (Pedrosa 
Carrasco et al., 2018). Patients can experience depressive symptoms (Starkstein et al., 
1998, Tandberg et al., 1996) as well as disorders of affect, including anxiety and 
apathy (Dissanayaka et al., 2010, Pontone et al., 2009). Impulse control disorders are 
common in PD, and can include compulsive gambling, purchasing, sexual behaviour 
and eating (Voon and Fox, 2007). Recognition of the high prevalence and significant 
impact of cognitive dysfunction in PD has drawn attention to disease-related mild 
cognitive impairment (MCI) (Goldman et al., 2018) which is associated with a 
significantly increased likelihood of developing dementia (Broeders et al., 2013, Emre 
et al., 2007). People diagnosed with PD-related dementia face significantly higher 
mortality and reduced quality of life (Kehagia et al., 2010, Williams-Gray et al., 
2007), underscoring the importance of studying cognitive impairment in the disorder.  
 
1.7.3. Cognitive impairment and dementia in PD 
Cognitive impairment in PD was traditionally thought to impact only a small subset of 
patients, however it is now recognised that it can present at any point during the 
disease course (Goldman et al., 2018) and is one of the most common and important 
non-motor symptoms (Aarsland et al., 2017). In the earliest stages of the disorder, 24 
to 36% of PD patients show cognitive impairments (Foltynie et al., 2004). Three years 
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after diagnosis this prevalence rate can be as high as 50% (Aarsland et al., 2009, 
Broeders et al., 2013). Cognitive dysfunction in PD occurs in a broad range of 
cognitive areas, including executive, (Williams-Gray et al., 2007), visuospatial 
(Cronin-Golomb and Braun, 1997), working memory (Lewis et al., 2003), attentional 
and language domains (Dujardin et al., 1999). The high prevalence and heterogeneity 
of cognitive impairment, and the lack of standardised protocol for its definition, led to 
the development of a formal diagnostic criteria of MCI in PD which identifies patients 
at greater risk of developing dementia (Litvan et al., 2012). The Litvan criteria (2012) 
will be used in this thesis to categorise participants as having MCI, aligning this work 
with other research studies in this field. However, it should be acknowledged that 
cognitive impairment in PD is a complex issue. Dementia in PD is a multifaceted co-
morbidity, impacting a high percentage of people with the disorder, and causing 
disruption to a range of functional domains. Longitudinal work has demonstrated that 
over a four year period 62% of patients with PD-related MCI will develop dementia, 
while only 20% of cognitively unimpaired patients will be diagnosed with dementia 
during the same period (Janvin et al., 2006, Williams-Gray et al., 2007). A diagnosis 
of dementia in PD identifies patients with a symptom profile that may involve 
impairment in memory, visuospatial, constructional and executive functions, impaired 
and fluctuating attention and apathy. Core language functions are generally preserved, 
however verbal fluency and anomia are common (Emre, 2014). Unlike a diagnosis of 
Alzheimer disease, people with a diagnosis of dementia in PD do not necessarily have 
to present with memory impairment. Non-memory related clinical features of PD-
dementia relate to clinical and behavioural features including apathy, excessive 
sleepiness (Goldman et al., 2018), motor and autonomic disturbances (Emre et al., 
2007) and visual hallucinations, all of which are often dysphoric and fear provoking 
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(Gomperts, 2016). PD-related dementia has been linked to diffuse cortical Lewy body 
disease pathology (Hurtig et al., 2000), amyloid-b plaque deposition (Emre et al., 
2007) and cerebrovascular disease (Halliday et al., 2014) while a substantial 
proportion of patients also meet the diagnostic criteria for Alzheimer disease-type 
pathology (Compta et al., 2011). Dementia in PD is associated with a range of 
neurotransmitter systems including acetylcholine (Bohnen and Albin, 2009), 
dopamine (Rinne et al., 2000) and norepinephrine circuits (Zweig et al., 1993).  
 
The profile of cognitive deficits in PD is heterogeneous, in terms of which domains of 
function are affected, but also due to the temporal nature of the symptoms. For 
instance, a dual-profile of cognitive impairment in PD has been suggested that might 
be able to differentiate between two broad syndromes. The first is a profile of 
neuropsychological deficit in non-demented people with PD who have MCI and also 
tremor-dominant motor phenotypes on tests of working memory and executive 
function and are more responsive to dopaminergic amelioration of symptoms 
(Kehagia et al., 2013). The second subtype, an akinetic subtype with pronounced gait 
disturbance, demonstrate deficits in visuospatial function and semantic fluency and 
have a more rapid decline to dementia and in whom cholinergic treatment can be 
effective (Kehagia et al., 2013). Further, it has been shown that the age of onset can 
also be an important factor. Studies have shown that older patients at diagnosis 
experience a more severe phenotype (Pagano et al., 2016). As these symptomatic and 
pathological profiles suggest, the clinical features of PD are multifaceted and likely 
the result of dysfunction in multiple systems in the brain (Postuma and Berg, 2019). A 
neural circuit-based approach involving basal ganglia-thalamocortical circuits offers 
an opportunity investigate such a multifaceted system, which may uncover 
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pathophysiological changes that underlie clinical dysfunction associated with the 
disorder. This thesis will now introduce basal ganglia-thalamocortical circuits and 
how they relate to symptoms in PD. It will then be shown how a search for 
neuroimaging biomarkers associated with clinical dysfunction can benefit from 
analyses within these brain circuits. 
 
1.8. Basal ganglia-thalamocortical circuits 
1.8.1. Circuit structure 
The basal ganglia are a set of highly organised subcortical nuclei that are crucial to 
effective movement, learning, working memory, emotion and behaviour (Obeso et al., 
2008). Component nuclei include the striatum, globus pallidus (pars externa and 
interna), the subthalamic nucleus and the substantia nigra (pars compacta and 
reticulata) (the thalamus is included for reference) (Figure 1.2).  
 
 
Figure 1.2: Structures of the basal ganglia. This figure displays the component structures 
of the basal ganglia overlaid on a Montreal Neurological Institute 152 standard T1-weighted 
structural MRI scan in the coronal plane. Abbreviations: CN, caudate nucleus; TH, 
thalamus; P, putamen; SN, substantia nigra; STN, subthalamic nucleus; GP, globus pallidus. 
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Nuclei of the basal ganglia connect with the bilateral thalami and cortical regions to 
form re-entrant basal ganglia-thalamocortical circuits. Originally thought to only 
subserve motor functions (Delong and Georgopoulos, 1981), Alexander et al. (1986) 
expanded this view to describe motor, dorsolateral prefrontal (associative), anterior 
cingulate (limbic), oculomotor and lateral orbitofrontal basal ganglia-thalamocortical 
circuits. The different behavioural associated with each of these circuits is linked to 
the functions performed by the site of origin of each circuit in the cortex (Delong and 
Wichmann, 2009). The basic architecture of each circuit is the same, with cortical 
areas connecting with the nuclei of the striatum (caudate nucleus and putamen), which 
then connect with the globus pallidus interna/substantia nigra complex, projecting to 
the thalamus and back to the site of origin in the cortex (Alexander et al., 1986).  
 
The three most commonly studied circuits are the motor, limbic and associative 
circuits. The motor circuit, involved in mediating the overall amount of movement, 
originates in the supplementary motor area, premotor and motor cortex and 
somatosensory cortex, projecting to the putamen in a topographic manner (Tekin and 
Cummings, 2002). The circuit then sends afferent input to the central and dorsal 
globus pallidus and also to the ventral substantia nigra (Haber and Calzavara, 2009). 
The circuit then connects with the ventrolateral and ventral anterior thalamic nuclei, 
reconnecting back with the somatomotor cortices (Tekin and Cummins, 2002).  
 
The limbic circuit mediates processes involved reward-based behaviour and learning. 
This circuit begins in the anterior cingulate and ventromedial prefrontal cortical 
regions, projects to the rostral and ventro-medial striatum, then projects to the ventral 
palladium and to the medial substantia nigra. From there, the circuit projects to 
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ventral anterior nucleus of the thalamus, which then closes the loop by reconnecting 
back with their site of origin in medial prefrontal cortical regions (Haber and 
Calzavara, 2009).  
 
The associative circuit mediates a range of processes involved in cognitive function, 
including strategic planning, working memory, and executive functioning. This circuit 
begins in the dorsolateral prefrontal cortex which projects to the rostral and dorsal 
caudate nucleus. The circuit then connects with the central part of the globus pallidus 
and substantia nigra, which projects to the ventral anterior and mediodorsal thalamus. 
The circuit closes by reconnecting back with the dorsolateral prefrontal cortex (Haber 
and Calzavara, 2009). While each of the motor, limbic and associative circuits follow 
a broadly similar structure, within each circuit there is a direct and indirect pathway 
that perform opposing functional roles based on their connectivity and 
neurotransmitter architectures. 
 
1.8.2. Direct and indirect pathways  
Both the direct and indirect pathways begin in the same cortical regions and connect 
with the caudate nucleus and putamen via excitatory glutamatergic transmission. The 
direct pathway, which bears D1 dopaminergic neurons, has inhibitory g-amino-butyric 
acid connections from the striatum to the globus pallidus interna/substantia nigra 
complex. The indirect pathway, which bears D2 dopaminergic neurons, has inhibitory 
g-amino-butyric acid connections from the striatum to the globus pallidus externa 
which then projects inhibitory g-amino-butyric acid connections to the subthalamic 
nucleus (Delong and Wichmann, 2009). The important connective distinction between 
these two pathways is the output from the subthalamic nucleus, which projects back 
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to the globus pallidus interna/substantia nigra complex via excitatory glutaminergic 
connections. Both circuits output from the globus pallidus interna to the thalamus via 
inhibitory g-amino-butyric acid fibres, with the final connection from the thalamus to 
the cortex being an excitatory glutaminergic connection (Figure 1.3) (Mega and 
Cummings, 1994). 
 
 
Figure 1.3: Basic organisation of basal ganglia-thalamocortical circuits. Solid lines 
indicate connectivity via direct circuits which input to the striatum, connect with the globus 
pallidus interna/substantia nigra complex, then to the thalamus, projecting back to their sites 
of origin in the cortex. Indirect pathways are represented by broken lines, connecting the 
striatal nuclei to the globus pallidus interna, the subthalamic nucleus, then connecting with 
the globus pallidus intern/substantia nigra complex. Abbreviations: CN, caudate nucleus; 
GPe, globus pallidus externa; GPi/SN, globus pallidus interna/substantia nigra complex; STN, 
subthalamic nucleus; VA, ventral anterior thalamic nuclei; VL, ventrolateral thalamic nuclei; 
MD/A, mediodorsal and anterior thalamic nuclei. This figure is adapted from Obseo et al. 
(2008). 
 
The direct and indirect pathways modulate circuit activity depending on the input they 
receive. Dysfunction of the direct pathway can cause abnormal thalamic inhibition, 
while dysfunction of the indirect circuit can cause disinhibition and thalamic 
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overactivity. This dual effect is due to the influence of dopamine over D1 and D2 
receptors, exciting D1 neurons in the direct pathway and inhibiting D2 neurons in the 
indirect pathway (Obeso et al., 2008). A clear example of how the breakdown of basal 
ganglia-thalamocortical circuitry can explain clinical dysfunction in PD relates to the 
cardinal motor symptoms of hypokinesia. 
 
1.8.3. Circuit dysfunction 
Loss of dopaminergic input to the striatum causes an imbalance between the direct 
pathway and the indirect pathway. The net effect of this imbalance is hypothesised to 
be disinhibition of the subthalamic nucleus that leads, in turn, to excessive inhibition 
of thalamo-cortical activity and the clinical symptoms of hypokinesia (Albin et al., 
1989, Braak and Del Tredici, 2008, Delong, 1990). There is a wealth of experimental 
and clinical evidence to support this framework (Alvarez et al., 2005, Aziz et al., 
1991, Bergman et al., 1990, Fine et al., 2000), which has resulted in the widespread 
use of dopaminergic medication and more recently deep brain stimulation (temporary 
lesioning of neuroanatomical sites in the indirect pathway) as evidence-based 
therapeutic options (Volkmann et al., 2010). However, the effects of restoring the 
balance between the two pathways within basal ganglia-thalamocortical circuits does 
not fully account for a number of clinical symptoms in the disorder. The role played 
by medication in mediating circuit activity in PD is crucial from a diagnostic and also 
treatment perspective, and warrants further discussion as it can reveal important 
information about the link between basal ganglia-thalamocortical circuits and clinical 
dysfunction. 
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1.8.4. Basal ganglia-thalamocortical circuits, treatments and clinical 
dysfunction 
The effects of dopaminergic medication and deep brain stimulation on non-motor 
symptoms in PD have traditionally been mixed (Volkmann et al., 2010). Clinical 
accounts in PD suggest that certain cognitive symptoms can improve (Kulisevsky, 
2000) and also worsen with dopaminergic therapy in PD (Frank, 2005). This is 
supported by research in primate models, where L-DOPA treatments that greatly 
improved motor symptoms were associated with minimal or worsening cognitive 
performance (Schneider et al., 2013). The use of dopaminergic medication to restore 
the balance of these circuits is also associated with dyskinesias (Connolly and Lang, 
2014) and impulse control disorders (Moustafa and Poletti, 2013), both which 
significantly increase disability in PD (Poewe, 2009). Recent research using 
probabilistic tractography on PD participants after deep brain stimulation surgery has 
been able to uncover distinct neural circuits associated with elements of impulse 
control disorders in PD, including faulty reward perception and impatience (Mosley et 
al., 2019). The first network, a ‘reward evaluation network’, was associated with 
stronger connectivity between the ventral striatum and the ventromedial prefrontal 
cortex in PD participants who demonstrated riskier behaviour, while a second 
network, a ‘response inhibition network’, was associated with weaker connectivity 
between the subthalamic nucleus and the pre-supplementary motor area in patients 
who demonstrated greater impulsivity (Mosley et al., 2019). As these studies show, 
there is strong evidence for a neural-circuit basis to some of the symptoms in PD, 
however due to the variability in findings, more investigation is required to fully 
understand the mechanisms associated with clinical dysfunction in the disorder. To 
investigate these potential pathophysiological mechanisms, a network-based approach 
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is thus important as it may reveal neuroimaging biomarkers associated with clinical 
dysfunction in the disorder. 
 
1.9. Network-based approaches to neuroimaging biomarkers 
1.9.1. Neuroimaging biomarkers in PD 
A number of methodologies have been used to investigate neuroimaging biomarkers 
associated with PD. These methodologies can provide insight to possible structural, 
functional and perfusion pattern changes in the disorder, and can be used for 
differential diagnosis as well as for more accurately understanding disease 
pathophysiology. Neuroimaging methodologies that have been used to search for 
biomarkers in PD include transcranial sonography (TCS), MR approaches utilising 
structural, functional and diffusion weighted MR imaging (DWI) sequences, and 
molecular techniques like positron-emission technology (PET) and single-photon 
emission computed tomography (SPECT). This thesis will now provide an overview 
of these neuroimaging methodologies and show how the work of the current thesis 
aims to build on this field of research. 
 
TCS is a technique that has been used mainly to search for biomarkers of dysfunction 
to the substantia nigra (Bouwmans et al., 2013). Changes found at the substantia nigra 
using TCS are evidenced by hyperechoic signals that are likely associated with 
increased iron deposition, leading to oxidative stress and associated cell loss (Hwang, 
2013). Increased echogenicity has been shown to be found in 90% of people with PD, 
however it is less effective in differentiating between different subgroups of PD 
participants, meaning that the biomarker can serve as a good measure for disease 
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detection (Postuma et al., 2015) but it has less utility in helping understand symptoms 
of the disorder. 
 
DWI enables the investigation of changes to white matter in the brain by measuring 
the random Brownian motion of water molecules within tissue (Baliyan et al., 2016). 
When used to search for biomarkers in neurodegenerative disorders like PD, tensor-
based approaches can reveal important information about the microstructural integrity 
of white matter tracts in the brain and how these changes relate to disease (Atkinson-
Clement et al., 2017). Two crucial measures of tensor-based diffusion imaging (DTI) 
are mean diffusivity (MD) and fractional anistrophy (FA) (Basser and Pierpaoli, 
1996). These metrics provide information about the movement and orientation of 
water molecules in the brain, which are considered reflective of white matter damage 
associated with disorders like PD. In the field of neuroimaging biomarkers in PD, DTI 
has primarily focussed on the differential diagnosis between PD and atypical 
Parkinsonian conditions (Meijer et al., 2013), as well as investigating the anatomical 
connectivity of important brain regions (Mishra et al., 2019). These studies have 
demonstrated that PD is associated with changes in white-matter structural integrity in 
a range of cortical and subcortical brain regions (Atkinson-Clement et al., 2017) and 
that white-matter structural changes are correlated with disease duration and clinical 
symptoms (Mishra et al., 2019). 
 
The role of structural and functional imaging will be expanded upon in more detail in 
Section 2.1.1 and 2.1.2, but it is important to note briefly some of the progress that 
has been made in the search for neuroimaging biomarkers in PD using these methods. 
Possible changes to the SN have been proposed as potential diagnostic neuroimaging 
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biomarkers for PD, with dorsolateral areas showing characteristic low signals on high 
field strength MRI with T2-weighted sequences compared to controls (Blazejewska et 
al., 2013). Possible improvements in structural biomarkers in PD are showing more 
promise due to important development in high-field imaging, improved spatial 
resolution and improved methods for analysing this brain imaging data (He et al., 
2018). Imaging of brain activity is performed with functional MRI, and using this 
technique it is possible to search for biomarkers of PD. The field has developed from 
investigating task-related activity changes to isolated brain regions, to searching for 
changes in and between intrinsic, large-scale networks associated with the disorder 
and its symptoms (Helmich et al., 2018). As explored in this thesis, the focus of 
analysis has mainly centred on changes within structures of the basal ganglia (He et 
al., 2018). Functional MRI analysis methods has shown promise from a diagnostic 
standpoint, able to find networks of interconnected brain regions can differentiate PD 
patients from control participants with high sensitivity and specificity (Szewczyk-
Krolikowski et al., 2014). However, how these network changes are related to clinical 
symptoms, coupled with the lack of few clear patterns between research studies (Khan 
et al., 2018), make this an area of research requiring further investigation. 
 
Another important methodology used to investigate neuroimaging biomarkers in PD  
centres around the imaging of dopamine. Due to the loss of dopaminergic cells of the 
SN and subsequent denervation of the striatum, various methods have been used to 
assess the altered function of nigrostriatal dopaminergic terminals. The most common 
approach is to use PET, or SPECT, which can be used to monitor the uptake of certain 
radiotracers that are linked to dopaminergic transmission. Uptake of 6-[18F]-fluoro-
L-3,4-dihydroxyphenylalanine has been shown to be reduced in the striatum in early 
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stages of PD, as well as in anterior thalamic regions as the disease progresses (Pavese 
et al., 2011). Due to success in this area, normal functional imaging of the presynaptic 
dopaminergic system is an exclusion criteria for the Movement Disorder Society 
diagnosis of PD (Postuma et al., 2015). Recent research using dopamine transporter 
imaging in people with non-manifest LRRK2 and GBA mutation carriers has shown 
that clinical symptoms may predate dopaminergic changes (Simuni et al., 2020), 
paving the way for improved understanding of the relationship between the 
pathophysiology of the disorder and its manifestation.  
 
As shown, clinical dysfunction in PD may be tied to changes in the structure of the 
brain as well as changes in the activity of brain regions. A neural circuit ‘hubs-and-
spokes’ approach can be used to investigate structure and function of brain regions 
(Mesulam, 1990), which has the potential to reveal neuroimaging biomarkers 
associated with the disorder. 
 
1.9.2. Hubs 
Networks in the brain rely on the function of important structures called ‘hubs,’ which 
occupy positions of topological centrality within brain networks and make strong 
contributions to their functioning (Van Den Heuvel and Sporns, 2013, Crossley et al., 
2014). While hubs within brain networks are crucial to functioning, they are uniquely 
vulnerable to the neuropathological processes underlying a range of brain disorders 
(Zhou et al., 2012). A key step in relating clinical dysfunction to the structure of the 
brain in neurodegenerative disorders like PD is to quantify disease related effects on 
brain morphology (Looi et al., 2014), which can be performed using T1-weighted 
structural MRI.  
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This thesis thus investigates the morphology of two crucial hubs within basal ganglia-
thalamocortical circuits, the striatum (Project one) and thalamus (Project two) in a 
search for neuroimaging biomarkers associated with clinical dysfunction in PD. 
Although analysing the structure of hubs within brain networks helps us understand 
the fundamental architecture of brain regions, and how this relates to clinical 
dysfunction, it is also necessary to consider the neural circuitry that connects brain 
regions. 
 
1.9.3. Spokes 
White matter tracts, which support functional dynamics of the brain (Bullmore and 
Sporns, 2009) can be considered ‘spokes’ along which neurodegenerative changes 
may take place (Looi et al., 2014). This thesis studies the spokes that interconnect 
brain regions using two approaches.  
 
The first approach involves the use of resting-state functional MRI (rs-fMRI) in 
Projects one through three. This method allows for the investigation of the activity of 
intrinsic connectivity networks in the brain while a participants are ‘at rest’, 
producing a measure of ‘functional connectivity’ between brain regions (Biswal et al., 
1995). A discussion of functional connectivity relative to ‘structural connectivity’ is 
presented in section 2.1.2 of this thesis. 
 
The second way that spokes are investigated in this thesis is via an analysis of the 
structure of the corpus callosum, the largest white matter tract in the brain (Project 
four). The corpus callosum is the major inter-hemispheric connection in the brain 
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enabling the efficient transfer of information for a number of sensory, motor and 
cognitive functions (Looi et al., 2014).  
 
Using this hubs-and-spokes framework, this thesis incorporates four projects to 
investigate neuroimaging biomarkers associated with clinical dysfunction in PD. 
Individual rationales, aims and hypotheses of each project are now presented. 
 
1.10. Aims and hypotheses 
1.10.1. Project one - Striatum  
1.10.1.1. Rationale 
Project one focusses on the striatum due to its position as a hub within basal ganglia-
thalamocortical circuits (Looi and Walterfang, 2013), and due to the functional 
consequences of the loss of nigrostriatal dopaminergic input associated with the 
disorder (Kish et al., 1988). 
 
1.10.1.2. Aims 
Project one of this thesis aimed to investigate how the volume and surface shape of 
striatal structures were impacted in PD, and how changes in morphology related to 
clinical dysfunction. Project one then aimed to investigate whether there were any 
functional connectivity changes to these structures in the disorder. 
 
1.10.1.3. Hypotheses 
We hypothesised that there would be (1) significant reductions in striatal volumes in 
the PD cohort relative to the control subjects and that these reductions would be more 
pronounced in advanced disease stages, as measured by disease duration. It was also 
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hypothesised that (2) the PD group would display localised shape changes to the 
dorsal caudate nucleus and the posterior putamen, due to disease-related 
dopaminergic depletion at these sites (Kish et al., 1988). In the PD cohort, it was 
hypothesised that (3) atrophy of striatal nuclei would be correlated with poorer 
performance on measures of clinical function. Finally, it was hypothesised that (4) PD 
patients would display altered functional connectivity that would relate to the clinical 
symptoms observed in the disease. 
 
1.10.2. Project two - Thalamus  
1.10.2.1. Rationale 
Project two of this thesis investigated the bilateral thalami due to their position as 
output hubs within basal ganglia-thalamocortical circuits (Power and Looi, 2014, 
Hwang et al., 2017), and due to the increased inhibition of thalamocortical projections 
consequent to dopaminergic depletion of the striatum. The thalami are also vulnerable 
to the underlying pathology of PD, with the presence of Lewy pathology and 
associated cell loss found in medial nuclear regions (Halliday, 2009). 
 
1.10.2.2. Aims 
Project two of this thesis therefore aimed to investigate the volume and the surface 
shape of the thalami, how these elements are impacted in PD, and how these variables 
are associated with clinical dysfunction. Project two then aimed to investigate 
whether the thalami undergo functional connectivity changes in PD.  
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1.10.2.3 Hypotheses 
Based on the location of Lewy pathology within the thalami in PD and associated cell 
loss found postmortem, we hypothesised that (1) there would be reductions in 
volumes of the thalamus in PD patients compared to controls, based on the presence 
of PD neuropathology and the associated cell loss found post-mortem (Halliday, 
2009). We also hypothesised that (2) there would be localised surface changes to 
medial regions of thalamus in PD, compared to controls. We hypothesised that (3) 
there would be a correlation between smaller overall volumes of the thalamus and 
poorer performance on measures of clinical function. Finally, we hypothesised that 
(4) there would be functional connectivity changes in our PD group due to the integral 
position the thalamus occupies within basal ganglia-thalamocortical circuits. 
 
1.10.3. Project three - Cognitive impairment stages 
1.10.3.1. Rationale 
Project three of this thesis investigated the morphology and functional connectivity of 
the striatum and thalamus using MCI and dementia as disease progression stages. The 
presence of cognitive impairment in PD is tied to an increased likelihood of 
developing dementia, which is associated with increased mortality and significant 
reductions in quality of life (Goldman et al., 2018), making an understanding of the 
pathophysiology behind cognitive impairment of crucial importance. 
 
1.10.3.2. Aims 
Project three of this thesis thus aimed to uncover any volumetric and surface shape 
changes to the caudate nucleus, putamen and thalamus, and how they were impacted 
in PD relative to the presence of MCI and dementia. Project three then aimed to 
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investigate possible changes in the functional connectivity of these structures. Finally, 
Project three aimed to better understand what may be driving changes in functional 
connectivity by performing a correlation analysis between functional connectivity of 
the caudate nucleus, putamen and thalamus and clinical variables.  
 
1.10.3.3. Hypotheses 
Functional MRI research in PD patients has revealed areas of both over- and under-
activity during the performance of cognitive tasks, suggesting a combined presence of 
decreased brain function and compensatory mechanisms (Ray and Strafella, 2012). 
Research has argued that such a compensatory response may rely on sufficient 
neuronal resources. Accordingly, we present novel hypotheses whereby (1) 
cognitively unimpaired participants with PD would have sufficient neural resources to 
support functional compensation, and display increased functional connectivity, 
concomitant with no volumetric or surface-based shape alterations to the caudate, 
putamen and thalamus. However, we hypothesise that (2) morphological alterations to 
these structures would take place in PD-MCI, representing a ‘critical threshold,’ 
where functional connectivity begins to decrease along with reductions in 
morphology, evidenced by reduced volumes and surface deflation when compared to 
cognitively unimpaired PD participants, and controls. Finally, we hypothesised that 
(3) PDD participants would demonstrate significant and profound reductions in 
volumes and surface shape, along with significant decreases in functional connectivity 
of the caudate nuclei, putamina and thalami compared to all experimental groups. 
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1.10.4. Project four - Corpus callosum and cortex 
1.10.4.1. Rationale 
Projects one, two and three focussed on intra-hemispheric neural circuits that mediate 
a range of behaviours linked to the clinical manifestations associated with PD. To 
extend this analysis and gain a fuller understanding of the neural circuit basis of 
clinical dysfunction, Project four investigates the morphology of the corpus callosum, 
the largest white matter structure in the brain. The corpus callosum is integral for the 
integration of inter-hemispheric cortical activity via its connectivity of homotopic 
cortical regions.  
 
1.10.4.2. Aims 
Project four aimed to uncover possible alterations to the morphology of the corpus 
callosum. An analysis of the cerebral cortex, which is the site of origin for basal 
ganglia-thalamocortical circuits, was also performed as this has the potential to yield 
neuroimaging biomarkers of clinical dysfunction, due to its link to both cognitive 
impairment and PD-related dementia (Halliday et al., 2008, Zarei et al., 2013), 
coupled with the fact that the cortex is the site of origin and termination of basal 
ganglia-thalamocortical circuits. 
 
1.10.4.3. Hypotheses 
Evidence suggests that white matter integrity of the corpus callosum is impacted in 
PD (Agosta et al., 2014a), while the thickness of the cortex decreases with disease 
progression (Wilson et al., 2019). It was thus hypothesised that (1) PD participants 
would demonstrate reduced thickness of the corpus callosum and cortex compared to 
controls. Research has shown that greater thickness of the callosum is linked to 
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measures of general cognitive ability (Luders et al., 2007) and as there are increased 
structural changes to both grey and white matter structures in the brain with 
increasing levels of cognitive impairment, we hypothesised that (2) changes in 
thickness of the corpus callosum would be more pronounced in MCI participants 
compared to cognitively unimpaired PD, and controls, while PD participants with 
dementia would have significant and widespread reductions in callosal thickness 
compared to PD with MCI and cognitively unimpaired PD participants. Due to the 
structural connectivity between the corpus callosum and cortex, we present the novel 
hypothesis that (3) the thickness of the corpus callosum would correlate with 
thickness at particular cortical regions, highlighting a potential usefulness for corpus 
callosal thickness as a proxy measure of cortical degeneration in PD. 
 
Before presenting the four project chapters, this thesis will now provide background 
to the main methodological approaches that were employed in these projects. 
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2. Methodology 
This chapter begins with a description of the Swedish BioFinder Study, the data of 
which forms the material for this PhD thesis. This chapter then presents the general 
methodology used, outlining concepts that are important to the understanding of 
neuroimaging biomarkers in PD. This chapter then outlines the use of structural and 
functional MRI data, followed by the presentation of the methods used to extract data 
from each modality. The chapter finishes by outlining the core data processing and 
analysis techniques used to investigate the structural and functional neuroimaging 
data. 
 
2.1. Swedish BioFinder Study Details 
2.1.1. Recruitment and participants 
The data for this PhD thesis derives from the Swedish BioFinder study, which is a 
prospective and longitudinal program aiming to learn more about the pathological 
mechanisms underlying important neurodegenerative disorders as well as in normal 
aging. According to my interest in neuroimaging biomarkers for PD, this thesis is a 
secondary analysis of existing data, and comprising the clinical and neuroimaging 
data of the parent BioFinder Parkinsonian cohort. The current thesis focusses on 
patients within the Parkinsonian cohort with a diagnosis of PD (n = 101) based on the 
National Institute of Neurological and Stroke Diagnostic Criteria (Gelb et al., 1999) 
who are treated at the Skåne University Hospital, in the Skåne region of Sweden. 
Participants received their clinical assessments between 23/05/2012 and 13/03/2014. 
The study also focuses on control participants who were also recruited from the Skåne 
region. Exclusion criteria for this study included refusing MRI, the presence of 
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significant alcohol or substance misuse and/or a significant systematic illness or organ 
failure. 
 
  
2.1.2. MRI Acquisition 
T1-weighted MRI was performed on a 3T scanner (Trio Magnetom, Siemens, 
Erlangen, Germany) equipped with a 20-channel head-coil. High-resolution three-
dimensional anatomical brain images were acquired using a magnetisation-prepared 
rapid acquisition technique with gradient-echo sequence (repetition time = 7 ms; echo 
time = 3 ms; flip angle = 90 degrees; voxel size = isotropic 1mm3). Image matrix size 
was 356 voxels in the coronal and sagittal planes and 176 voxels in the axial plane, 
with no interslice gap. 
 
Functional imaging was also performed on participants in the BioFinder Study. This  
consisted of 256 T2*-weighted echo planar imaging volumes (repetition time = 1850 
ms; echo time 30 ms; flip angle = 90 degrees; matrix 64 × 64; voxel size 3 × 3 × 3.75 
mm3). Image matrix size was 64 voxels in the coronal and sagittal planes and 36 
voxels in the axial plane. Participants were instructed to lie still with their eyes closed, 
not to fall asleep and not to think of anything in particular during the scan. 
 
2.1.3. Clinical Assessment 
All participants underwent a cognitive and neurological examination by a medical 
doctor with extensive experience with movement disorders, while PD participants 
remained on their usual medication regimes. Clinical functioning was quantified using 
the Hoehn and Yahr staging, assessing the progression of the disorder; the Unified 
Parkinson’s Disease Rating Scale Part-III test (UPDRS-III), assessing the motor signs 
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of PD (Fahn and Elton, 1987); the Mini Mental State Examination (MMSE), 
assessing cognitive mental state (Folstein et al., 1975); the Animal Fluency and Letter 
S Fluency tests, assessing verbal fluency and executive function (Tombaugh et al., 
1999) and the A Quick Test of cognitive speed assessing perceptual and cognitive 
speed (Palmqvist et al., 2010). 
 
2.2. Neuroimaging data and analysis methods 
2.2.1. Structural MRI data 
Structural T1-weighted MRI (structural MRI) is used in this thesis to investigate 
neuroimaging biomarkers via the analysis of changes in brain morphology. To do this, 
regions-of-interest (ROI) are segmented within participant’s structural MRI using 
observable boundaries between anatomical structures or brain tissue types. Different 
segmentation methods are used depending on the research aims, and once performed, 
elements of morphology can be calculated and analysed. This thesis models elements 
of  morphology using volumes, surface shape and structure thickness. 
 
2.2.2. Functional MRI data 
T2*-weighted echo planar functional MRI (functional MRI) is a commonly used tool 
for mapping brain activity, as well as a means of investigating the dynamics of 
neuronal circuits (Logothetis et al., 2001). Functional MRI provides information 
about haemodynamic changes after increased neural activity, producing observable 
changes in the blood-oxygen-level-dependent (BOLD) signal. Functional MRI works 
on the premise that increases in the BOLD signal relate to neural activation which 
induces a localised increase in blood flow producing hyperoxygenation and a relative 
decrease in the concentration of deoxyhaemoglobin (Logothetis, 2008). BOLD 
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functional MRI images are obtained sequentially over a series of timepoints, with 
each image made up of small volume elements (voxels). Each voxel within these 
three-dimensional images, once stacked sequentially, can be considered a vector of 
signal intensities over time, and are thus referred to as timeseries data (Bandettini et 
al., 1993).  
 
After its inception into neuroimaging research, functional MRI was primarily used 
with stimuli or task-based paradigms to investigate BOLD timeseries data in different 
brain regions (Shen, 2015). Biswal et al. (1995) first investigated spontaneous 
timeseries data in participants who lay in fMRI scanner and performed no tasks. This 
pioneering resting-state fMRI research showed that during ‘rest’, brain activity is both 
structured and organised, and that the activity of brain regions that are known to 
function together demonstrate ‘functional connectivity’ (Biswal et al., 1995). 
Functional connectivity indicates areas of the brain with a temporal dependence 
between neuronal activity patterns (Friston et al., 1993). Significant research has since 
corroborated this theory, showing that areas in the brain that share similar temporal 
BOLD timeseries form functional networks (Murphy et al., 2013). 
 
It is important to note, though, that functional connectivity does not measure direct 
structural connectivity of white matter tracts as afforded using diffusion weighted 
imaging. Despite this, there are a number of important factors that make the use 
functional connectivity a valuable approach for this thesis. Firstly, research has shown 
that the method is able to successfully probe brain networks, evidenced by the high 
correspondence between resting-state networks and the underlying white matter 
architecture of the brain (Van Den Heuvel et al., 2009). There is also a strong 
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correspondence between the brain’s functional architecture during task activation and 
at rest (Smith et al., 2009). This correspondence enables researchers to use rs-fMRI 
functional connectivity as a valid measure to study brain networks that are tied to 
behavioural processes (i.e. sensorimotor, visual, auditory and executive control), 
indicating that the networks utilised by the brain during action are continuously and 
dynamically active in the brain during the resting state. Finally, this approach has a 
number of methodological benefits, including being low-cost, non-invasive, it has 
high spatial resolution and it does not require participants to engage in difficult 
behavioural programs which can be difficult with certain experimental cohorts (Gao 
and Wu, 2016).  
 
2.3. Structural MRI: ROI segmentation 
This thesis investigates the morphology of structural ROIs using volume, surface-
based shape analysis and thickness measures. Investigating volumes of ROIs in the 
brain can inform on atrophy/hypertrophy, while surface-based shape analyses can 
reveal subtle localised morphological changes that may not be discoverable using 
volumetry. The third metric used to investigate morphology in this thesis is thickness, 
which is used to model changes in the morphology of the corpus callosum and 
neocortex. 
 
The two main ways that brain morphology can be quantified in structural MRI data 
are manual and semi-automated segmentation approaches. When aiming to quantify 
volume or surface-based shape changes of brain ROIs, manual segmentation is 
considered the gold-standard, especially when dealing with patient cohorts (Morey et 
al., 2009, Power and Looi, 2015). However as brain imaging datasets have increased 
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in size, semi-automated segmentation approaches have become a necessity. Further, 
to have a potential for clinical application, semi-automated segmentation techniques 
hold more promise given that time-consuming manual segmentation approaches by 
clinicians are likely not a feasible option (Guenette et al., 2018). As striatal and 
thalamic structures were segmented on a cohort of 101 (Projects one and two), 
manual segmentation methods were used for these projects. The statistics on the 
reliability and reproducibility this tracing approach is presented in Appendix 1: 
Manual ROI segmentation tracing reliability. Due to the complex nature of 
quantifying morphology of the corpus callosum and cortex, semi-automated software 
pipelines were used for Project four. 
 
2.3.1. ROI segmentation: caudate nucleus 
Segmentation of the bilateral caudate nuclei and putamina from participant’s 
structural MRI data was performed using validated manual tracing protocols (Looi et 
al., 2009, Looi et al., 2008) with the aid of a neuroanatomical atlas (Duvernoy, 2012). 
These tracing methods produce 3-D object maps of the structures that can be analysed 
at the group-level for any experimental effects on volume and surface shape. The 
protocol for manually segmenting the caudate nucleus (Looi et al., 2008) begins with 
the most inferior MRI slice where the head of the caudate is distinct from the 
putamen, separated by the internal capsule. The medial border of the caudate is the 
lateral wall of the lateral ventricle, while the lateral surface of the caudate is the 
medial border of the internal capsule. Tracing of the caudate is performed in each 
axial 2D slice moving in the superior direction until the caudate is no longer visible 
next to the wall of the lateral ventricle in its most superior slice (Figure 2.1).  
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Figure 2.1: Segmentation of the caudate nucleus. An example tracing of the bilateral 
caudate nuclei on a participant’s structural MRI in the axial plane. The caudate nuclei are 
highlighted in light blue. 
 
2.3.2. ROI segmentation: putamen 
The protocol for manually segmenting the putamen (Looi et al., 2009) begins in the 
same axial slice as the caudate nucleus, where the two structures are separated by the 
anterior limb of the internal capsule. The medial border of the putamen is traced along 
the lamina of white matter of the internal capsule separating the structure from the 
globus pallidus while the lateral border of the structure follows the white matter of the 
external capsule running between the putamen and the claustrum. The superior 
boundary of the putamen is selected as the slice prior to the structure no longer being 
visible (Figure 2.2). 
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Figure 2.2: Segmentation of the putamen. An example tracing of the bilateral putamina on 
a participant’s structural MRI in the axial plane. The putamina are highlighted in green. 
 
2.3.3. ROI segmentation: thalamus 
Segmentation of the bilateral thalami from participant’s structural MRI data was also 
performed using a validated manual tracing protocol (Power et al., 2015) with the aid 
of two neuroanatomical atlases (Duvernoy, 2012, Morel, 2007). Segmentation was 
performed in the coronal plane and proceeded in a caudal-rostral direction, starting by 
tracing the most caudal part of the thalamus (pulvinar) as it emerges under the crux 
fornix. ROIs in subsequent slices are traced in the rostral direction until the crus 
cerebri is seen to separate from the body of the pons. The medial border of the 
structure is clearly defined by the third ventricle, and the superior cistern in more 
caudal sections. The lateral border of the structure is defined by the reticular nucleus, 
while the inferior border is defined by characteristic white matter tracts proximal to 
prominent neuroanatomical landmarks including those adjacent to the red nucleus and 
subthalamic nucleus, and in more rostral slices, the hypothalamic sulcus. The superior 
border was defined by the floor of the lateral ventricle. The rostral aspect of the 
thalamus is characterized by the emergence of the mamillary bodies and 
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hypothalamus, with the most rostral slice visualised at the inferior pole of the head of 
the caudate (Figure 2.3). 
 
 
Figure 2.3: Segmentation of the thalamus. An example tracing of the bilateral thalami on a 
participant’s structural MRI in the coronal plane. The thalami are highlighted in red. 
 
 
2.3.4. ROI segmentation: corpus callosum 
Morphology of the corpus callosum was modelled using midsagittal corpus callosal 
thicknesses, segmented using an automated pipeline described in published works 
(Adamson et al., 2014, Adamson et al., 2011) (Figure 2.4).  
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Figure 2.4: Midsagittal corpus callosum and thickness streamlines. This figure displays 
an example of a corpus callosum midsagittal plane that has been segmented from a structural 
MRI. Thickness streamlines are drawn at the 100 nodes along the structure, represent evenly 
spaced non-overlapping thickness profiles that connect perpendicularly with the upper (green) 
and lower (red) boundaries of the structure. 
 
The production of these thickness streamlines involves three key steps: the 
identification of the midsagittal plane within a participant’s structural image; 
segmentation of the structure; and the generation of a thickness profile. Extracting the 
midsagittal plane from the original structural MRI is performed by finding the plane 
that intersects the falx cerebri, the cerebral aqueduct, the pineal stalk and the peaked 
roof of the fourth ventricle (Mitchell et al., 2003). Once the midsagittal plane has been 
identified, the corpus callosum is segmented using a template guided method that 
corrects for topological errors and removes any anterior and posterior pericallosal 
vessels. After segmentation, the software generates the thickness profile of each 
participant’s corpus callosum using the following steps: the corpus callosum is split 
into left (posterior) and right (anterior) halves; endpoints are defined as the bottom-
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right and bottom-left extrema of the structure, which form the start and end of a 
midline contour. This midline contour runs equipotentially (at an even distance from 
top and bottom boundaries), subdividing the outside of the corpus callosum into 
superior and inferior contours. 100 streamlines are then generated at evenly spaced 
intervals along the centre contour, which are non-overlapping nominally parallel lines 
intersecting the superior and inferior contours orthogonally along the anterior-
posterior trajectory. The length of each streamline is then saved for each participant 
and used as a dependent variable during subsequent statistical analyses. 
 
2.3.5. ROI segmentation: cerebral cortex 
The quantification of cortical thickness in the current thesis was performed using 
semi-automated FreeSurfer analyses, described in published works (Dale et al., 1999, 
Fischl and Dale, 2000). This process involves motion correction and averaging of 
multiple volumetric structural MRI images (if working on multiple participants) 
(Reuter et al., 2010), removal of non-brain tissue using a deformation procedure 
(Segonne et al., 2004), automated Talairach transformation, intensity normalisation 
(Sled et al., 1998), tessellation of the grey matter-white matter boundary, automated 
topology correction (Fischl et al., 2001, Segonne et al., 2007), surface deformation 
along intensity gradients to optimally define cortical surface borders, registration to a 
spherical atlas using individual cortical folding patterns to align cortical anatomy 
between participants (Fischl et al., 1999), and finally, the parcellation of the cerebral 
cortex into units with respect to gyral and sulcal structure based on the Desikan-
Killiany atlas (Desikan et al., 2006, Fischl et al., 2004). Once this processing has been 
performed, an average thickness of each cortical ROI in the Desikan-Killainy atlas is 
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saved for each participant and used as a dependent variable during subsequent 
statistical analyses. 
 
2.4. Structural ROI analysis techniques 
2.4.1. Volumetrics 
Quantitative morphological assessment of brain structures is commonly performed 
using volumetric measurements. First suggested by Lande (1979) as a way to 
investigate morphology of brain regions, volumetry can inform on atrophic or 
hypertrophic changes that take place in response to healthy aging or disease 
processes. Studies have revealed atrophy of several brain regions in disorders 
including Alzheimer disease (Apostolova et al., 2006), Huntington disease (Aylward 
et al., 1997) and schizophrenia (Vita et al., 2006), while innovative work by Maguire 
et al. (2000) showed that hypertrophy of the hippocampus was associated with 
navigational experience in London taxi drivers. Assessment of volumes are performed 
by summing the voxels within a ROI mask or segmentation, adjusting for partial 
volume effects (due to the effect of dealing with MRI voxels containing multiple 
tissue types), and multiplying this number by the size of an individual voxel. 
 
2.4.2. Shape analyses 
Shape analysis has become a significant neuroimaging tool used in the analysis of 
brain morphology due to its potential to locate precise changes between pathological 
and non-pathological brain structures. This is due to the fact that structural shape 
changes at specific neuroanatomical locations are not sufficiently reflected in 
volumetric measurements (Styner et al., 2006). Shape analysis can thus be used as a 
complementary technique to measure morphological changes that might be missed at 
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by analysis at the volumetric level. Early work by Wang et al. (2001) was able to 
demonstrate the usefulness of localised shape analysis methods, as they found that 
shape of the hippocampus could differentiate between control participants and 
participants with schizophrenia, whereas volumetry of the hippocampus could not. 
Research such as this spurred the development of techniques that can fully 
characterise biological and pathological-based shape variability in neuroanatomical 
ROIs (Gerig et al., 2001). The shape of an object provides information on quantities 
that do not vary when the object is moved, rotated, enlarged or reduced (Bookstein, 
1997). Shape analysis can be performed using a number of methods, such as tensor-
based morphology (Chiang et al., 2007), radial distance mapping (Thompson et al., 
2004), voxel based morphometry (Wright et al., 1995) or spherical harmonic point 
distribution models (SPHARM-PDM) (Cootes et al., 1995, Gerig et al., 2001, Styner 
et al., 2006). The approach chosen to analyse possible localised morphological 
changes to brain structures in the current thesis is surface analysis, performed using 
SPHARM-PDM. This approach maps nodes on the surface of a ROI to the surface of 
sphere, with every node being associated with a voxel vertex. The resulting 
arrangement of vertex nodes on the sphere accurately reflects the geometry of the 
original ROI (Brechbühler et al., 1995). This parametrisation of the ROI surface onto 
a sphere produces one-to-one mapping of surface vertices and makes possible a 
comparison of object average surfaces between experimental groups or in relation to 
clinical variables (Figure 2.5). 
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Figure 2.5: SPHARM-PDM Example. This figure demonstrates A) how points are 
distributed over the surface of a ROI segmentation. These then get parametrised onto the 
surface of a sphere B) which enables the comparison of surface shape between experimental 
groups, producing inflation and deflation maps C) indicating regions with significant surface 
change in one group compared to another. 
 
2.4.3. Thickness of corpus callosum  
To model the morphology of the corpus callosum, this thesis used a midsagittal 
thickness metric. As cortico-cortical connections through the corpus callosum are 
primarily arranged topographically, an investigation of the thickness of the corpus 
callosum serves two purposes. The first is that it may reveal information about the 
impact of primary white matter pathology on the corpus callosum (i.e myelin injury). 
The second purpose is that it may be able to inform on changes to the structure that 
are the result of neurodegenerative changes to connected cortical ROIs (Goldman et 
al., 2017). MRI studies investigating callosal morphology have found midsagittal 
thickness of the corpus callosum is associated with levels of clinical function (Luders 
et al., 2007), while morphological changes to the structure have been found in a 
number of disorders including frontotemporal lobar degeneration (Walterfang et al., 
2014), Huntington (Di Paola et al., 2012) and Alzheimer disease (Ardekani et al., 
2014). A number of schemes have been used to describe the morphology of the 
corpus callosum, including subdivision based on arithmetic fractions of the maximum 
anterior-posterior extent (Witelson, 1989), cortical endpoint (Hofer and Frahm, 2006) 
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and boundary tangent models (Joshi et al., 2013). The current thesis employed a 
cross-sectional midsagittal thickness approach. This approach can be easily quantified 
using an automated pipeline and shows a high segmentation accuracy when compared 
to manual segmentation. Further, the macroscopic properties of the wider corpus 
callosum can be extracted from the analysis of the midsagittal plane alone (Adamson 
et al., 2014).  
 
2.4.4. Thickness of the cerebral cortex 
To model the morphology of the cortex, this thesis uses an average cortical thickness 
metric. The cerebral cortex is the outermost layer of the brain, comprised of a highly 
folded sheet of neurons varying greatly in thickness, from 1 to 4.5 mm  (Kandel et al., 
2000). Cortical thinning is regionally specific, and the progress and positioning of 
atrophy can reveal important information about brain disorders (Fischl and Dale, 
2000). Investigating cortical thickness relies on the fact that the cerebral cortex is 
organised into ontogenetic columns that run perpendicular to the surface of the brain 
(Kandel et al., 2000, Rakic, 1988). This means that cortical thickness is likely driven 
by the number of cells within each of the cortical columns, suggesting that cortical 
thickness reflects the arrangement of neurons in a biologically and topologically 
meaningful way (Hanganu and Monchi, 2016).  
 
Cortical thickness has also shown to be effective in matching of neuronally 
homologous cortical regions between participants giving it an advantage over other 
cortical morphology approaches such as cortical volumes or surface areas (Zarei et 
al., 2013). Cortical thickness has been investigated in a wide variety of disorders 
including mild cognitive impairment and Alzheimer disease (Dickerson et al., 2008), 
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frontotemporal dementia (Du et al., 2007), amyotrophic lateral sclerosis (Schuster et 
al., 2014) as well as in PD (Pereira et al., 2012, Wilson et al., 2019). 
 
2.5. Resting-state functional MRI: preprocessing 
In order to investigate the connectivity of spokes between brain hubs, this thesis 
analysed functional MRI using a resting-state (rs-fMRI) functional connectivity 
approach. This form of analysis involves two major stages: preprocessing and data 
analysis. Significant preprocessing is necessary in rs-fMRI functional connectivity 
analyses as the neuronal BOLD signals-of-interest comprise around 3% of the total 
fMRI signal, with the rest considered noise (Bianciardi et al., 2009). If implemented 
correctly, preprocessing and data analysis can accurately and reliably detect BOLD 
activation in the resting brain, despite this noisy structure of the data. In what follows, 
an overview of preprocessing and data analysis methodologies are presented, with any 
deviations from the approach for a particular project stipulated in the relevant chapter. 
 
2.5.1. Registration 
One of the first steps in rs-fMRI preprocessing is functional image registration. 
Movement of research participants during the acquisition of a functional image can 
lead to specific brain tissue shifting from one voxel location to another over time. 
This can produce both false positives (voxels being incorrectly labelled as “active”) 
and false negatives (voxels being incorrectly labelled as “inactive”) during the 
analysis of data. This potential confound can be addressed by aligning each scan 3D 
fMRI scan within a 4D timeseries dataset to a reference scan, in a process called 
registration. Registration also serves the dual purpose of spatially aligning images 
with each other so that subsequent analysis steps can extract MRI data from consistent 
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anatomical locations across different scans or modalities (structural and functional 
MRI) for the same subject, or from the same location in different participants (Figure 
2.6). 
 
 
Figure 2.6: Image registration. An example of two BOLD images, one on the left that has 
not been registered to the target, and one on the right that has. The red squares indicate where 
a consistent neuroanatomical region should exist, the posterior horn of the left lateral 
ventricle, which aligns in the registered image but not the unregistered image. 
 
2.5.2. Temporal and spatial filtering 
Temporal and spatial filtering can be used to improve the signal-to-noise ratio (SNR) 
of functional MRI data. Temporal filtering is a process of identifying noise 
components by their frequencies. These noise components can be related to non-
neuronal sources due to scanner-related drifts or physiological effects. Scanner-
related drifts are slowly changing signals produced by imperfections of the MRI 
hardware, such as the heating of components within the scanner. Physiological effects 
are mainly induced by cardiac and respiratory processes (e.g. pulsatile motion of brain 
due to cardiac cycles). These effects are typically low frequency and their presence 
can be minimised within the data using temporal filtering (Woolrich et al., 2001). To 
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remove low frequency components, high-pass filtering is performed via the 
convolution of timeseries with the hemodynamic response function. The underlying 
idea is that the rate at which BOLD signal can change in the brain occurs at 
frequencies that are relatively well-defined, as they are constrained by blood flow 
around the brain. Therefore it is possible to choose a ‘smoothing kernel’ that 
maximises of the signal-of-interest relative to other frequencies. Assuming that the 
fMRI timeseries has a set of linearly separable components, including for instance 
high-frequency noise, low-frequency noise and low-frequency signal, using temporal 
filtering in this way can highlight the haemodynamics contributing to a functional 
MRI timeseries and reduce the noise. 
 
Spatial filtering (often referred to as spatial smoothing) involves using a smoothing 
kernel to blur data by calculating a locally weighted average of the intensities around 
each voxel at each point in time (Jenkinson and Chappell, 2018). Spatial filtering is 
able to increase SNR because averaging noise within the data will reduce the 
amplitude, whereas averaging signal has the effect of maintaining the same value. 
This is possible as long as neighbouring voxels contain signal of interest. The amount 
of smoothing that is chosen, specified as the full width at half maximum in 
millimetres, sets the size of the Gaussian kernel that is used to calculate the weights 
for local averaging. Performing spatial smoothing also enables the use of Gaussian 
random field theory which is used to correct for the issue of multiple testing (multiple 
comparisons) that assumes a level of smoothness to the data. An example of the effect 
of spatial smoothing on functional MRI data is shown in Figure 2.7. Implications of 
smoothing functional MRI data are discussed in Discussion section 7.3.3. 
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Figure 2.7: Spatial filtering. Spatial filtering enables an image to be smoothed to increase 
SNR, however it has the effect of blurring the image, as can be seen in this figure 
demonstrating the appearance of the same functional MRI image with no smoothing, 
smoothing with a 5mm and with a 10mm full width half maximum Gaussian kernel. 
 
2.5.3. Intensity normalisation 
Intensity normalisation (or grand mean scaling) is an important process applied in all 
fMRI analysis pipelines. The process provides a way of compensating for a variety of 
changes that exist between subject fMRI data. The mean intensity of an fMRI image 
is taken over all voxels and all points in time, and is then scaled to some fixed value. 
The effect is then consistent across all participants, and allows for a reduction in 
between-subject variance, improving statistical power at the group level (Jenkinson 
and Chappell, 2018). 
 
2.5.4. Independent component analysis denoising 
This thesis also used independent component analysis (ICA)-based denoising 
procedure to further increase the SNR. This process involves the decomposition of 4D 
fMRI data into sets of spatially-structured components (Beckmann and Smith, 2004). 
These vectors describe signal variation across the temporal domain (time-courses) and 
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across the spatial domain (maps) by optimising for non-Gaussian spatial source 
distributions using a fixed-point iteration technique (Hyvarinen, 1999). Component 
maps are also divided by the standard deviation of the residual noise and thresholded 
by fitting a mixture model to the histogram of intensity values. The value of each 
component in the spatial map represents the amount of that particular component’s 
timecourse that exists in the functional MRI data at each location (Jenkinson and 
Chappell, 2018). This process identifies voxels in a statistic image that share a large 
proportion of the same timecourse and therefore show areas of the brain that share a 
common signal and are likely part of the same network. This process produces a set of 
neuronal network components, however it can also be used to identify structured 
noise within the 4D image. Components labelled as signal can be left in the data, 
while the variance associated with noise components can be removed from the data 
using linear regression.  
 
2.6. Resting-state functional MRI: data analysis 
2.6.1. Resting-state fMRI data analysis: seed-based correlation analysis  
Seed-based correlation mapping is one of the most widely used approaches to study 
functional connectivity of brain regions (Zhang and Raichle, 2010). In a seed-based 
correlation analysis, a seed-ROI is chosen that forms the basis for the resulting 
functional connectivity map. This seed-ROI can be a single voxel, a whole structure 
or a functional region that is made up of a group of voxels. The aim of a seed-based 
correlation analysis is to create a ‘statistic image’ that describes the strength of 
functional connectivity of all voxels in the brain with the chosen seed-ROI. While 
seed-based analysis is not the only option for functional connectivity analyses, they 
are appropriate for hypothesis-driven experimentation with a priori ROIs (Zhang and 
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Raichle, 2010), as is undertaken in this thesis. To create this functional connectivity 
statistic image, average BOLD timeseries data is extracted from within the seed-ROI 
and correlated with all voxels in the brain at the individual-level general linear model 
(GLM) stage in a mass univariate approach (Figure 2.8). 
 
 
Figure 2.8: rs-fMRI seed-based correlation analyses. This figure shows how the average 
BOLD signal (activity) can be taken from a seed-ROI (A) and correlated with activity all 
around the brain using a general linear model framework. Areas of the brain that share a high 
temporal dependency in their timeseries (B, C, D) are said to show high functional 
connectivity with the seed region and are thus potentially part of the same functional network. 
Abbreviation: FC, functional connectivity. 
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2.6.2. General linear modelling: mass univariate approach 
Statistical analysis of functional MRI data begins at the voxel level, involving the 
analysis of the statistic image to assess possible experimental effects. This requires 
the use of a method that accounts for the inherent multiplicity of testing thousands of 
voxels simultaneously. This is performed using general linear modelling, first at the 
individual-level and secondly at the group-level. 
 
2.6.2.1. Individual-level GLM 
Individual-level GLMs are used to probe the relationship between the BOLD signal 
within seed-ROIs and the rest of the brain, in a voxelwise mass univariate manner. 
The goal of this process is to separate signal from noise, while maximising the true 
positive rate and minimising the false positive rate. To perform these individual-level 
GLMs, BOLD timeseries data extracted from within a seed-ROI act as explanatory 
variable, while timeseries data from nuisance variables serves as covariates that are 
regressed from the data. Nuisance regression involves extracting data from sources 
that may contribute noise to the functional MRI signal. Potential sources of noise 
include white matter, ventricles and whole brain activity (global signal) as well as 
head motion. Timeseries data for white matter, ventricles and whole brain regions 
area are created by using masks of these regions and extracting average activity at 
each point in the timeseries which can be regressed from the data. Head motion 
parameters can be quantified by calculating values for the rigid-body transformations 
used during image registration, which are then saved as a set of parameters that are 
regressed from the data. The output from the individual-level GLM approach is a 
whole-brain functional connectivity statistic image which is used in subsequent 
group-level analyses.  
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2.6.1.2. Group-level GLM 
In this thesis, comparing statistic images between experimental groups was performed 
using a group-level mass univariate GLM framework. This framework relates a 
dependent variable, which is each voxel within a statistic image, to an independent 
variable (an experimental condition), after removing the effects of group-level 
covariates (i.e. age, sex, years of education or medication data). The resulting statistic 
image is then assessed for statistical significance using random field theory which 
identifies voxels in the image where there is significant evidence to reject the null 
hypothesis (Friston et al., 1994, Poline et al., 1997, Worsley, 1995). This analysis is 
performed at each voxel within the brain, resulting in tens of thousands of voxels 
being analysed. Because of this, the problem of multiple comparisons is significant 
and a correction needs to be applied to the p-values to ensure the statistics are valid.  
 
Among the many approaches available, cluster-extent based thresholding is the most 
popular when analysing functional MRI data at the group level. This approach detects 
statistically significant clusters within a statistic image based on the number of 
contiguous voxels where the test statistic is above a pre-determined cluster-forming 
threshold (Woo et al., 2014). Rather than controlling the false positive probability of 
every voxel in the contiguous region, cluster-extent thresholding enables researchers 
to control the false positive probability of the region as a unified whole. A p-value is 
then calculated for each cluster based on its size and mass using the principles of 
Gaussian random field theory or permutation testing (Smith and Nichols, 2009). 
Benefits of cluster-extent thresholding include its high sensitivity when compared to 
other approaches such the Bonferroni method, and it accounts for the fact that 
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activation of voxels does not occur in isolation, but rather is dependent on the activity 
of neighbouring voxels, particularly in spatially smoothed data (Wager et al., 2007). 
There are other alternatives to cluster-based thresholding, addressed in Discussion 
section 7.3.3. 
 
2.7. Methodology summary 
This chapter has presented the key methodological components used for each project 
of this thesis. As all four projects were performed sequentially, there are a number of 
adaptations that were made between each one, based on feedback from both co-
authors and journal peer-reviewers. These iterations are stipulated within each project 
chapter, along with some necessary duplicity of methodological components as 
described above. Each subsequent chapter also contains the detailed literature as it is 
relevant to each project. This thesis will now present the body of research that 
comprises this PhD study, beginning with Project one, the analysis of the striatum.  
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3. Project one: Striatum 
This thesis begins by investigating the morphology and functional connectivity of the 
input structures to basal ganglia-thalamocortical circuits, the caudate nucleus and the 
putamen.  
 
 
Figure 3.1: Project One. The current project focusses on the morphology and functional 
connectivity of the striatum, as the key input hub to basal ganglia-thalamocortical circuitry. 
 
Research for this chapter is based on the following publication 
(https://doi.org/10.1016/j.pscychresns.2018.03.004): Striatal changes in Parkinson 
disease: An investigation of morphology, functional connectivity and their 
relationship to clinical symptoms. Psychiatry Research: Neuroimaging, 275, 5-13. 
 
This work can be presented in this thesis as the publisher Elsevier allow authors the 
right to distribute the article for Scholarly Sharing purposes (confirmed with the 
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publisher). The chapter appears in its published form, excluding page and section 
numbering, acronyms, small amendments and supplementary information which are 
changed to match the overall format of this thesis. Edits were also made based on 
feedback from thesis reviewers. 
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3.1. Abstract 
We sought to investigate morphological and resting state functional connectivity 
changes to the striatal nuclei in PD and examine whether changes were associated 
with measures of clinical function. Striatal nuclei were manually segmented on 3T-T1 
weighted MRI scans of 74 PD participants and 27 control subjects, quantitatively 
analysed for volume, shape and also functional connectivity using functional MRI 
data. Bilateral caudate nuclei and putamen volumes were significantly reduced in the 
PD cohort compared to controls. When looking at left and right hemispheres, the PD 
cohort had significantly smaller left caudate nucleus and right putamen volumes 
compared to controls. A significant correlation was found between greater atrophy of 
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the caudate nucleus and poorer cognitive function, and between greater atrophy of the 
putamen and more severe motor symptoms. Resting-state functional MRI analysis 
revealed altered functional connectivity of the striatal structures in the PD group. This 
research demonstrates that PD involves atrophic changes to the caudate nucleus and 
putamen that are linked to clinical dysfunction. Our work reveals important 
information about a key structure-function relationship in the brain and provides 
support for caudate nucleus and putamen atrophy as neuroimaging biomeasures in 
PD. 
 
3.2. Introduction 
PD is the second most common neurodegenerative disorder in the world, affecting 2-
3% of the population over the age of 65. Cardinal manifestations of PD include 
bradykinesia, postural instability, resting tremor and rigidity (Poewe et al., 2017). 
These motor symptoms are accompanied and often preceded by non-motor symptoms 
including executive dysfunction, impulse control disorders, obsessive compulsive 
disorders, psychotic symptoms, disorders of mood, autonomic dysfunction as well as 
sensory dysfunction and pain (Weintraub and Burn, 2011). Widespread 
neuropathological changes are found at autopsy in PD, relating to the presence of α-
synuclein-immunopositive Lewy bodies and neurites. This neuropathology is 
associated with a loss of dopaminergic neurons in the substantia nigra pars compacta, 
resulting in depletion of dopamine in the connected nuclei of the striatum (Obeso et 
al., 2008). 
 
Significant efforts have been made to better understand the neural basis of PD, with 
mounting evidence supporting the notion that clinical symptoms of the disease arise 
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from system-level dysfunctions in neuronal networks (Caligiore et al., 2016). To 
understand how neuronal network dysfunction in PD may produce clinical symptoms, 
both the component elements and also the interconnections within these networks 
require further examination (Looi et al., 2014). Investigating the component elements 
can be achieved by measuring morphological changes to neuroanatomical loci or 
‘hubs’ which are central nodes within neuronal networks (Buckner et al., 2009). The 
interconnections between hubs can be investigated by studying white matter tracts of 
the brain, or ‘spokes’, which potentially yield information about disease related 
connectivity changes (Looi et al., 2014). A growing number of resting-state functional 
MRI (rs-fMRI) studies are using activation in brain regions and the correlation of 
timeseries fluctuations between brain regions to infer information the connectivity of 
the brain. While these methods do not directly investigate white matter tracts in the 
brain, the hypothesis is that correlated fluctuations accurately reflect synchronised 
variations of neuronal activity in a network of regions (Birn et al., 2008). Studying 
functional connectivity in this way enables us to investigate possible connectivity 
changes to the nuclei of the striatum associated with PD.  
 
Using the theoretical framework of hubs and spokes and how they are affected in PD 
may produce neuroimaging biomeasures that reveal information about the neural 
circuit basis of the clinical dysfunction observed in PD. If empirically validated, these 
biomeasures can be used as biomarkers that help clinicians monitor disease 
progression and aid surgical treatments that target the restoration of function to large-
scale networks in neurodegenerative diseases such as PD (Looi et al., 2014). 
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Our study focuses on two subcortical nuclei within the basal ganglia, the bilateral 
caudate nucleus and bilateral putamen, which form the dorsal striatum (herein 
referred to as the striatum). The caudate nucleus is primarily involved with emotion 
regulation, reward processing, decision making and executive functioning, while the 
putamen is primarily associated with the planning and implementation of motor 
functions (Alexander et al., 1986). Neuroimaging research has supported these 
putative functional roles as being related to the connectivity of fronto-striato-palladio-
thalamo-cortical re-entrant circuits (herein referred to as basal ganglia-thalamocortical 
circuits) that link specific areas of the cortex with the nuclei of the striatum, globus 
pallidus and the thalamus (Haber, 2003). Due to the to the strategic location and 
connectivity of the caudate nuclei and the putamen within basal ganglia-
thalamocortical circuits, morphological changes to these nuclei may be linked to the 
clinical functioning of patients with the disease. Further, changes to the functional 
connectivity of basal ganglia-thalamocortical circuitry may uncover more information 
about the putative network breakdown that underpins clinical symptoms in PD.  
 
The findings of research in this field are varied and thus necessitate further 
investigation. A number of research groups have demonstrated significant striatal 
volumetric differences in PD cohorts compared to control groups (Geng et al., 2006, 
Hopes et al., 2016, Pitcher et al., 2012, Sterling et al., 2013), while other studies have 
failed to detect these atrophic changes (Almeida et al., 2003, Apostolova et al., 2010, 
Garg et al., 2015, Menke et al., 2014, Messina et al., 2011). Research investigating 
localised shape changes to the striatum has demonstrated that the head of the caudate 
nucleus (Apostolova et al., 2010, Pitcher et al., 2012, Sterling et al., 2013) and the 
more caudal regions of the putamen (Nemmi et al., 2015, Sterling et al., 2013) are 
3.Project one: Striatum 
 60 
structurally affected in PD, while other research groups have failed to find such 
changes (Garg et al., 2015, Menke et al., 2014, Messina et al., 2011). A number of 
research groups have demonstrated relationships between morphology of the striatum 
and the clinical functioning of PD patients (Apostolova et al., 2010, Geng et al., 2006, 
Nemmi et al., 2015, Pitcher et al., 2012, Sterling et al., 2013). Apostolova et al., 
(2010) demonstrated a trend-level correlation between atrophy of the head of the 
caudate and scores of general cognitive function in a PD cohort. Nemmi et al., (2015) 
demonstrated a correlation between atrophy of the putamen and general motor 
function as measured by the UPDRS-III, while Pitcher et al., (2012) demonstrated a 
correlation between striatal volumes and disease staging as measured by the H&Y 
test. Finally, Sterling et al., (2013) found that surface deflation of the ventrolateral 
putamen and body and dorsal surfaces of the caudate was correlated with cognitive 
function. Despite this, a number of other groups have failed to find associations 
between structural changes to the striatal nculei and measures of clinical function, 
necessitating further investigation (Almeida et al., 2003, Garg et al., 2015, 
Geevarghese et al., 2014, Lewis et al., 2016, Mak et al., 2015). Regarding intrinsic 
connectivity differences between PD cohorts and controls, rs-fMRI research using a 
comparable seed-based methodology has demonstrated altered connectivity of the 
putamen with the parietal lobe (Helmich et al., 2010) and reduced connectivity of the 
striatal nuclei with the extended brainstem region (Hacker et al., 2012).  
 
We investigated striatal changes in PD by performing a region-of-interest manual 
segmentation of the caudate nucleus and putamen in participants MRI data, producing 
morphological information for subsequent analysis. The relationship between striatal 
morphology and clinical function was assessed using regression models, and further 
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investigated via the use of rs-fMRI analysis. Due to our use of a manual region-of-
interest tracing of striatal structures, comprehensive clinical data set and adjunct 
resting-state functional connectivity analysis, our study is well positioned to help 
clarify areas of ambiguity and further develop this field of enquiry.  
 
We hypothesised that there would be significant reductions in striatal volumes in the 
PD cohort relative to the control subjects and that these reductions would be more 
pronounced in advanced disease stages, as measured by disease duration. We 
hypothesised that the PD group would display localised shape changes to the anterior 
caudate nucleus and the posterior putamen, due to disease-related dopaminergic 
depletion at these sites. In the PD cohort, we hypothesised that atrophy of the caudate 
nucleus and putamen would be correlated with poorer performance on measures of 
cognitive and motor performance, respectively. We hypothesised that localised 
atrophy (represented by surface change) to the head of the caudate nucleus would be 
associated with poorer cognitive function, while atrophy of the posterior putamen 
would be associated with poorer motoric function. Finally, we hypothesised that PD 
patients would display altered frontostriatal functional connectivity that would relate 
to the clinical symptoms observed in the disease. 
 
3.3. Methods 
3.3.1. Subjects 
Participants in this research (n = 101) were derived from the Lund University 
BioFinders Study. All participants gave informed written consent, the research was 
performed in accordance with the World Medical Association’s Declaration of 
Helsinki, and ethical approval was obtained through the Ethical Review Board of 
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Lund, Sweden, and the Human Research Ethics Committee at the Australian National 
University, Canberra, Australia. Diagnosis of probable PD (Total PD cohort of n = 
74) was based on the National Institute of Neurological and Stroke Diagnostic 
Criteria (Gelb et al., 1999). Categorisation of participants into PD disease subgroups 
was based on years since clinical diagnosis, with Early PD (n = 34) 5 years or less, 
Late PD (n = 23) longer than 5 years and advanced PD (PDD) (n = 17) comprising 
individuals with PD who also received a diagnoses of probable PD dementia (Emre et 
al., 2007). The demarcation of early and late PD based on a disease duration of 5 
years has been experimentally chosen as a crucial disease progression milestone due 
to changes in medication response often found after this time period. This is shown by 
the fact that positive response to levodopa medication within 5 years of diagnosis is 
one of the supportive diagnostic criteria in the UK Parkinson’s Disease Society Brain 
Bank for diagnosing Parkinson disease (Jankovic, 2008). A healthy control group 
(Control) (n = 27) was used for comparison. All participants underwent a thorough 
medical history, cognitive and neurological examination. Exclusion criteria included 
poor knowledge of the Swedish language, developmental disability, psychiatric 
disorder and a history of alcohol or substance abuse, as detailed in (Hall et al., 2012). 
A resting-state functional connectivity analysis was performed on 53 PD and 25 
Control subjects, after meeting image quality assurance standards outlined in section 
‘3.3.4 Resting-state functional connectivity of the striatum.’ 
 
Clinical functioning of participants was measured using the following tests; The 
Unified Parkinson’s disease Rating Scale part-III (UPDRS-III) assessing the motor 
signs of PD (Fahn and Elton, 1987); the Timed Up and Go (TUG) test, assessing 
mobility (Podsiadlo and Richardson, 1991); the Animal Fluency and Letter S Fluency 
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tests, assessing verbal fluency and executive function (Tombaugh et al., 1999); the 
Mini Mental State Examination (MMSE), assessing cognitive mental state  (Folstein 
et al., 1975) and the A Quick Test of Cognitive Speed (AQT) test, assessing 
perception and cognitive speed (Palmqvist et al., 2010). 
 
3.3.2. MRI acquisition 
Magnetic resonance imaging was performed on a 3T scanner (Trio, Siemens 
Magnetom, Erlangen, Germany) equipped with a 20-channel head-coil. High-
resolution T1-weighted three-dimensional anatomical brain images were acquired 
using a magnetisation-prepared rapid acquisition technique with gradient-echo 
sequence (repetition time = 7 ms; echo time = 3 ms; flip angle = 90 degrees; voxel 
size = 1mm3 isotropic). Parameters were 256 mm in the coronal and sagittal planes 
and 176 mm in the axial plane. The rs-fMRI protocol consisted of 256 T2*-weighted 
echo planar imaging volumes (repetition time = 1850 ms; echo time 30 ms; flip angle 
= 90 degrees; voxel size 3 × 3 × 3.75 mm3). Parameters were 61 voxels in the sagittal 
and axial planes and 73 voxels in the coronal plane. Subjects were instructed to lie 
still with their eyes closed, not to think of anything in particular and not to fall asleep 
during the scan. 
 
3.3.3. Manual segmentation of the striatum 
Manual region-of-interest segmentations of the bilateral caudate nucleus and putamen 
were performed in a blinded fashion by C-OW, using ANALYZE 11.0 software 
(Mayo Clinic, Rochester, Minnesota, USA) on an Apple Mac computer (MacBook 
Pro, Apple Inc., Cupertino, California, USA) using previously validated protocols  
(Looi et al., 2009, Looi et al., 2008). For a detailed description, see Methodology 
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section 2.2.1 and 2.2.2. Test-retest reliability statistics of the manual segmentation 
process is provided in Appendix 1. 
 
3.3.4. Resting-state functional connectivity of the striatum 
The rs-fMRI analysis was performed using a pipeline involving AFNI and FSL 
software packages (Cox, 1996, Jenkinson et al., 2012). Quality assurance criteria 
excluded subjects who had more than 1.5mm maximum displacement in the x, y, or z 
plane or greater than 1.5° of angular rotation about any axis. As an extra 
precautionary step, the voxel-to-voxel BOLD-signal correlations across the whole 
brain (including GM, WM and CSF) were calculated and summed with outliers in this 
measure (4%) removed as they are likely to have originated in a motion-induced 
global signal capable of eluding conventional motion detection  (He and Liu, 2012). 
Pre-processing of the fMRI data included deletion of the first 5 time frames in each 
dataset to ensure signals reached the steady state, spatial smoothing with a Gaussian 
filter (full width half maximum = 4mm) and temporal filtering with a band-pass filter 
(0.01–0.1Hz). Data was then corrected for slice-dependent time shifts and a head 
motion correction was performed using AFNI’s 3dvolreg based on 6-parameter rigid 
body image registration. T1-weighted images were then skull-stripped and segmented 
in grey matter, white matter, and cerebrospinal fluid maps using FSL’s automated 
Brain Extraction Tool (Smith, 2002). The fMRI data was first co-registered to the T1-
weighted images acquired from the same subject and then normalised to the 152-brain 
Montreal Neurological Institute normalised space. The timeseries of regions-of-
interest in the white matter and cerebrospinal fluid, as well as the 6 affine motion 
parameters, were used as nuisance variables and regressed out of the data using a 
general linear model. 
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Functional connectivity was examined using a seed voxel correlation approach. Two 
seed areas representing the caudate nucleus and putamen were based on the manual 
segmentation mask for each individual, resampled to 3 x 3 x 3 mm3 standard space to 
enable extraction of timeseries from each subject’s rs-fMRI data. Correlation 
functional analyses were performed by computing temporal correlation between each 
seed reference area and the rest of the brain in a voxel-wise manner. The correlation 
coefficients in each voxel were then transformed to z-value images using the Fisher r-
to-z transformation to improve normality, creating an entire brain z-value map for 
each subject. 
 
3.3.5. Statistical analysis  
Statistical analyses were performed using SPSS 22.0 (IBM Corporation, Somers, New 
York, USA). Estimated total intracranial volumes (eTIV) were used to control for 
head size derived from FreeSurfer’s recon-all analysis (Fischl, 2012).  This research 
was conducted in an a priori planned-analysis style based on the hypotheses of the 
study. When comparing the morphology of striatal structures between the groups, 
significant volumetric findings were a prerequisite for further investigation of 
localised shape changes. Similarly, when investigating the relationship between 
striatal morphology and clinical functioning of PD patients, significant volumetric 
findings were a prerequisite for further investigation of localised shape change. 
Significant results at the Total PD level was also a prerequisite for further analysis at 
the PD disease subgroup level. Bonferroni family-wise error rate corrections were 
incorporated into our analyses to control for the problem of multiple 
comparisons/tests (Mcdonald, 2014). 
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3.3.6. Group comparisons: volume 
Between-groups striatal volumetric differences were investigated via a multivariate 
analysis of covariance (MANCOVA) model with adjustments for age, eTIV and sex 
(covariates). Effect sizes are represented via partial eta squared values (h2). 
Preliminary checks were conducted to ensure that there was no violation of the 
assumptions of normality, linearity, homogeneity of variances, homogeneity of 
regression slopes, and reliable measurement of the covariate (Pallant, 2013). 
 
3.3.7. Group comparisons: shape 
Shape analysis was performed using spherical harmonic parameterization and 
sampling in a three-dimensional point distribution model (SPHARM-PDM) (Styner et 
al., 2006), outlined in full in Methodology section 2.3.2. Generally speaking, 
SPHARM-PDM shape analysis uses the masks of participants right and left caudate 
nucleus and putamen created during the manual segmentation process, providing 
visualisations of the local surface changes to the structures via mean difference 
displacement maps. These maps display the magnitude of surface change (deflation or 
inflation) in millimeters between corresponding points on the mean surfaces of the 
caudate nuclei or putamen in patients with PD relative to the Control group, or 
between disease subgroups. 
 
3.3.8. Correlations between morphology and clinical symptoms: volume  
Correlational analyses between clinical function and striatal volume were investigated 
via the use of hierarchical multiple regression analyses controlling for covariates and 
also years of education (the latter only for measures of cognitive function). Effect 
sizes are represented by standardised beta values (b). Preliminary checks were 
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conducted to ensure that there were no violations of the assumptions of normality, 
linearity, multicollinearity and homoscedasticity (Pallant, 2013). 
 
3.3.9. Correlations between morphology and clinical symptoms: shape 
Shape analysis investigating the relationship between surface morphology and 
measures of clinical function followed a SPHARM-PDM method that produces local 
correlation coefficient maps that represent the relationship between inflation/deflation 
at surface regions and performance on clinical function tests. 
 
3.3.10. Resting-state functional connectivity analysis 
Individual z-value maps were entered into a 2-sample t-test to identify group 
differences in connectivity between the Total PD group and Control groups for the 
right and left caudate nucleus and putamen. Age and gender were used as nuisance 
covariates in all statistical analyses, as well as grey matter intensity maps as a voxel-
level covariate. We employed a spatially connected minimum cluster size of 14 
voxels (p < 0.05) and a t-value of > 2.90 (p < 0.05) with a false discovery rate 
correction at the cluster level. Multiple correction values were produced using an 
AFNI AlphaSim Monte Carlo inference tool which indicated that a minimum cluster 
size of 14 was significant at p < 0.05 (uncorrected voxel threshold p = 0.005, 1-sided 
t-test, FWHM = 4mm, 1000 iterations). 
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3.4. Results 
Table 3.1: Demographic and clinical characteristics of participants 
Items Control Early PD Late PD PDD Total PD 
N 27 34 23 17 74 
Sex (m:f) 15:12 16:18 12:11 10:7 38:36 
Age (years) 69.47 
± 6.09 
69.65  
± 5.42 
70.19  
± 6.57 
73.70 ± 
6.67 
70.75 
± 6.22 
eTIV (cm3) 1550.68  
± 156.38 
1539.17 
± 187.02 
1584.01 
± 183.65 
1562.33 
± 225.09 
1558.43  
± 193.55 
DD (years) - 2.82  
± 1.38 
10.43  
± 3.76 
11.88  
± 5.48 
7.27 
± 5.39 
Edu (years) 12.54 
± 3.47 
9.29  
± 5.79 
13.05  
± 5.65 
11.5  
± 4.52 
11.02 
± 5.69 
UPDRS-III$ -2.26 
± 2.82 
-11.29  
± 5.76 
-15.78  
± 12.61 
-33.00  
± 12.21 
-17.68  
± 12.67 
TUG$ -8.59 
± 1.45 
-10.33  
± 2.47 
-15.78  
± 12.61 
-12.73  
± 6.47 
-10.48 
± 3.48 
AF 23.56 
± 6.80 
22.21  
± 5.75 
21.09  
± 7.23 
11.81  
± 4.18 
19.58 
± 7.22 
LSF 18.56 
± 6.26 
13.41  
± 4.67 
16.76  
± 6.66 
9.31  
± 4.24 
13.48 
± 5.83 
MMSE 28.56 
± 1.34 
28.26  
± 1.54 
28.30  
± 1.36 
22.88  
± 3.77 
27.04 
± 3.16 
AQT$ -60.41 
± 15.73 
-71.09  
± 24.32 
-66.26  
± 13.73 
-132.93  
± 73.26 
-81.72  
± 44.64 
Key: Values are expressed as mean ± standard deviation excluding the variable of sex which 
denotes the male to female ratio; all data correct to 2 decimal places. Abbreviations: N, 
number of participants; eTIV, estimated total intracranial volume ; DD, disease duration; 
Edu, years of education; UPDRS-III, Unified Parkinson’s Disease Rating Scale part III; 
TUG, Timed Up and Go; AF, Animal Fluency; LSF, Letter S Fluency; MMSE, Mini Mental-
State Examination; $ scores for these clinical measures were inverted so that increasing scores 
became representative of better performance; AQT, A Quick Test of Cognitive Speed;  
 
3.4.1. Participant characteristics 
Two chi-square tests for independence were used to investigate the relationship 
between sex and group membership between Total PD and Control groups as well as 
between the disease progression and Control groups (p = 0.88 and p = 0.086, 
respectively). Three independent samples t-tests were conducted to investigate the 
relationships between age, eTIV, years of education and group membership at the 
Total PD and Control group level (p = 0.36, 0.85 and 0.22, respectively). Three one-
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way analyses of variance were conducted to investigate the relationships between 
these participant characteristics and group membership at the PD disease progression 
subgroup and Control group level (p = 0.11, p = 0.84 and p = 0.04, respectively). 
While a significance was found between years of education and group membership at 
the disease subgroup level, post hoc tests found no significant differences between 
any disease subgroups and or between subgroups and the Control group. Estimated 
mean volumes of striatal structures are presented in Table 3.2. 
 
Table 3.2: Estimated mean volumes of striatal structures 
Region of interest  
Control 
(mm3) 
Total PD 
(mm3) 
Early PD 
(mm3) 
Late PD 
(mm3) 
PDD  
(mm3) 
Bilateral caudate nucleus 7571.33  
± 839.17 
7138.32 
± 1105.11  
7397.18 
± 1084.78 
7325.22  
± 997.73  
6367.76  
± 976.10  
Right caudate nucleus 3796.89 
± 422.36  
3600.28 
± 565.83  
3746.00 
± 569.69  
3662.22 
± 446.95 
3225.06 
± 562.53  
Left caudate nucleus 3774.44 
± 449.53 
3538.04  
± 565.04  
3651.18 
± 539.11 
3663.00  
± 564.64 
3142.71  
± 450.88  
Bilateral putamen 6669.74 
± 1048.03 
6233.69  
± 1019.62  
6374.76 
± 965.83  
6337.91 
± 937.811  
5810.53  
± 1167.00  
Right putamen  3263.22 
± 539.19  
3047.62  
± 514.71 
3125.06 
± 534.45 
3065.74  
± 464.64  
2868.24  
± 524.72  
Left putamen 3406.52 
± 578.86 
3186.07  
± 573.31  
3249.71 
± 485.86 
3272.17 
± 562.92 
2942.29 
± 703.30  
Key: Data presented as mean ± standard deviation; data correct to 2 decimal places. 
 
3.4.2. Group comparisons: volume 
Pairwise comparisons of the striatal structures are presented in Table 3.3. Bilateral 
caudate nuclei and bilateral putamina volumes were significantly reduced in the Total 
PD cohort compared to the Control group (p = 0.049 and p = 0.032 respectively). Left 
caudate nucleus and the right putamen volumes were significantly reduced in the 
Total PD cohort compared to the Control group (p = 0.041 and p = 0.038 
respectively). Due to these significant results, following our a priori planned 
comparisons style, disease subgroup analysis (Table 3.4) only focussed on bilateral 
caudate nucleus and putamen volumes, left caudate nucleus and right putamen 
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volumes. This analysis revealed the bilateral caudate nuclei volumes in the PDD 
group to be significantly smaller than the Control and Early PD groups (p = 0.001 and 
p = 0.004 respectively). Volumes of the left caudate nucleus were found to be 
significantly smaller in the PDD group compared to the Control, Early PD and Late 
PD groups (p = 0.001, p = 0.01 and p = 0.038, respectively). The effect sizes for all 
significant results were all of a small magnitude as indicated by their h2 values. 
 
Table 3.3: MANCOVA comparisons of striatal structures - Total PD and Controls 
Region of interest [Group 1] [Group 2] 
Mean difference 
[1-2] (mm3) p value h2 
Bilateral caudate nucleus Control Total PD 400.391 0.049* 0.040 
Right caudate nucleus Control Total PD 181.024 0.081 0.031 
Left caudate nucleus Control Total PD 219.367 0.041* 0.043 
Bilateral putamen Control Total PD 397.185 0.032* 0.047 
Right putamen Control Total PD 196.553 0.038* 0.044 
Left putamen Control Total PD 200.632 0.070 0.034 
Key: h2, partial eta squared; * significant at p < 0.05; p-values adjusted for multiple 
comparisons in the model using a Bonferroni correction; data correct to 3 decimal places with 
mean differences in mm3. 
 
Table 3.4: MANCOVA comparisons of striatal structures - PD disease groups and 
Controls 
Region of interest [Group 1] [Group 2] 
Mean difference  
[1-2] (mm3) p value$ h2 
Bilateral caudate nucleus 
 
Control 
Control 
Control 
Early PD 150.817 1.000 0.154 
Late PD 321.433 1.00 0.154 
PDD 1054.166 0.001* 0.154 
Early PD 
Early PD 
Late PD 170.617 1.000 0.154 
PDD 903.349 0.004* 0.154 
Late PD PDD 732.732 0.055 0.154 
Left caudate nucleus 
 
Control 
Control 
Control 
Early PD 112.66 1.000 0.147 
Late PD 146.923 1.000 0.147 
PDD 553.770 0.001* 0.147 
Early PD 
Early PD 
Late PD 34.263 1.000 0.147 
PDD 441.111 0.01* 0.147 
Late PD PDD 406.847 0.038* 0.147 
Bilateral putamen 
 
 
Control 
Control 
Control 
Early PD 260.705 1.000 0.075 
Late PD 410.964 0.463 0.075 
PDD 673.908 0.058 0.075 
Early PD 
Early PD 
Late PD 150.26 1.000 0.075 
PDD 413.203 0.574 0.075 
Late PD PDD 262.944 1.000 0.075 
Right putamen 
 
 
Control 
Control 
Control 
Early PD 120.379 1.000 0.068 
Late PD 237.956 0.275 0.068 
PDD 303.18 0.134 0.068 
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Early PD 
Early PD 
Late PD 117.577 1.000 0.068 
PDD 182.802 0.89 0.068 
Late PD PDD 65.225 1.000 0.068 
Key: h2, partial eta squared; * significant at p < 0.05; $ adjustment for multiple comparisons 
incorporated into the model: Bonferroni; data are correct to 3 decimal places. Note that 
duplicates of MANCOVA comparisons were removed from the table (i.e 1 – 2 and 2 – 1). 
 
3.4.3. Group comparisons: shape 
SPHARM-PDM shape analysis found no localised areas of shape change to the 
surface of the caudate nucleus or putamen in the Total PD group compared to the 
Control group, after accounting for the false-discovery rate (Figure 3.2). Following 
the a priori planned comparisons style, further between-group investigation at the 
disease subgroup level was not performed. 
 
 
Figure 3.2: Group difference in localised shape of the caudate nucleus and putamen 
between Total PD and Control groups. For ease of reference we present the data by 
structure (caudate nucleus top, putamen bottom), with medial and lateral views of structure 
shown. Mean difference displacement maps occupy the left two columns, raw p-value 
significance maps occupy the middle two columns and false-discovery rate (FDR) corrected 
p-value significance maps the right two columns. Displacement colour scale corresponds to 
the millimetres of deflation/inflation of the surface in that region; warmer colours 
corresponding to greater degrees of deflation and cooler colours corresponding to greater 
degrees of inflation. For the raw and FDR p-value significance scale, warmer colours 
correspond to lower p values while cooler colours correspond to higher p values. Anterior 
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ends of the structures are to the left of the image. 
 
3.4.4. Correlations between morphology and clinical symptoms: volume 
The results from the hierarchical regression analyses of striatal volumes and 
performance on measures of clinical function are presented in Table 3.5 and 
Appendix Table 1 for PD disease subgroups. When investigating the relationship 
between volume and clinical function in the Total PD cohort, after controlling for 
family-wise error rate using the Bonferroni method, the amended p-value required to 
reach significance (based on performing 36 individual regression analyses) was p < 
0.0014. Using this criteria, a significant positive correlation was found between 
volumes of the bilateral putamen and improved performance on the UPDRS-III test (p 
= 0.001358). Significant positive correlations were also found between volumes of 
the bilateral, right and left caudate nuclei and improved performance on the MMSE 
test (p = 0.000563, p =  0.00132 and p = 0.000565, respectively) and also on the ‘A 
Quick Test of Cognitive Speed’ test (p = 0.000113, p =  0.000189 and p = 0.000193, 
respectively) in the Total PD group. Based on standardised beta values, these 
relationships were all of medium and large effect size as shown in Table 3.3 (small 
effect, b: 0.01-0.29; medium effect, b: 0.30-0.49; large effect, b: 0.50-1.00 ) (Cohen, 
1992). At the disease subgroup level of analysis, no significant results were found 
after controlling for multiple comparisons. 
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Table 3.5: Correlations between striatal volumes and clinical function - Total PD and 
Controls 
Group Nuclei 
Clinical 
measure R2 change b p value 
Control BPV UPDRS-III 0.002 -0.064 0.83 
Total PD   0.118 0.438 0.001358** 
Control RPV  0.011 0.246 0.615 
Total PD   0.105 0.410 0.0027 
Control LPV  0.026 -0.213 0.429 
Total PD   0.091 0.360 0.005 
Control BPV TUG 0.000 -0.02 0.946 
Total PD   0.057 0.305 0.050 
Control RPV  0.013 0.161 0.584 
Total PD   0.035 0.237 0.127 
Control LPV  0.014 -0.159 0.559 
Total PD   0.056 0.284 0.052 
Control BCV AF 0.010 0.085 0.593 
Total PD   0.085 0.350 0.021 
Control RCV  0.005 -0.102 0.694 
Total PD   0.081 0.341 0.024 
Control LCV  0.012 -0.134 0.545 
Total PD   0.078 0.331 0.027 
Control BCV LSF 0.134 -0.482 0.029 
Total PD   0.069 0.315 0.037 
Control RCV  0.094 -0.432 0.075 
Total PD   0.066 0.306 0.042 
Control LCV  0.149 -0.470 0.021 
Total PD   0.064 0.300 0.045 
Control BCV MMSE <0.001 -0.009 0.963 
Total PD   0.176 0.504 0.000563** 
Control RCV  <0.001 0.023 0.911 
Total PD   0.154 0.47 0.00132** 
Control LCV  <0.001 -0.031 0.863 
Total PD   0.176 0.497 0.000565** 
Control BCV AQT 0.013 -0.152 0.531 
Total PD   0.224 0.569 0.000113** 
Control RCV  0.017 -0.183 0.483 
Total PD   0.211 0.550 0.000189** 
Control LCV  0.009 -0.116 0.606 
PD   0.210 0.544 0.000193** 
Key: b, standardised beta values; ** significant at the Bonferroni corrected p < 0.0014; Data 
correct to 3 decimal places, except where expanded to display statistical accuracy.. 
Abbreviations: BCV, bilateral caudate nucleus volume; RCV, right caudate nucleus volume; 
LCV, left caudate nucleus volume; BPV, bilateral putamen volume; RPV, right putamen 
volume; LPV, left putamen volume; UPDRS-III, Unified Parkinson’s Disease Rating Scale 
part III; TUG, Timed Up and Go; AF, Animal Fluency; LSF, Letter S Fluency; MMSE, Mini 
Mental-State Examination; AQT, A Quick Test of Cognitive Speed.  
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3.4.5 Correlations between morphology and clinical symptoms: shape  
SPHARM-PDM shape analysis found a significant positive correlation between 
surface volumes of the medial-anterior and dorsal areas of the right caudate nucleus 
and performance on the Animal Fluency test in the Total PD group (Figure 3.3). 
 
 
Figure 3.3: SPHARM-PDM within-group correlational analysis of the right caudate 
nuclei surfaces with performance on the Animal Fluency test in the Total PD group. 
Pearson correlation coefficient colour map (left) and false discovery rate corrected p-value 
(right). Pearson correlation coefficient colour maps visualise the degree of positive and 
negative correlation of the surface at that region. Warmer colours (red) correspond to negative 
correlation coefficients while cooler colours (blue) to positive correlation coefficients. 
 
3.4.6. Resting state functional connectivity of striatal nuclei 
The results of the investigation into the functional connectivity of the striatal nuclei 
are shown in Figure 3.4 and Figure 3.5 with the data displayed in Table 3.6 and 3.7. 
In the Total PD group, we found areas of increased functional connectivity of the 
caudate nucleus with medial frontal gyrus, anterior cingulate and superior frontal 
gyrus. Decreased functional connectivity was found between the caudate nucleus and 
the brainstem, thalamus, parahippocampal gyrus and precuneus. The PD group also 
showed decreased connectivity of the putamen with the cerebellum, inferior and 
superior parietal lobules. 
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Table 3.6: Group difference on functional connectivity with caudate between Total PD 
and Controls 
 
Brain regions Hemisphere Voxels 
MNI coordinate 
t-  x y z 
Increased Medial Frontal Gyrus R 63 -6 -57 4 4.05 
 Anterior Cingulate R 19 -3 1 -5 4.48 
 Superior Frontal L 17 26 -54 5 3.84 
Decreased Brainstem - 20 -2 26 -45 -3.39 
 Thalamus R 18 0 3 4 -3.12 
 Parahippocampus L 14 14 4 -11 -3.24 
 Precuneus L 14 19 55 30 -3.34 
Key: Coordinates were defined in the MNI space. Abbreviations: FC, functional 
connectivity; R, right; L, left. 
 
 
Figure 3.4: Group difference in functional connectivity of the caudate between Total PD 
and Controls. The statistical maps are overlayed on a T1-weighted MNI template at the 
threshold of p < 0.05, corrected for multiple comparisons. Hot colours (red) represents 
increased functional connectivity whereas cold colours (blue) represents decreased functional 
connectivity in the Total PD group compared to the Control group. The colour bar displays 
the t-value. Abbreviations: R, right; L, left. 
 
Table 3.7 Reduced putamen seed functional connectivity in Total PD group comparing with 
Controls. 
 
Brain regions Hemisphere Voxels 
MNI coordinate 
t-  x y z 
Decreased Cerebellum L 263 15 55 -58 -3.64 
 Inferior Parietal L 31 52 46 46 -4.25 
 Superior Parietal L 25 30 62 46 -3.22 
Key: Coordinates were defined in the MNI space. Abbreviations: FC, functional 
connectivity; R, right; L, left. 
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Figure 3.5: Reduced putamen seed functional connectivity in Total PD group compared 
with the Controls. The statistical maps are overlayed on a T1-weighted MNI template at the 
threshold of p < 0.05, corrected for multiple comparisons. Cold colours (blue) represents 
decreased functional connectivity in the Total PD group compared to the Control group. The 
colour bar displays the t-value. Abbreviations: R, right; L, left.   
 
3.5. Discussion  
3.5.1. Discussion 
We conducted a thorough morphological investigation of the striatum in PD, how 
morphological changes relate to clinical symptoms, and how the functional 
connectivity of the striatum is altered in the disease. We found that PD subjects had 
significantly smaller bilateral caudate nuclei and putamina volumes compared to the 
Control group, supporting the findings of similar research in this field (Pitcher et al., 
2012, Sterling et al., 2013). As lateralised analysis only demonstrated volumetric 
reductions of the left caudate nucleus and the right putamen, our results only partially 
support our hypotheses. Regarding possible mechanisms that may explain these 
findings, research in this field often argues that atrophy of striatal nuclei is linked to 
the loss of nigrostriatal neurons, resulting in fluctuating or depleted levels of 
dopamine in the striatum (Pitcher et al., 2012, Sterling et al., 2013). Supporting this 
explanation, experimental research using MPTP-treated monkeys has demonstrated 
that striatal spine loss is dependent on the degree of dopamine depletion, even in the 
absence of observable motor symptoms  (Villalba et al., 2009). Another possibility is 
that PD related Lewy pathology in striatal projection sites may cause structural 
changes to the striatum via a trans-synaptic spread of neurodegeneration. Researchers 
have argued that proteopathic agents may take seed in projection sites and spread 
along the neuraxis over time (Power and Looi, 2015) with the striatum particularly 
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vulnerable to this neurodegenerative process due to its position as a key hub within 
widescale neuronal networks (Looi and Walterfang, 2013).  
 
Our findings contrast with a number of research groups who found no volumetric 
difference between a PD cohort and a control group  (Garg et al., 2015, Menke et al., 
2014, Messina et al., 2011, Nemmi et al., 2015). As these previous studies used semi-
automated region-of-interest segmentation methods, our results are important because 
we employed a manual segmentation protocol which is considered the gold-standard 
approach  (Morey et al., 2009). However, a methodological factor that should be 
raised when considering our findings is our inclusion of 17 participants in the Total 
PD group who had received a clinical diagnosis of PD with dementia. The inclusion 
of these participants raises the possibility that the pathophysiology underlying the 
dementia diagnosis may contribute to atrophic changes to the striatum in the Total PD 
group. Supporting this idea, when investigating striatal volumes at the disease 
subgroup level, we found considerable bilateral and left caudate nuclei atrophy when 
comparing Controls and the PDD group, but not when comparing Controls to PD 
patients without dementia (the Early PD and Late PD groups). The inclusion of PD 
patients with dementia is an important issue and warrants further discussion. 
Estimates of the point prevalence of PD patients who are also diagnosed with 
dementia is around 30-40% (Emre et al., 2007). Longitudinal research indicates that 5 
years after initial diagnosis, 28% of PD patients will be diagnosed with dementia, 
while after 15 years this prevalence increases to 50% (Emre et al., 2007). These 
statistics indicate a strong temporal link between the progression of PD and patients 
developing dementia, and it was for this reason that participants who were diagnosed 
with dementia were not excluded from our study. Our research approach ensures that 
3.Project one: Striatum 
 78 
the PD cohort analysed is a comprehensive one that closely resembles a clinical PD 
cohort, including participants from across the entire spectrum of the PD disease 
course.  
 
A conceivable reason why we only found volumetric changes to the left caudate 
nucleus and the right putamen could relate to disease lateralisation. In PD the decline 
in dopamine capacity in the striatum has been shown to be pronounced in the 
contralateral hemisphere to the more clinically affected side (Politis, 2014). If the 
proposed mechanism linking fluctuating or depleted levels of dopamine with cellular 
and structural changes in the striatum is accepted, PD participants with motor 
symptom dominance to a particular hemisphere may have lateralised disease related 
structural changes that were not controlled for in this research. 
 
Using an advanced shape analysis technique, we attempted to uncover the exact 
location of the atrophic changes that were found at the volumetric level by analysing 
surface changes between the Total PD and Control groups, however, no localised 
surface changes were found. Our results thus do not support our between-group 
comparison hypotheses and they contrast with previous research (Apostolova et al., 
2010, Nemmi et al., 2015, Pitcher et al., 2012, Sterling et al., 2013) that has 
demonstrated localised striatal atrophy corresponding to areas of the greatest 
dopaminergic depletion. A possible explanation for the differences in findings across 
this field of research may relate to variability in symptom profiles of PD patients. It is 
widely recognised that PD is a complex heterogeneous neurodegenerative syndrome 
with a range of clinicopathologic phenotypes. For this reason, we should consider the 
possible effects of disease subtype variability across studies, as different subtypes 
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may have unique pathological footprints in the brain (Thenganatt and Jankovic, 2014) 
making the comparison between studies difficult. 
 
When investigating the relationship between morphology and clinical function in the 
Total PD group, we found significant positive correlations between caudate nuclei 
volumes and higher levels of cognitive function, and also between putamen volumes 
and higher levels of motor function, supporting our hypotheses. Specifically, we 
demonstrated that higher caudate nuclei volumes were positively correlated with 
better performance on the MMSE and A Quick Test of Cognitive Speed tests. We also 
found that higher bilateral putamen volumes were correlated with better performance, 
or lower levels of motor dysfunction, as measured by the UPDRS-III test. After 
surviving a strict corrections for multiple comparisons, and with relationships of 
medium and large effect sizes, our findings clearly demonstrate that greater atrophy of 
the caudate nuclei is associated with poorer cognitive functioning, and that greater 
atrophy of the putamen is associated with greater motor dysfunction. Interestingly, the 
relationship between striatal volumes and clinical function was not found in Control 
subjects, highlighting the importance of the PD disease process in influencing the 
structure of the striatal nuclei and consequently clinical function in turn. Our results 
indicate that the striatum plays an important role in the cognitive and motor 
symptomology of PD and that atrophy of the caudate nucleus and putamen may be 
indicative of a breakdown to the frontostriatal circuits subserving cognitive and motor 
function.  
 
Our findings for the caudate nucleus support previous research (Pitcher et al., 2012), 
however they contrast with recent studies that found no relationship between caudate 
3.Project one: Striatum 
 80 
volumes and measures of executive or general cognitive function (Lewis et al., 2016, 
Mak et al., 2015). Our findings showing the relationship between putamen atrophy 
and UPDRS-III scores also contrast with recent research (Mak et al., 2014, Nemmi et 
al., 2015), and as discussed, possible differences in symptom and disease subtype 
profiles of participants between studies may contribute to these inconsistencies. 
 
In the Total PD group, analyses of striatal shape found significant positive 
correlations between performance on the Animal Fluency test and surface volumes in 
general areas of the right caudate nucleus connected to the dorsolateral prefrontal 
cortex, the area of the brain that mediates executive function (Haber, 2003). This 
particular result makes intuitive sense as the Animal Fluency test is designed to 
measure aspects of executive function. However, there were a number of non-
significant results in this section of analysis, meaning our findings only partially 
support our hypotheses.  
 
Our results contrast with previous research that has demonstrated regionally 
pronounced trend-level correlations between MMSE scores and the head of the 
caudate nucleus (Apostolova et al., 2010) and significant correlations between the 
volumes of the head of the caudate nucleus and measures of cognitive performance 
(Sterling et al., 2013). Due to these inconsistencies, further work is still needed to 
precisely map how the morphology of these structures change in PD and how this 
relates to clinical functioning of patients with the disease.  
 
Adding to the findings of volumetric changes to the striatal nuclei in PD, we also 
detected changes to the functional connectivity of both the caudate nucleus and the 
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putamen in PD. We found minor increases in functional connectivity between the 
caudate nucleus and the medial frontal and superior frontal gyri, as well as to the 
anterior cingulate. We found decreases in functional connectivity between the caudate 
nucleus and regions of the brainstem, thalamus, parahippocampal gyrus and 
precuneus, while the putamen showed decreases in functional connectivity with the 
cerebellum, inferior and superior parietal lobes.  
 
Our findings of decreased connectivity with the brainstem concord with recent 
research (Hacker et al., 2012) and support the notion that certain clinical 
manifestations of PD such as sleep disturbances and dysautonomia may relate to 
brainstem dysfunction. Reduced connectivity of the caudate nuclei with the thalamus 
supports the notion that changes to the striatal nuclei in PD may indicate a breakdown 
in frontostriatal circuits that help execute and mediate planned, motivated behaviours  
(Haber, 2003). The findings of reduced connectivity of the putamen with the areas of 
the parietal lobule support previous research and may indicate a change in functional 
connectivity between the structure and components of the sensorimotor system 
(Helmich et al., 2010). While it may seem counter-intuitive to find both increases and 
decreases in intrinsic connectivity of the caudate nucleus in our PD group, similar 
results have been found in previous research, and may reflect functional 
compensation of the brain in response to disease related damage (Helmich et al., 
2010). Our morphological results support this proposition, as while the PD group 
demonstrated atrophy of the caudate nucleus that correlated with poorer cognitive 
performance, our functional connectivity analysis revealed increases in functional 
connectivity of the structure with regions of frontal cortex that mediate aspects of 
cognitive function. It is possible that these increases of functional connectivity in PD 
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are a response to the atrophic damage that takes place in the caudate nucleus in the 
disease (Helmich et al., 2010).   
 
While our findings of altered functional connectivity to both striatal nuclei conform 
with recent work, dealing with the caudate nucleus and putamen as unitary structures 
in functional connectivity analyses may obscure more precise changes that may be 
able to be demonstrated if functional subterritories were used (Hacker et al., 2012). 
Future research on how these modalities could be used in a more complimentary 
fashion will now be discussed along with possible limitations of this research. 
 
3.5.2. Limitations and future research 
Our methodological approach investigated possible localised shape change using 
SPHARM-PDM in an adjunct fashion, only when we had found significant 
volumetric results for a particular section of the analysis. Using this a priori planned 
analysis approach, it is possible that we may have missed a range of subtle disease 
related changes that were not found when investigating morphology at the volumetric 
level. We should also acknowledge the small number of control subjects in this 
research, which may have impacted our results. To bring more clarity to the 
relationship between morphology, functional connectivity and clinical symptoms, 
future research will use parcellations of striatal nuclei with targeted regions of interest 
in the cortex also incorporating clinical function data into the functional connectivity 
analyses. It is hoped that this will improve the concordance between the different 
neuroimaging processing modalities and may yield more precise information about 
the relationship between striatal morphology, functional connectivity and their 
relationship to specific clinical symptoms in PD. 
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3.5.3. Conclusion 
This research serves as a comprehensive morphological, clinical and functional 
connectivity analysis of the striatum in PD. We have demonstrated that atrophic 
changes to the striatal nuclei take place in PD compared to controls. We found that 
atrophy of the caudate nucleus within the PD group is associated with slower 
processing and poorer overall cognitive performance, while atrophic changes to the 
putamen are associated with more significant motor symptoms. We also found altered 
resting-state connectivity of both striatal nuclei in PD compared to Controls. Our 
research indicates that both the ‘hubs’ and ‘spokes’ within neuronal networks are 
affected in PD, supporting a neural circuit basis for the clinical dysfunction observed 
in the disease. Our research highlights the importance of the striatum as a crucial 
neuroanatomical structure within frontostriatal networks and indicates a potential 
usefulness of striatal volumes as neuroimaging biomeasures in PD, reinforcing the 
importance of these nuclei to the clinical manifestations of the disease. 
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4. Project two: Thalamus 
Project one of this thesis investigated the morphology and functional connectivity of 
the caudate nucleus and putamen, the main input structures of basal ganglia-
thalamocortical circuits. Project two focusses on the output structures of these 
circuits, the bilateral thalami, to investigate possible neuroimaging biomarkers of 
clinical dysfunction in PD. This chapter is based on a published manuscript, however 
as with Project one, certain elements have been changed to streamline the project with 
the thesis. 
 
 
Figure 4.1: Project two. The current project focusses on the thalamus as the key output 
hub of basal ganglia-thalamocortical circuitry, coupled with the fact that the structure 
contributes to the abnormal neural activity in PD and is vulnerable to the Lewy pathology 
underlying the disorder (Halliday, 2009). 
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This chapter is based on the following publication; Owens-Walton, C., Jakabek, D., 
Power, B. D., Walterfang, M., Velakoulis, D., Van Westen, D., Looi, J. C. L., Shaw, 
M. & Hansson, O. 2019. Increased functional connectivity of thalamic subdivisions in 
patients with Parkinson’s disease. PLOS ONE, 14, e0222002. However, it appears in 
here in a modified form to streamline it with the thesis as a whole.  
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4.1. Abstract 
Parkinson’s disease (PD) affects 2-3% of the population over the age of 65 with loss 
of dopaminergic neurons in the substantia nigra impacting the functioning of basal 
ganglia-thalamocortical circuits. The precise role played by the thalamus is unknown, 
despite its critical role in the functioning of the cerebral cortex, and the abnormal 
neuronal activity of the structure in PD. Our objective was to more clearly elucidate 
how functional connectivity and morphology of the thalamus are impacted in PD (n = 
32) compared to Controls (n = 20). To investigate functional connectivity of the 
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thalamus we subdivided the structure into two important regions-of-interest, the first 
with putative connections to the motor cortices and the second with putative 
connections to prefrontal cortices. We then investigated potential differences in the 
size and shape of the thalamus in PD, and how morphology and functional 
connectivity relate to clinical variables. Our data demonstrate that PD is associated 
with increases in functional connectivity between motor subdivisions of the thalamus 
and the supplementary motor area, and between prefrontal thalamic subdivisions and 
nuclei of the basal ganglia, anterior and dorsolateral prefrontal cortices, as well as the 
anterior and paracingulate gyri. These results suggest that PD is associated with 
increased functional connectivity of subdivisions of the thalamus which may be 
indicative alterations to basal ganglia-thalamocortical circuitry. 
 
4.2. Introduction 
PD is the second most common neurodegenerative disorder in the world, affecting 2-
3% of the population over the age of 65 (Poewe et al., 2017). Characteristic motor 
symptoms of the disorder include resting tremor, rigidity and postural instability. 
These are accompanied by non-motor symptoms including cognitive impairment 
(executive dysfunction, memory deficits, hallucinations and dementia), autonomic 
dysfunction (urogenital dysfunction, hypotension and constipation), disorders of 
sleep-wake cycle regulation, sensory disturbances (hyposmia) and pain (Schapira et 
al., 2017). The neuropathological hallmark of PD is the presence of α-synuclein-
immunopositive Lewy bodies and neurites (Dickson et al., 2009). This 
neuropathology results in a degeneration of nigrostriatal dopaminergic neurons, 
depletion of dopamine across the striatum (Kish et al., 1988) and consequent 
dysfunction of basal ganglia-thalamocortical networks (Alexander et al., 1986). 
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Dysfunction of these circuits is critical as they work in concert with the cortex to 
orchestrate and mediate a range of cognitive, motor and limbic functions in the brain 
(Haber, 2003).  
 
To understand the functioning of a network, it is necessary to study the elements of 
the network and also their interconnections (Sporns et al., 2005). Investigating 
elements of brain networks can be done via studying the morphology of key 
neuroanatomical nuclei acting as ‘hubs’ within these networks (Sporns et al., 2007). 
Hubs are nodes within brain networks that make strong contributions to global 
network function (Van Den Heuvel and Sporns, 2013) and the interconnections 
between these hubs can be investigated through the use of resting-state functional 
connectivity MRI methods that measure the functioning of intrinsic connectivity 
networks in the brain at rest (Biswal et al., 1995). Spontaneous fluctuations of the 
blood oxygen level-dependent (BOLD) signal that are temporally coherent indicate 
areas in the brain that may be functionally and anatomically related (Fox and Raichle, 
2007).  
 
As dopamine replacement therapies provide some relief of motor symptoms in PD, 
significant research effort has focused on the role played by dopaminergic-depleted 
nuclei of the striatum (Caligiore et al., 2016). However, there is now considerable 
evidence that the pathology underlying PD affects certain nuclei in the thalamus, and 
that the structure plays an important role in PD as loss of dopaminergic input to the 
striatum results in increased GABA-mediated inhibition of thalamocortical 
projections (Obeso et al., 2008). The thalamus, considered an integrative hub within 
functional brain networks (Hwang et al., 2017), is thus an important neuroanatomical 
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structure which we can use to investigate how basal ganglia-thalamocortical circuits 
are affected in PD, potentially revealing important information about the 
pathophysiology of the disease. 
 
There is a clear lack of consensus in this field of research, necessitating further 
investigation. Functional connectivity studies implicating the thalamus have yielded 
inconsistent results with research demonstrating both increased coupling between the 
thalamus and sensorimotor regions in PD (Agosta et al., 2014b) and no significant 
differences in thalamic functional connectivity in PD (Bell et al., 2015). Studies have 
indicated that PD is associated with thalamic volumetric changes compared to control 
groups (Lee et al., 2011), while other work presents conflicting results showing no 
differences in thalamic volumes in a PD cohort compared to control participants  (Lee 
et al., 2014, Mak et al., 2015, Mckeown et al., 2008, Menke et al., 2014, Messina et 
al., 2011, Nemmi et al., 2015, Tinaz et al., 2011). Research has demonstrated subtle 
changes to the surface of the thalamus in a PD cohort compared to controls (Garg et 
al., 2015, Mckeown et al., 2008). Garg et al., (2015) found atrophy primarily in the 
mediodorsal aspect of the thalamus in PD compared to controls, which has 
connectivity with limbic and cognitive areas of the brain. McKeown et al., (2008) 
found a small area of atrophy to midline areas of the thalamus, which they link to the 
centre-median parafasicular region of the thalamus. This area receives input from the 
cerebral cortex as well as subcortical structures like the globus pallidus, midbrain 
regions like the superior colliculus, and plays an important role in attention and 
arousal (Jones, 2012). Other research has found no significant localised shape changes 
to the thalamus in PD participants compared to controls (Lee et al., 2014, Menke et 
al., 2014, Nemmi et al., 2015). Although the thalamus plays a key modulatory role in 
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the brain, there is a lack of evidence for a relationship between thalamus volumes and 
clinical function (Lee et al., 2014, Mak et al., 2014, Mak et al., 2015, Tinaz et al., 
2011).  
  
We hypothesised that there would be reductions in volumes of the thalamus in PD 
patients compared to controls based on the presence of PD neuropathology and the 
associated cell loss found post-mortem (Halliday, 2009). We also hypothesised that 
there would be localised surface changes to medial regions of thalamus in PD, 
compared to controls. We hypothesised that there would be a correlation between 
smaller overall volumes of the thalamus and poorer performance on measures of 
clinical function. Finally, we hypothesised that there would be functional connectivity 
changes in our PD group due to the integral position the thalamus occupies within 
basal ganglia-thalamocortical circuits. 
 
4.3. Methods 
4.3.1. Participants 
Participants in this research were members of the Swedish BioFINDER Study 
(www.biofinder.se). The study is based in Sweden and is affiliated with the Clinical 
Memory Research Unit and The Biomedical Centre, both at Lund University. 
Participants were recruited from the Memory and neurology clinics at Skåne 
University Hospital. Participants gave written informed consent and this research was 
performed in accordance with the World Medical Association’s Declaration of 
Helsinki. Participants in the current study received their clinical assessments between 
23/05/2012 and 13/03/2014. Ethical approval was obtained through the Ethical 
Review Board of Lund, Sweden, and the Human Research Ethics Committee at the 
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Australian National University, Canberra, Australia. Diagnosis of PD (n = 32) was 
made by a neurologist using the National Institute of Neurological and Stroke 
Diagnostic criteria (Gelb et al., 1999). A healthy control group (Controls) (n = 20) 
was used for comparison. Exclusion criteria for the Swedish BioFinder study included 
poor knowledge of the Swedish language, developmental disability, psychiatric 
disorder, alcohol or substance abuse or the presence of a metabolic disorder. This 
current study also had an exclusion criteria of a diagnosis of probable PD dementia 
(Emre et al., 2007). A healthy control group (Controls) (n = 26) was used for 
comparison. As new and more thorough preprocessing analyses were performed by 
the primary author, COW, relative to Project one, the numbers of participants in the 
current study were different to those outlined in the previous chapter, primarily 
relating to the use in this project of more stringent head motion exclusion criteria 
during functional MRI acquisition, which resulted in the exclusion of a number of 
participants. A preliminary investigation of functional MRI data indicated a 
significant difference in subject head motion during image acquisition. We therefore 
implemented a strict study-specific head motion exclusion criterion of > 0.26mm 
(defined as mean relative displacement) and used advanced denoising procedures 
(FSL-FIX) as nuisance regression can be insufficient in removing the spurious effects 
of movement artefacts in MRI data (Power et al., 2012). 
 
All participants underwent a cognitive and neurological examination by a medical 
doctor with extensive experience in movement disorders. PD patients remained on 
medication as per their usual regime for both MRI acquisition and clinical assessment, 
with a levodopa equivalent daily dosage (LEDD) metric recorded for each participant. 
Functioning of participants was quantified using the Unified Parkinson’s Disease 
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Rating Scale Part-III test (UPDRS-III), to assess the motor signs of PD (Fahn and 
Elton, 1987); the Mini Mental State Examination (MMSE), to assess cognitive mental 
state (Folstein et al., 1975); the Timed Up and Go (TUG) test, assessing mobility 
(Podsiadlo and Richardson, 1991), the Animal Fluency and Letter S Fluency tests, 
assessing verbal fluency and executive function (Tombaugh et al., 1999) and the A 
Quick Test of Cognitive Speed (AQT) test, assessing perception and cognitive speed 
(Palmqvist et al., 2010). 
 
4.3.2. MRI acquisition 
Magnetic resonance imaging was performed on a 3T scanner (Trio, Siemens 
Magnetom, Erlangen, Germany) equipped with a 20-channel head-coil. High-
resolution T1-weighted three-dimensional anatomical brain images were acquired 
using a magnetization-prepared rapid acquisition technique with gradient-echo 
sequence (repetition time = 7 ms; echo time = 3 ms; flip angle = 90 degrees; voxel 
size = isotropic 1=mm3). Image matrix size was 356 voxels in the coronal and sagittal 
planes and 176 voxels in the axial plane.  
 
Resting state functional magnetic resonance images (rs-fMRI) (256 volumes per 
subject) were acquired using T2*-weighted echo planar imaging volumes (repetition 
time = 1850 ms; echo time 30 ms; flip angle = 90 degrees; matrix 64 × 64; voxel size 
3 × 3 × 3.75 mm3). Image matrix size was 64 voxels in the coronal and sagittal planes 
and 36 voxels in the axial plane. Subjects were instructed to lie still with their eyes 
closed, not to fall asleep and not to think of anything in particular during the scan, 
which lasted for approximately 8 minutes. 
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4.3.3. Manual segmentation of the thalamus 
Manual ROI tracing was performed on participant’s T1-weighted structural MRI data 
using ANALYZE 12.0 software (Mayo Biomedical Imaging Resource, Rochester, 
Minnesota, USA) following a validated method (Power et al., 2015). See 
Methodology 2.2.3 for a full description. Associated reliability statistics are presented 
in Appendices Section 1: Tracing reliability of manual ROI segmentation. The tracing 
for each thalamus was saved as a binary image for rs-fMRI seed-based functional 
connectivity and shape-based morphological analyses.  
 
4.3.4. Resting-state functional connectivity preprocessing 
All rs-fMRI preprocessing used FMRIB Software Library (FSL) software package 
tools (FMRIB Software Library, Oxford, UK; FSL version 5.0.10, 
RRID:SCR_002823) (Jenkinson et al., 2012). FMRI Expert Analysis Tool (FEAT) 
(version 6.00) was used for the removal of the first 6 volumes, motion correction 
using FMRIB Motion Correction Linear Registration Tool (MCFLIRT) (Jenkinson et 
al., 2002); slice-timing correction using Fourier-space timeseries phase-shifting, 
removal of non-brain structures using FSL’s Brain Extraction Tool (BET) (Smith, 
2002); spatial smoothing using a full-width half-maximum gaussian kernel of 5 mm, 
grand mean intensity normalization and high-pass temporal filtering (gaussian-
weighted least-squares straight line fitting, with sigma = 50.0s) (Woolrich et al., 
2001). Registration of functional images to participant’s high resolution T1-weighted 
structural images used boundary-based registration (Greve and Fischl, 2009) within 
the FLIRT linear registration tool (Jenkinson et al., 2002, Jenkinson and Smith, 2001). 
Registration of functional images to Montreal Neurological Institute (MNI) 152 T1 
2mm3 standard space was also performed using FLIRT with 12 degrees of freedom, 
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further refined using FNIRT nonlinear registration (Andersson et al., 2007a, 
Andersson et al., 2007b) with a warp resolution of 10mm and a resampling resolution 
of 4mm. Denoising of head motion, scanner and cerebrospinal fluid artefacts was 
performed using a probabilistic Multivariate Exploratory Linear Optimized 
Decomposition into Independent Components (MELODIC version 3.15) independent 
component analysis method (Beckmann and Smith, 2004). To do this, observations 
were decomposed into sets of vectors describing the variation of signal across both 
the temporal (time-courses) and spatial (maps) domains, optimising for non-Gaussian 
spatial source distributions using a fixed-point iteration technique (Hyvarinen, 1999). 
The FSL-FIX classifier (version 1.06) (Salimi-Khorshidi et al., 2014) was then trained 
on our particular dataset by first running the ‘Standard.RData trained-weights’ 
classifier over a sample of ICA maps for 10 Controls and 10 PD participants, with the 
classifier categorising maps as either ‘signal’ or ‘noise’. We checked each 
classification against the validated guidelines of Griffanti et al. (2014), choosing the 
conservative approach to component reclassification as outlined in that work. 
Following this, the FIX classifier was re-trained using this new data and run over the 
ICA datasets for all participants, regressing out noise components while also cleaning 
up motion confounds (24 regressors: 6 motion parameters, 6 first derivatives and the 
squares of these 12 regressors). This process creates a de-noised filtered functional 
file which is used at the individual-level GLM stage. 
 
The Oxford Thalamic Structural Connectivity Probability Atlas (Behrens et al., 2003) 
within FSL’s visualization GUI FSLEyes was used to parcellate bilateral thalamic 
manual segmentation masks into two seed regions-of-interest masks (seed-ROIs) 
(Figure 4.2), representing important functional subdivisions of the thalamus. Due to 
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the cardinal motor symptoms in PD, our first seed-ROI incorporated voxels with the 
highest probability of connectivity with pre- and primary motor cortices and are 
intended to represent the ventral lateral posterior, ventral lateral and ventral anterior 
thalamic nuclei. Due to the significant cognitive dysfunction observed in PD, our 
second seed-ROI incorporated voxels with the highest probability of connectivity to 
the prefrontal cortex, intended to represent the mediodorsal and anterior thalamic 
nuclei (Behrens et al., 2003). For ease of reference we will refer to these seed-ROIs as 
the VLp/VA thalamus and MD/A thalamus, respectively. Generic VLp/VA and 
MD/A thalamic masks were thresholded to only include voxels that had a greater than 
50% chance of inclusion, then registered to subject-specific functional MRI space, 
and finally eroded by zeroing non-zero voxels when found in kernel, to reduce partial 
volume effects. A visual inspection of a subset of VLp/VA and MD/A masks was 
then performed to check the alignment of masks within functional data. We then 
extracted the mean activation of the functional data within the two seed-ROI masks at 
each functional timepoint for use as explanatory variables at the individual-level 
general linear model (GLM) stage in a mass univariate voxelwise whole-brain 
analysis.  
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Figure 4.2. Positioning and likelihood-map of seed voxels for VLp/VA and MD/A 
thalamic masks. This figure displays the voxels used in seed-ROI masks for the 
functional connectivity analyses, overlaid on MNI T1 0.5mm images. Key: This 
image was produced by combining all of the binary masks of each participant into one 
unified mask, with warm (yellow - red) colors indicating the positioning of the 
VLp/VA voxels and cold colors (light blue - dark blue) indicating the positioning of 
the MD/A voxels. Darker tones are indicative of a greater proportion of voxels in that 
region being included in the relevant seed-ROI mask. VLp/VA, ventral lateral 
posterior and ventral anterior thalamic voxels; MD/A, mediodorsal and anterior 
thalamic voxels. 
 
4.3.5. Resting-state fMRI statistical analyses 
Two individual-level FC analyses were performed for each participant, using a GLM 
approach (Woolrich et al., 2004). BOLD timeseries data within the VLp/VA and 
MD/A thalamus were correlated with activity in the rest of the brain, shifting the 
model with a temporal derivative to account for lags in the onset of the hemodynamic 
response function, removing volumes corrupted by large motion and regressing out 
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average timeseries data from whole brain (global signal regression), white matter and 
ventricle masks. Higher-level analysis of FC differences between PD and Control 
subjects were investigated in standard space using FSL-FEAT. We chose a 
nonparametric permutation-based approach (n = 5000) (Nichols and Holmes, 2002) 
via FSL-randomise (Winkler et al., 2014) with a threshold-free cluster enhancement 
method controlling the family-wise error rate at p < 0.05. This approach avoids 
selecting arbitrary threshold values, while also potentially improving sensitivity to test 
signal shapes and SNR values (Smith and Nichols, 2009). Due to there being a 
significant difference in education between PD and Control groups, we included years 
of education as a covariate, along with age and sex. 
 
4.3.6. Correlation between functional connectivity and clinical data 
To investigate the relationship between FC and clinical variables we conducted a 
series of post-hoc partial correlational analyses. These focused on the average 
parameter estimate for VLp/VA and MD/A thalamus at the peak voxel locations 
derived from the between group analyses. Spherical ROIs (7mm radius) were 
generated around the voxel locations with the average parameter estimate extracted 
for each subject. Average FC for each ROI was then correlated against LED, disease 
duration, UPDRS-III, TUG, AQT and Animal Fluency scores. 
 
 
4.3.7. Group comparisons: volume 
Statistical analyses of volumetric data were performed with SPSS 22.0 (IBM 
Corporation, Somers, New York, USA) utilising multivariate analysis of covariance 
models controlling for head size (eTIV, derived from recon-all FreeSurfer processing 
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(Fischl, 2012), age and sex. p-values were adjusted for family-wise error rate using a 
Bonferroni correction. Effect sizes are represented by partial eta squared values (h2). 
 
4.3.8. Group comparisons: shape 
Shape analysis was performed using spherical harmonic parameterisation and 
sampling in a three-dimensional point distribution model (SPHARM-PDM) (Styner et 
al., 2006) outlined in detail in Methodology section 2.4.2. Generally speaking, 
SPHARM-PDM shape analysis provides visualisations of the local surface changes to 
the thalamus between groups via mean difference displacement maps, mapping the 
magnitude of surface change (deflation or inflation) in millimetres between 
corresponding points on the mean surfaces of the PD participants compared to 
Controls. Significant surface change was displayed at p < 0.05 with a correction for 
multiple comparisons performed using a false-discovery rate (FDR) bound q of 5% 
(Genovese et al., 2002). 
 
4.3.9. Correlations between morphology and clinical symptoms: volume 
We used hierarchical multiple regression models to assess whether thalamic volumes 
can predict clinical symptoms. These models incorporated two levels, the first level 
controlled for eTIV, age, sex and years of education (the latter when dealing with 
measures of cognitive function), and the second level held the independent variable of 
interest (volume of right or left thalamus), measuring the unique contribution of that 
variable in predicting each measure of clinical function. Effect sizes are represented 
by standardized beta values (b).  
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4.3.10. Correlations between morphology and clinical symptoms: shape 
Shape analyses investigating the relationship between surface morphology and 
measures of clinical function followed a SPHARM-PDM method that produces local 
correlation coefficient maps that represent the relationship between inflation/deflation 
at surface regions and performance on clinical function tests. 
 
4.4. Results 
4.4.1. Participant characteristics 
There were no significant differences in age, head size (eTIV) or proportions of males 
and females in groups, between the PD cohort and Controls. Years of education, 
UPDRS-III and AQT performance was significantly reduced in PD compared to 
Controls (Table 4.1). 
 
Table 4.1. Demographic and clinical characteristics of participants. 
Item Controls PD p-value 
Number of participants 20 32 - 
Female/Male 10/10 18/14 0.878 
Age 69.06 ± 6.86 69.36 ± 5.82 0.868 
LED - 523.36 ± 295.31 - 
Disease duration - 5.16 ± 3.62 - 
eTIV (cm3) 156.81 ± 15.84 152.06 ± 17.71 0.333 
Years of education 13.14 ± 3.68 9.78 ± 6.05 0.042 
Relative displacement 0.13 ± 0.06 0.16 ± 0.06 0.066 
H&Y - 1.75 ± 0.55 - 
UPDRS-III 2.40 ± 3.02 10.69 ± 7.06 <0.001 
TUG 8.60 ± 1.54 9.68 ± 2.39 0.079 
MMSE 28.8 ± 1.2 28.28 ± 1.42 0.18 
AQT 57.25 ± 15.09 66.47 ±14.78 0.035 
AF 24.80 ± 6.59 23.03 ± 5.67 0.309 
Data presented as mean ± standard deviation; p-values, one-way independent samples t-test, 
excluding male/female numbers which was analyzed via a chi-square test for independence; 
LED, levodopa equivalent dosage (mg); eTIV, estimated total intracranial volume; Relative 
displacement, mean value derived from MCFLIRT FSL motion correction; H&Y, Hoehn and 
Yahr Scale; UPDRS-III, Unified Parkinson’s Disease Rating Scale part III; TUG, Timed Up 
and Go test; MMSE, Mini Mental-state Examination; AQT, A quick test of cognitive speed; 
AF, Animal fluency test. 
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4.4.2. Functional connectivity of the VLp/VA thalamus in PD 
Analysis of the VLp/VA thalamus in PD found significant clusters of increased FC 
with the right supplementary motor area (BA6) and the left paracingulate gyrus 
(BA32). Analysis of the VLp/VA thalamus also found a significant cluster of 
decreased FC with the left lateral occipital cortex (BA19) (Fig 4.3, Table 4.2). 
 
 
Figure 4.3: VLp/VA thalamus functional connectivity. p-value images showing 
neuroanatomical regions with significant between-group changes in functional 
connectivity with the VLp/VA thalamus in PD subjects compared to Controls. Key: 
Warm colours (yellow-orange) represent areas of increased functional connectivity in 
PD and cool colours (light-dark blue) represent areas of decreased functional 
connectivity in PD. Spacing between each slice in the z-direction is 4.2mm beginning 
at z = -3.18 in the top left slice (MNI T1 2mm image). R, right; A, anterior; PCG, 
paracingulate gyrus; SMA, supplementary motor area; LOC, lateral occipital cortex. 
 
Table 4.2.  Regions showing functional connectivity differences with the VLp/VA 
thalamus in PD. 
FC 
Cluster Peak Brain Regions Voxels 
MNI 
x y z 
Increased 1 R Supplementary motor area (BA6) 64 12 -2 42 
 2 L Paracingulate gyrus (BA32) 11 -4 10 42 
 3 R Supplementary motor area (BA6) 10 10 6 44 
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Decreased 4 L Lateral occipital cortex (BA19) 18 -30 -86 24 
 5 L Lateral occipital cortex (BA19) 10 -26 -66 46 
 6 L Lateral occipital cortex (BA19) 3 -26 -68 56 
Brain regions and associated coordinates represent significant peaks within each cluster (p < 
0.05). Abbreviations: FC, functional connectivity; L, left hemisphere; R, right hemisphere; 
BA, Brodmann area; MNI, coordinates for location of peak voxels in Montreal Neurological 
Institute 152 T1 2mm space. Labelling of brain regions based on the Harvard-Oxford 
Cortical/Subcortical Atlases. 
 
4.4.3. Functional connectivity of the MD/A thalamus in PD 
Analysis of the MD/A thalamus in PD found significant clusters of increased FC with 
the left anterior cingulate (BA24) and left putamen (Fig 4.4, Table 4.3). These clusters 
extended across the following brain regions: the bilateral anterior (BA24) and 
paracingulate gyri (BA32), left caudate nucleus, left putamen, left globus pallidus, 
bilateral dorsolateral prefrontal cortex (BA9) and bilateral anterior prefrontal cortex 
(BA8). Analysis of the VLp/VA thalamus also found a significant cluster of decreased 
FC with the left lateral occipital cortex (BA19). 
 
 
 
Figure 4.4: MD/A thalamus functional connectivity. p-value images showing 
neuroanatomical regions with significant between-group changes in functional 
connectivity of the MD/A thalamus in PD subjects compared to Controls. Warm 
colors (yellow-orange) represent areas of increased functional connectivity in PD. 
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Spacing between each slice in the z-direction is 4mm beginning at z = -2.3 in the top 
left slice (MNI T1 2mm image). R, right; A, anterior; Put, putamen; GP, globus 
pallidus; CN, caudate nucleus; PCG, paracingulate gyrus; ACC, anterior cingulate 
cortex; DLPFC, dorsolateral prefrontal cortex; APFC, anterior prefrontal cortex. 
 
Table 4.3.  Regions showing functional connectivity differences with the MD/A thalamus 
in PD. 
FC 
Cluster Peak Brain Regions Voxels 
MNI 
x y z 
Increased 7 L anterior cingulate (BA24) 4319 -8 18 22 
 8 L putamen (BA49) 268 -20 10 -4 
Decreased 9 L lateral occipital cortex (BA19) 10 -18 -78 52 
Brain regions and associated coordinates represent significant peaks within each cluster (p < 
0.05). Abbreviations: FC, functional connectivity; L, left hemisphere; R, right hemisphere; 
BA, Brodmann area; MNI, coordinates for location of peak voxels in Montreal Neurological 
Institute 152 T1 2mm space; Labelling of brain regions are based on the Harvard-Oxford 
Cortical/Subcortical Atlases. 
 
4.4.4. Correlation between functional connectivity and clinical data 
In PD patients we observed a positive correlation between LED and mean FC of the 
right supplementary motor area (peak 3; r = 0.46, p = 0.01) and a negative correlation 
with the left lateral occipital cortex (peak 4; r = -0.41, p = 0.04). We also observed a 
positive correlation between disease duration and mean FC of the right supplementary 
motor area (peak 1; r = 0.41, p = 0.03; peak 3; r = 0.57, p = 0.01). We also observed a 
positive correlation between TUG scores and mean FC of the left paracingulate gyrus 
(peak 2; r = 0.43, p = 0.02) and lateral occipital cortex (peak 6; r = 0.43, p = 0.02; 
peak 9; r = 0.37, p = 0.047). None of these results survived correction for multiple 
comparisons. 
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4.4.5. Morphology of the thalamus in PD 
Comparisons of thalamic volumes found no difference between the PD group and 
Controls (Table 4.4).  
 
Table 4.4: Estimated mean volumes of right and left thalamus and pairwise comparison. 
Structure Control PD Mean difference p-value 
Right thalamus volume (mm3) 5774.13 5927.45 -153.32 0.25 
Left thalamus volume (mm3) 5594.47 5749.24 -154.78 0.18 
Estimated volumes of the right and left thalamus after adjusting for age, eTIV and sex. p-
value presented has been adjusted for family-wise error rate using a Bonferroni correction. 
 
4.4.6. Surface based shape analysis 
Shape analysis found no localized areas of shape change to the surface of the right or 
left thalamus in the PD group compared to Controls, after correcting for false-
discovery rate (Fig 4.5). 
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Figure 4.5: Shape analysis of thalamus in PD compared to Controls. Displayed are 
superior and inferior views of bilateral thalami overlaid on axial MNI T1 0.5mm 
images. Warmer colors indicate regions of greater inflation in the PD group compared 
to Controls using point-wise significance tests (p < 0.05, uncorrected). No regions 
were significant after false-discovery rate correction. 
 
4.4.7. Correlations between thalamic volumes and clinical symptoms in PD 
We found no significant relationships between volumes of the right or left thalamus 
and clinical function in the PD or Control groups. 
 
4.5. Discussion 
4.5.1. Findings 
The results of this study demonstrate that PD patients on medication have increased 
FC within motor, dorsolateral and anterior cingulate basal ganglia-thalamocortical 
circuits. Our data support the findings of a recent meta-analysis showing that PD 
patients have increased FC of basal ganglia-thalamocortical circuity (Ji et al., 2018). 
and extend these findings by showing for the first time how important functional 
subterritories of the thalamus are impacted in PD. These changes in functional 
connectivity were found despite any evidence of morphological alterations to the 
structure, or any evidence of a relationship between thalamic morphology and clinical 
dysfunction.  
 
Our findings of increased FC between the VLp/VA thalamus and the supplementary 
motor area may be indicative of changes within one segment of the classic ‘motor’ 
basal ganglia-thalamocortical circuit (Alexander et al., 1986). In this model, the motor 
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circuit originates at the supplementary motor area, receiving input from the primary 
and the premotor cortices. These areas connect with the nuclei of the basal ganglia, 
which project back to the ventral anterior and ventral lateral nuclei of the thalamus, 
closing the loop by reconnecting with the site of origin in motor cortical areas 
(Alexander et al., 1986). Increased FC between the putamen and the supplementary 
motor area has been demonstrated previously (Yu et al., 2013) while other research 
using graph theoretical analyses has demonstrated increased functional connectivity 
within the sensorimotor network in PD (Göttlich et al., 2013). Evidence suggests that 
increased FC of sensorimotor networks is likely related to dopaminergic medication 
usage (Esposito et al., 2013) potentially facilitating increases in FC, which is a 
mechanism that will be discussed momentarily.  
 
Our research also demonstrates significant and far more widespread increases in FC 
in PD between the MD/A thalamus and the anterior and dorsolateral prefrontal 
cortices, potentially indicating a disease related change to the ‘dorsolateral prefrontal’ 
basal ganglia-thalamocortical circuit (Alexander et al., 1986). This circuit originates 
in Brodmann areas 9 and 10 on the lateral surface of the anterior frontal lobe, and 
after traversing the basal ganglia, connects directly with our intended seed-ROIs at the 
anterior and mediodorsal nuclei of the thalamus. From there, the circuit projects back 
to the anterior and dorsolateral prefrontal cortices to form a closed loop (Alexander et 
al., 1986). Our findings of increased FC between the MD/A thalamus and the 
dorsolateral prefrontal cortex may represent functional compensatory mechanisms 
due to the significant cognitive dysfunction common in PD. The dorsolateral 
prefrontal cortex helps to execute tasks that contribute to cognitive functioning, 
including working memory, decision-making and action control, achieved through a 
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top-down modulation of behaviour in concert with diverse cortical and subcortical 
structures (Caspers et al., 2017). Research has shown that FC is significantly 
increased across the prefrontal cortex in PD subjects on medication, as the brain 
potentially recruits new anatomical areas to aid in the performance of cognitive tasks. 
It is argued that changes in FC may indicate a functional compensation to help restore 
cognitive processes in PD (Caspers et al., 2017). Interestingly, we also found 
significant increases in FC between the MD/A thalamus and the anterior cingulate 
cortex in PD subjects, indicating a disease related change to the ‘anterior cingulate’ 
basal ganglia-thalamocortical circuit. In this circuit, the anterior cingulate cortex links 
with the ventral basal ganglia structures, outputs to the ventral anterior nuclei of the 
thalamus, and links back with the anterior cingulate cortex (Alexander et al., 1986). 
Our findings of increased FC with the anterior as well as paracingulate gyri fit with 
the concept of increased FC due to compensatory mechanisms, as this region of the 
brain interacts with the lateral prefrontal cortex to mediate performance in tasks 
linked to cognitive processes (Fornito et al., 2004). Research has shown that a 
common response to neurological disruption is the hyper-connectivity of brain 
circuits, which may reflect a protective mechanism in the brain to maintain normal 
functioning (Hillary et al., 2015). Such a mechanism has been proposed in PD 
previously (Gorges et al., 2015, Helmich et al., 2010), as well as in mild cognitive 
impairment and Alzheimer disease (Mevel et al., 2011, Sheline and Raichle, 2013), 
and taken together, our results provide support for this model.  
 
There are nonetheless inconsistencies with similar FC research that require 
consideration. Our data contrast with work demonstrating no significant FC changes 
between the thalamus and widescale brain networks in subjects on medication (Bell et 
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al., 2015). A possible explanation for this inconsistency may relate to how FC 
changes across different disease stages. When compared to the current work, the 
study in question focused on PD subjects with both a longer disease duration as well 
as a higher average Hoehn and Yahr stage (Bell et al., 2015). This is important 
because research has shown that FC in PD may undergo periods of both hyper-
connectivity and hypo-connectivity as the disease progresses (Gorges et al., 2015). 
Potential FC changes across the course of PD thus make difficult to compare studies 
with subjects at different disease stages. 
 
Our data also indicate that PD is associated with increases in FC between the MD/A 
thalamus and the left dorsal caudate nuclei, anterior putamen and globus pallidus. 
Strong evidence suggests that the output of the basal ganglia, mainly the globus 
pallidus interna, is hyperactive in PD (Duval et al., 2016) and our results of increased 
FC with this area suggest that increased activity may be accompanied by increased 
FC. Increased FC between the caudate nuclei and the thalamus has been shown in a 
PD cohort on medication (Müller-Oehring et al., 2015), however two studies have 
demonstrated conflicting results (Agosta et al., 2014b, Owens-Walton et al., 2018). A 
crucial difference separating these studies relates to patient inclusion. One of these 
studies focused on early PD patients with a mean disease duration of 1.7 years 
(Agosta et al., 2014b), which differs markedly from the current study where the 
average disease duration is 5.16 years. The present study also excluded PD subjects 
with dementia, fundamentally distinguishing it from our previous work (Owens-
Walton et al., 2018). This is crucial as PD dementia is associated with decreases in FC 
compared to subjects without the diagnosis (Ponsen et al., 2013). Our findings of 
increased FC between the MD/A thalamus and the anterior putamen are supported by 
4. Project two: Thalamus 
 108 
similar research in this field (Helmich et al., 2010). This research demonstrated that 
increased inter-regional coupling of the anterior putamen, the region anterior to the 
anterior commissure, follow the specific spatial pattern of dopamine depletion in PD 
(Kish et al., 1988). This research suggests that PD patients may undergo a shift in 
cortico-striatal connections from the neuro-chemically more affected posterior 
putamen toward the relatively spared anterior putamen. Our results support this 
finding, suggesting that the anterior putamen may undergo increased FC with the 
MD/A thalamus, further supporting the model that the pathophysiology of PD may 
involve compensatory alterations in the FC of key nuclei within basal ganglia-
thalamocortical circuits. 
 
While conceiving of FC changes in terms of segregated basal ganglia-thalamocortical 
circuits is attractive, this inference is theoretical. It is therefore helpful to consider the 
results of other imaging techniques to substantiate our findings. Graph-based 
eigenvector centrality mapping research (which informs on the number and quality of 
node connections within networks) has shown that this metric is increased in the 
thalamus in PD (Guan et al., 2017). Interestingly, we also found a significant (though 
small) cluster of reduced FC of both the VLp/VA and MD/A thalamus with the lateral 
occipital cortex in PD patients, supporting previous work which found reductions in 
FC between nuclei of the extended basal-ganglia (including the thalamus) and this 
area of the brain (Guan et al., 2017). The findings from 18F-flurodeoxyglucose PET 
imaging has indicated that PD is associated with increased pallidothalamic activity 
(Eckert et al., 2007), which supports our findings. However, this research also 
demonstrated that regions of the dorsolateral prefrontal cortex and the supplementary 
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and premotor areas show reductions in metabolic activity in PD, contrasting with our 
results (Eckert et al., 2007).  
 
We found no significant correlation between FC of our seed-ROI in the thalamus and 
measures of clinical function, disease duration or antiparkinsonian medication use. 
This supports previous meta-analytic research which indicates that FC within a basal-
ganglia networks does not correlate with clinical indices of disease severity 
(Szewczyk-Krolikowski et al., 2014), arguing instead that altered FC reflects a 
constitutional alteration of the networks under consideration. Our results are also 
bolstered by meta-analytic findings which indicate that increased FC of the thalamus 
were unaffected by medication status (Ji et al., 2018). 
 
The morphological data from our study are consistent with previous reports indicating 
that PD is not associated with atrophy of the thalamus (Lee et al., 2014, Mak et al., 
2014, Mckeown et al., 2008, Menke et al., 2014, Messina et al., 2011, Nemmi et al., 
2015, Tinaz et al., 2011). We also found no significant localized surface shape 
changes in the PD group, supporting a number of studies (Lee et al., 2014, Menke et 
al., 2014, Messina et al., 2011). After investigating between-group morphological 
differences we investigated potential relationships between volumes of the thalamus 
and measures of clinical function. These analyses revealed no significant findings, 
supporting previous research (Lee et al., 2014, Mak et al., 2014, Tinaz et al., 2011). 
These results make intuitive sense, as we found no significant volumetric or localized 
shape changes in the PD cohort, suggesting there was no discernible relationship 
between atrophy of the thalamus and the PD disease process. 
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4.5.2. Strengths and limitations 
Possible limitations of the current work warrant further attention. The first is our 
small sample size. While this is an important factor that negatively impacts the power 
of our study, our sample size was the result of choosing a highly stringent head 
motion exclusion criteria, which we believe is a strength of our work. A second 
possible limitation is the use of atlas-based seed-ROI segmentation, defined by the 
structural connectivity of thalamic nuclei (Behrens et al., 2003). Future work may 
benefit from a data-driven parcellation scheme as it may better capture functional 
boundaries of seed-ROIs. A final limitation is the influence of dopaminergic 
medication on the functional connectivity of brain networks, which has shown to be 
impacted in PD participants on this type of medication of medication (Bell et al., 
2015). Despite these considerations we believe our data make important statements 
about the role of the thalamus within basal ganglia-thalamocortical circuits in PD. 
 
4.5.3. Conclusions 
We found increases in functional connectivity between the VLp/VA thalamus and the 
supplementary motor area and paracingulate gyrus, and also between the MD/A 
thalamus and basal ganglia nuclei, anterior and paracingulate cingulate gyri, anterior 
and also dorsolateral prefrontal cortical regions. Significant increases in functional 
connectivity were found despite any observable volumetric or localized shape 
alterations to the thalamus. The results of this study indicate that functional 
connectivity changes occur in PD, which likely result from disease-related system 
level dysfunction of the thalamus as a network hub within basal ganglia-
thalamocortical circuits. 
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5. Project three: Cognitive impairment 
Project one and two looked at subcortical input and output structures of basal ganglia-
thalamocortical circuits, the striatum and thalamus. Project one looked at morphology 
of these structures by classifying all of the PD patients as one cohort, then looking at 
disease progression using years since diagnosis to define early and late PD, and 
finally PD-dementia to represent the most advanced disease stage. Project two 
excluded participants with PD-related dementia, and did not break the PD cohort into 
disease progression groups. Both of these projects did not  take into account levels of  
cognitive impairment beneath the level of dementia. This is an important 
consideration as there is evidence that structural changes to the brain increase relative 
to level of cognitive impairment, which can be found in participants diagnosed with 
only mild cognitive impairment  (Melzer et al., 2012).  
 
Regarding analyses of functional connectivity of structures, there was also 
opportunity to build on Projects one as this work investigated the caudate and 
putamen as whole structures. Research has shown that different regions of the 
striatum are connected to varied regions of the cortex (Draganski et al., 2008) and 
mediate different types of functioning based on this connectivity profile (Haber, 
2003). Accordingly, Project three divides the PD cohort into subgroups based on 
levels of cognitive impairment and investigates the functional connectivity of 
subregions of the caudate nucleus, putamen and thalamus that have putative 
connectivity with prefrontal regions of the brain, areas involved in cognitive function. 
This chapter is based on a manuscript under revision, however certain elements have 
been changed to streamline the project with this thesis. 
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Figure 5.1: Project three. The current project focusses on the caudate nucleus, 
putamen and thalamus as key hubs within basal ganglia-thalamocortical circuitry, 
investigating morphology and functional connectivity based on levels of cognitive 
impairment. 
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5.1. Abstract 
Cognitive impairment in PD places a high burden on patients and is likely a precursor 
to PD -related dementia. The pathophysiology of cognitive impairment in PD is 
complex, and involves networks in the brain that are distinct from those that underlie 
the motor symptoms of the disorder. Studying the functional connectivity and 
morphology of subcortical hubs within basal ganglia-thalamocortical circuits may 
uncover neuroimaging biomarkers of cognitive dysfunction in PD. We first 
investigated the size and shape of the caudate, putamen and thalamus and how these 
morphological characteristics differ between groups. We then used an atlas-based 
seed region-of-interest approach to investigate resting-state functional connectivity of 
important subdivisions of the caudate nucleus, putamen and thalamus, between 
Controls (n = 33), cognitively unimpaired PD participants (n = 33), PD participants 
with mild cognitive impairment (MCI) (n = 22) and PD participants with dementia (n 
= 17). Extensive volumetric and surface-based deflation was found in PD participants 
with dementia. The results of pairwise comparisons indicate that cognitively 
unimpaired PD participants, compared to Controls, display increased functional 
connectivity of the dorsal caudate, anterior putamen and mediodorsal thalamic 
subdivisions with areas across the frontal lobe, as well as reduced functional 
connectivity of the dorsal caudate with posterior cortical and cerebellar regions. 
Compared to cognitively unimpaired participants, PD participants with MCI 
demonstrated reduced functional connectivity of the mediodorsal thalamus with 
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midline nodes within the executive-control network. Compared to participants with 
MCI, participants with dementia demonstrated reduced functional connectivity of the 
mediodorsal thalamus with the posterior cingulate cortex, a key node within the 
default-mode network. Our research demonstrates how functional connectivity of the 
caudate, putamen and thalamus are implicated in the pathophysiology of cognitive 
impairment and dementia in PD, with MCI and dementia in PD associated with a 
breakdown in functional connectivity of the mediodorsal thalamus with para- and 
posterior cingulate regions of the brain, respectively. 
 
5.2. Introduction 
PD is the second most common neurodegenerative disorder in the world, affecting 2-
3% of the population over the age of 65 (Poewe et al., 2017). Traditionally 
categorized as a disorder of movement, it is now widely recognised that patients 
experience significant neuropsychiatric symptoms relating to executive, memory, 
attentional and visual disturbances (Litvan et al., 2012). Recent recognition of the 
high prevalence and substantial impact of cognitive impairment in PD has drawn 
research attention to PD-related MCI (Goldman et al., 2018) which is associated with 
a significantly higher likelihood of developing dementia (Broeders et al., 2013). 
 
The neural processes that distinguish PD patients with cognitive impairment from 
those without it are poorly understood (Williams-Gray et al., 2007). The pathological 
hallmark of PD is the presence of α-synuclein-immunopositive Lewy bodies and 
neurites (Obeso et al., 2000) resulting in a loss of dopaminergic neurons in the 
substantia nigra pars compacta, and subsequent depletion of dopamine at the striatum 
(caudate nucleus and putamen) (Kish et al., 1988). While nigrostriatal dopamine loss 
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is a core feature of PD, evidence suggests that pathology within the thalamus also 
contributes to the abnormal neural activity associated with the disorder (Halliday, 
2009). The combined neural activity in these nodes within basal ganglia-
thalamocortical circuits results in brain network abnormalities being key aspects of 
PD pathophysiology (Strafella, 2013). 
 
To understand the functioning of brain networks it is necessary to study both the 
constituent neuronal elements of networks, as well as their interconnections (Sporns 
et al., 2005). Investigating neuronal elements can be done by quantifying disease-
related effects on the morphology of ‘hubs’ (Looi et al., 2014) while interconnections 
can be investigated via resting-state functional connectivity analyses (Damoiseaux et 
al., 2006). Due to the importance of the caudate nucleus, putamen and the thalamus to 
the abnormal neural activity associated with PD, coupled with the fact that these 
structures are considered important hubs in brain networks (Hwang et al., 2017, Looi 
and Walterfang, 2013), an analysis of the morphology and functional connectivity of 
these structures may yield neuroimaging biomarkers of brain network abnormalities 
in PD that relate to cognitive dysfunction. 
 
Data on the morphological changes to the caudate, putamen and thalamus in PD 
participants without dementia is also varied. Research groups have demonstrated both 
the presence (Garg et al., 2015, Mckeown et al., 2008) and absence (Menke et al., 
2014, Messina et al., 2011) of morphological changes to the thalamus, while others 
have shown either the presence (Pitcher et al., 2012, Sterling et al., 2013) or absence 
(Menke et al., 2014, Owens-Walton et al., 2018) of morphological changes to the 
caudate or putamen. Studies suggest that PD with dementia is associated with atrophic 
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changes to the caudate nucleus, putamen and thalamus (Owens-Walton et al., 2018, 
Summerfield et al., 2005), however the presence and extent of such changes in PD-
MCI is uncertain (Chen et al., 2016, Melzer et al., 2012). As this demonstrates, there 
is a significant variability in the field of neuroimaging biomarkers in PD, with 
reviews of structural and functional studies revealing few clear patterns (Khan et al., 
2018). This may be due to the fact that research studies often to not consider the 
presence of MCI within PD cohorts, instead considering non-demented PD cohorts as 
a single experimental group. This project seeks to address this area of concern by 
using MCI as an important clinical staging milestone. 
 
Research in this field has yielded important information about how functional 
connectivity of widescale intrinsic connectivity networks is impacted in PD relative to 
cognitive status, however the specific role played by important hubs within basal 
ganglia-thalamocortical circuitry is yet to be fully elucidated. Studies have found 
cognitively unimpaired PD is associated with both increases (Gorges et al., 2015) and 
decreases (Bell et al., 2015) in functional connectivity of basal ganglia-
thalamocortical circuitry, while PD participants with MCI have been shown to display 
decreases in functional connectivity (Amboni et al., 2015, Gorges et al., 2015). 
Gorges et al. (2015) suggest that PD may involve a transient process from the hyper- 
to the hypo-connected state which is linked to cognitive decline. Using a well-defined 
clinical cohort, and a targeted rs-fMRI functional connectivity approach, the current 
study aims to better understand how functional connectivity and morphology of the 
caudate nucleus, putamen and thalamus are impacted in PD, and how these factors 
may vary between cognitively unimpaired PD patients, PD-MCI and PD patients with 
dementia. 
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A common response to neurological disruption is hyper-connectivity of brain circuits, 
and it is suggested that such a response reflects compensatory mechanisms in the 
brain to maintain normal levels of neuronal functioning (Hillary et al., 2015). This 
mechanism has been used to explain increases in functional connectivity of structures 
within basal ganglia-thalamocortical circuits in PD (Gorges et al., 2015, Helmich et 
al., 2010) and also in disorders such as MCI and Alzheimer’s disease (Mevel et al., 
2011, Sheline and Raichle, 2013). Hillary et al. (2015) argue that hyper-connectivity 
relies on the availability of sufficient neuronal resources, however these resources can 
be diminished via the loss of grey matter as diseases processes advance, thus 
depleting and ultimately exhausting any capacity that might underpin a compensatory 
response. When this neuronal resource loss reaches a hypothetical ‘critical threshold,’ 
increased functional connectivity is no longer a viable response to situational demand, 
and subsequent reductions in functional connectivity ensue. While the presence and 
extent of grey matter loss in cognitively unimpaired PD is questionable, PD-MCI and 
PDD more consistently display grey matter atrophy (Chen et al., 2016, Melzer et al., 
2012). Accordingly, we hypothesised that cognitively unimpaired participants with 
PD would have sufficient neural resources to support functional compensation, and 
display increased functional connectivity, concomitant with no volumetric or surface-
based shape alterations to the caudate, putamen and thalamus. However, we 
anticipated the presence of morphological alterations in PD-MCI, representing a 
‘critical threshold,’ where functional connectivity begins to decrease along with 
reductions in morphology, evidenced by reduced volumes and surface deflation when 
compared to cognitively unimpaired PD participants, and controls. Finally, we 
hypothesised that PDD participants would demonstrate significant and profound 
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reductions in volumes and surface shape, along with significant decreases in 
functional connectivity of the caudate nuclei, putamina and thalami compared to all 
experimental groups (Figure 5.2). 
 
 
Figure 5.2: Hypothetical ‘critical threshold’ framework. This figure demonstrates onset of 
a ‘critical threshold,’ indicated by red crosses, after which point functional connectivity and 
morphology (volume and surface shape) changes can be found (Hillary et al., 2015). 
Abbreviations: PD-CU, cognitively unimpaired PD participants; PD-MCI, PD participants 
with mild cognitive impairment; PDD, PD participants with dementia. 
 
5.3. Methods 
5.3.1. Participants 
Participants in this study were from the Swedish BioFinder study (www.biofinder.se) 
and gave informed written consent. All elements of the research were performed in 
accordance with the World Medical Association’s Declaration of Helsinki and ethical 
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approval was obtained through the Ethical Review Board of Lund, Sweden, and the 
Human Research Ethics Committee at the Australian National University, Canberra, 
Australia.  
 
5.3.2. Parkinson disease cognitive impairment subgroups 
Diagnosis of probable PD was made by a neurologist using the National Institute of 
Neurological and Stroke Diagnostic Criteria (Gelb et al., 1999). The total PD cohort 
was subdivided into three cognitive impairment disease groups. The first group 
comprises cognitively unimpaired PD patients (PD-CU; n = 33). The second group 
comprises PD patients with MCI (PD-MCI; n = 22), based on the Movement Disorder 
Society Task force guidelines (Litvan et al., 2012). This criterion is met when patients 
score at least 1 standard deviation below the normative mean in at least two cognitive 
tests, including executive function, attention, visuospatial, memory and language 
domains. The third subgroup consists of PD participants with dementia (PDD; n = 17) 
diagnosed using the Clinical Diagnostic Criteria for Dementia Associated with PD 
(Emre et al., 2007). A healthy control group (Controls) was included for comparative 
purposes (n = 26). Exclusion criteria for this study included refusing MRI, the 
presence of significant alcohol or substance misuse and/or a significant systematic 
illness or organ failure. All participants underwent a cognitive and neurological 
examination by a medical doctor with extensive experience with movement disorders, 
while PD participants remained on their usual medication regimes. Clinical 
functioning of participants was quantified using the Hoehn and Yahr staging, 
assessing the progression of the disorder; the Unified Parkinson’s Disease Rating 
Scale Part-III test (UPDRS-III), assessing the motor signs of PD (Fahn and Elton, 
1987); the Mini Mental State Examination (MMSE), assessing cognitive mental state 
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(Folstein et al., 1975); the Animal Fluency and Letter S Fluency tests, assessing 
verbal fluency and executive function (Tombaugh et al., 1999) and the A Quick Test 
of cognitive speed assessing perceptual and cognitive speed (Palmqvist et al., 2010). 
 
5.3.3. MRI acquisition 
Structural MRI data was obtained on a 3T scanner (Trio, Siemens Magnetom, 
Erlangen, Germany) with a 20-channel head-coil. High resolution T1-weighted three-
dimensional anatomical brain images were acquired using a magnetisation-prepared 
rapid acquisition technique with gradient-echo sequence (repetition time = 7 ms; echo 
time = 3 ms; flip angle = 90 degrees; voxel size = isotropic 1mm3). Image matrix size 
was 356 voxels in the coronal and sagittal planes and 176 voxels in the axial plane. 
Functional MRI data consists of 256 T2*-weighted echo planar imaging volumes 
(repetition time = 1850 ms; echo time 30 ms; flip angle = 90 degrees; matrix 64 × 64; 
voxel size 3 × 3 × 3.75 mm3) for each participant. Matrix size was 64 voxels in the 
coronal and sagittal planes and 36 voxels in the axial plane. Participants were 
instructed to lie still with their eyes closed, not to fall asleep and not to think of 
anything in particular during the scan, which lasted for approximately 8 minutes. 
 
5.3.4. Preprocessing of T1 structural MRI data 
Preprocessing of T1-weighted structural data was performed using the FSL software 
package (FSL, Oxford, UK; version 5.0.10) (Jenkinson et al., 2012). Images 
underwent brain extraction using the FSL-BET tool (Smith, 2002) which were then 
processed using FSL-FAST, segmenting the T1 structural MRI into brain tissue types 
whilst correcting for image intensity fluctuations caused by inhomogeneities in the 
radio frequency field (Zhang et al., 2001). 
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5.3.5. Volumetrics: Statistical analyses 
Volumes of the caudate, putamen and thalamus were estimated using the 
segmentation and registration tool FSL-FIRST (Patenaude et al., 2011). This uses a 
model-based approach to segment subcortical structures producing output meshes and 
volumetric data. Investigating differences between experimental groups was 
performed with SPSS 22.0 (IBM Corporation, Somers, New York, USA) utilising 
two-tailed multivariate analysis of covariance models controlling for intracranial 
volume (ICV) (derived from FSL-FAST) and age. Multivariate partial eta squared 
values (η2) are used to report effect sizes (Cohen, 1992). 
 
5.3.6. SPHARM-PDM surface shape: Statistical analyses 
Volumetric analyses can investigate overall size differences between groups, however 
they cannot highlight where atrophy/hypertrophy takes place. Accordingly, we used 
spherical harmonic parametrization three-dimensional point distribution model 
(SPHARM-PDM) to investigate localised surface changes to the segmentations of the 
caudate, putamen and thalamus between experimental groups (Styner et al., 2006) 
described in Methodology section 2.3.2. Segmentations were preprocessed to ensure a 
spherical topology, then described by spherical harmonic functions and sampled onto 
surfaces of 1002 points. Surfaces were then aligned using a rigid-body Procrustes 
alignment to a mean template created from a group sample. Comparisons between 
groups were performed using multivariate analysis of covariance models with a 
Hotelling statistic in R (version 3.2.1, R Development Core Team, 2014). All analyses 
included covariates of ICV, age and sex. SPHARM-PDM produces mean 
displacement maps which show the magnitude of surface displacement (deflation or 
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inflation in mm) between corresponding points on the mean surface of one 
experimental group compared to another. Significant surface changes are indicated by 
regions with a p-value < 0.05, corrected for multiple comparisons with a FDR bound 
q of 5% (Genovese et al., 2002). Results are presented as a composite map of each 
structure with inflation/deflation only displayed in regions that are significant after 
FDR correction. 
 
5.3.7. Preprocessing of resting-state fMRI data 
Preprocessing of resting-state functional images was performed using FSL-FEAT 
(v6.0). Steps included deletion of first 6 volumes, motion correction using FSL-
MCFLIRT (Jenkinson et al., 2002) and removal of non-brain tissue using FSL-BET 
(Smith, 2002). Registration of participant’s functional images to high resolution T1-
weighted structural images used a boundary-based registration (Greve and Fischl, 
2009) within FSL-FLIRT linear registration tool (Jenkinson et al., 2002, Jenkinson 
and Smith, 2001). Registration of functional images to MNI 152 T1 2mm3 standard 
space was performed with FSL-FLIRT with 12 degrees of freedom, further refined 
using FSL-FNIRT nonlinear registration (Andersson et al., 2007a, Andersson et al., 
2007b) with a warp resolution of 10mm and a resampling resolution of 4mm.  
 
Data denoising was then performed with FSL-MELODIC (v3.15) independent 
component analysis (ICA) (Beckmann and Smith, 2004) to identify any potential 
influence of head motion, scanner and cerebrospinal fluid artefacts. FSL-FIX (v1.06) 
(Salimi-Khorshidi et al., 2014) was then used to remove components classified as 
‘noise’ and also correct for motion confounds. This approach masks non-brain voxels, 
performs a voxel-wise demeaning of the data, followed by normalisation of the voxel-
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wise variance. Data were whitened and projected onto a 53-dimensional subspace as 
estimated by a Laplace approximation of the Bayesian evidence of the model order 
using a principal component analysis. Observations were decomposed into sets of 
vectors describing the variation of signal across both the temporal (time-courses) and 
spatial (maps) domains, optimising for non-gaussian spatial source distributions using 
a fixed-point iteration technique (Hyvarinen, 1999). We then trained a classifier for 
our particular dataset by first using the ‘Standard.RData trained-weights’ classifier 
over a sample of ICA maps for 10 Controls and 10 PD subjects, with the classifier 
categorising maps as either ‘signal’ or ‘noise’. We checked each classification against 
validated guidelines, choosing the conservative approach to component 
reclassification as outlined in that work (Griffanti et al., 2014). Following this, the 
FIX classifier was re-trained using this new data and run over the ICA datasets for all 
subjects, regressing out noise components while also cleaning up motion confounds 
(24 regressors: 6 motion parameters, 6 first derivatives and the squares of these 12 
regressors). This process creates a de-noised filtered functional file which is used at 
the individual level GLM stage. Spatial smoothing was then performed (full width 
half maximum Guassian kernel = 5mm) followed by a multiplicative mean intensity 
normalisation and a high-pass temporal filtering Gaussian-weighted least-squares 
straight line fitting with sigma = 50.0s (Woolrich et al., 2001). 
 
Three nuisance-variable masks were created for each participant, intended to 
encompass the white matter, ventricle and whole-brain regions (including both grey 
and white matter territory). These were produced from participants T1-structural 
images using the recon-all command from FreeSurfer (Fischl, 2012). These masks 
were converted to functional space using FSL-FEAT registration warp files, where 
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they were then thresholded to only include voxels with a greater than 70% chance of 
inclusion. Masks were then eroded using the fslmaths tool to reduce partial volume 
effects. Average timeseries data were then extracted from these masks to be regressed 
from the data at the individual-level GLM stage. 
 
To reduce potential spurious effects of head motion we used the FSL Motion Outliers 
tool to identify timepoints in fMRI data that were potentially corrupted by large 
motion. This step was performed as research has indicated that traditional linear 
regression methods cannot fully resolve head motion-related signal changes (Power et 
al., 2012). We chose to identify outliers based on a DVARS metric which indexes the 
rate of change of BOLD signal across the entire brain at each frame of data (Smyser 
et al., 2011), with ‘D’, referring to the temporal derivative of timecourses, and 
‘VARS’ referring to the variance over all voxels of the root mean realignment 
estimates. We identified timepoints for outliers on this metric as timepoints with a 
score outside the 75th percentile plus 1.5 multiplied by the interquartile range, which 
were then removed from the data at the individual GLM stage. 
 
5.3.8. Resting-state fMRI: Seed-based region-of-interest approach 
To investigate how the caudate, putamen and thalamus are impacted in PD groups 
with varying levels of cognitive impairment, we used an atlas-based method to 
subdivide the structures into functionally relevant regions-of-interest (ROI). We 
performed this step using the Oxford Thalamic Connectivity Atlas (Behrens et al., 
2003) and the Oxford-GSK-Imanova Connectivity Atlas (Tziortzi et al., 2014) within 
FSLEyes. Regions of the dorsal and central caudate nucleus and the anterior putamen 
have the highest probability of connectivity with the anterior and dorsolateral 
5. Project three: Cognitive impairment 
 126 
prefrontal cortices in the brain (BA9, 9/46 and 10) and are said to be involved in 
cognitive processes, including perception, memory, reasoning and judgement (Haber, 
2003). The mediodorsal and anterior thalamic nuclei have the highest probability of 
connectivity to the dorsolateral and prefrontal cortices (Behrens et al., 2003) and these 
thalamic nuclear regions are said to be involved in limbic, episodic memory and 
cognitive functions (Power and Looi, 2015). For ease of reference, we will refer to 
these three seed-ROIs as the ‘dorsal caudate’, ‘anterior putamen’ and ‘mediodorsal 
thalamus’ respectively. These three bilateral standard space MNI 152 2mm3 seed-ROI 
masks were thresholded to only include voxels that had a greater than 50% chance of 
inclusion (Figure 5.3A). Masks were then registered to T1-weighted structural space 
where we used them to ‘cookie-cut’ ROIs from the FSL-FIRST segmentation masks. 
These seed-ROIs were then converted to subject-specific functional MRI space where 
we performed a final erosion to avoid partial volume effects (Caballero-Gaudes and 
Reynolds, 2017). Mean activation data from within the three seed-ROIs at each 
timepoint was used as explanatory variables for subsequent statistical analyses.  
 
Before investigating the differences in functional connectivity between groups we 
conducted three one-sample t-tests on all of the Control participants to look at the 
functional connectivity of our seed-ROIs with the rest of the brain. This step indicates 
the areas of highest functional connectivity with our seed-ROIs and provides a 
backdrop on which to interpret our results (Figure 5.3B). 
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Figure 5.3: Seed regions-of-interest and one-sample t-tests demonstrating putative 
functional connectivity pathways in Controls. A) Subject specific seed regions-of-interest 
masks were converted to MNI 152 T1 standard space and combined to produce this image. 
Lighter areas of each colour are indicative of a greater proportion of voxels in that area being 
included in the relevant mask. B) Z-statistic (Gaussianised) images from Control participant’s 
individual-level general linear model statistic image, thresholded non-parametrically using 
clusters determined by Z > 3.1 and a (corrected) cluster significance of p < 0.05 (Worsley, 
2001). 
 
5.3.9. Resting-state fMRI: Statistical analyses 
Three individual-level functional connectivity analyses were performed for each 
participant using a general linear model (GLM) in a mass univariate voxelwise whole-
brain analysis (Woolrich et al., 2004). This GLM approach measures the correlation 
between activity within each of the three seed-ROIs and the rest of the brain. We used 
a FILM pre-whitening correction, shifted the model with a temporal derivative to 
account for slice timing effects and variations in the hemodynamic response function, 
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removed volumes potentially corrupted by large motion and regressed out average 
signal from within white matter, ventricle and whole-brain masks.  
 
The following higher-level analyses of functional connectivity differences were 
conducted: PD-CU compared to Controls (section 5.4.4.1); PD-MCI compared to PD-
CU (section 5.4.4.2); PDD compared to PD-CU (section 5.4.4.3) and PDD compared 
to PD-MCI (section 5.4.4.4). These analyses were performed using FSL-FLAME in a 
mixed-effects design (Woolrich et al., 2004). Age and gender data were included as 
covariates. When investigating functional connectivity between the PD-CU, PD-MCI 
and PDD groups we also included levodopa-equivalent daily dosage (LEDD) data as 
a covariate. Z-statistic (Gaussianised) images from participants individual-level GLM 
statistical maps were thresholded non-parametrically using clusters determined by Z > 
3.1 and a (corrected) cluster significance of p < 0.05 (Worsley, 2001). 
 
5.3.10. Correlation between functional connectivity and clinical variables 
After comparing functional connectivity between groups, we performed a series of 
post-hoc partial correlation analyses to investigate the relationship between functional 
connectivity and clinical variables. To do this we investigated functional connectivity 
at the neuroanatomical sites of significant between group differences, stipulated by 
the MNI coordinates listed in Tables 5.2, 5.3 and 5.4. In total there were 21 
significant clusters found. To sample functional connectivity around these locations, 
5mm spheres were placed at the MNI coordinates for each cluster, with the average 
parameter estimate for each statistic image extracted for each participant. The 
parameter estimate is an indication of the strength and directionality of the correlation 
between activity in that brain region and the activity in the seed-ROI. This variable 
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was then correlated with measures of clinical function within each group. For 
locations of significant difference when comparing PD-CU and Controls we 
performed this correlation in PD participants. For locations of significant difference 
when comparing PD-CU and PD-MCI we performed this correlation for participants 
in both groups. For locations of significant difference when comparing PD-MCI and 
PDD, we performed this correlation for participants in both groups.  
 
5.4. Results 
5.4.1. Participant characteristics 
The characteristics of participants are displayed in Table 5.1. A chi-square test for 
independence found no significant difference in sex between the groups [c2 (3, n = 
98) = 0.89, p = 0.86]. One-way analyses of variance found no significant difference in 
age [F (3, 94) = 2.169, p = 0.10], ICV [F (3, 94) = 0.323, p = 0.81], years of education 
[F (3, 79) = 1.255, p = 0.30] or average DVARS [F (3, 94) = 2.460, p = 0.07] between 
groups (Table 5.1). As expected, measures of clinical function were significantly 
different between disease groups. 
 
Table 5.1: Participant characteristics 
Item Controls PD-CU PD-MCI PDD p-value 
Number of  
participants 
26 33 22 17 - 
Female/Male 
 
12/14 15/18 12/10 7/10 0.86 
Average age in 
years 
69.59 
± 6.17 
69.25 
± 6.31 
70.53 
± 5.38 
73.70 
± 6.68 
0.10 
ICV (cm3) 1456.00 
± 135.93 
1491.68 
± 139.08 
1471.06 
± 132.13 
1481.80 
± 168.95 
0.81 
Years of education 12.73 
± 3.41 
11.34 
± 5.36 
9.66 
± 6.81 
11.50 
± 4.52 
0.30 
DVARS 11.97 
± 3.21 
14.96 
± 3.87 
17.46 
± 12.71 
15.62 
± 6.39 
0.07 
Years since 
diagnosis 
- 6.30 
± 5.24 
5.54 
± 3.56 
11.88 
± 5.48 
- 
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LEDD - 639.60 
± 485.23 
610.73 
± 262.11 
1010.72 
± 625.53 
- 
H&Y - 1.742 
± 0.73 
2.00 
± 0.72 
2.853 
± 0.77 
- 
UPDRS-III 2.35 
± 2.84 
12.61 
± 9.55 
14.27 
± 9.07 
33.00 
± 10.21 
<0.01* 
MMSE 28.69 
± 1.16 
28.76 
± 1.00 
27.41 
± 1.65 
22.88 
± 3.77 
<0.01* 
AF 23.88 
± 6.71 
23.88 
± 5.71 
18.86 
± 6.24 
11.81 
± 4.18 
<0.01* 
LSF 19.00 
± 5.93 
15.90 
± 5.26 
12.5 
± 5.61 
9.31 
± 4.24 
<0.01* 
AQT 59.08 
± 14.41 
63.12 
± 11.308 
78.38 
± 28.01 
132.93 
± 73.26 
<0.01* 
Key: Participant data presented as mean ± standard deviation. All data corrected to two 
decimal places. *, significant difference in means between groups compared using one-way 
anova. Abbreviations: ICV, total intracranial volume; DVARS, average image intensity of 
each frame n in relation to n+1; LEDD, levodopa-equivalent daily dosage (mg); H&Y, Hoehn 
and Yahr Scale; UPDRS-III, Unified Parkinson’s Disease Rating Scale, part-III; MMSE, Mini 
Mental-state Examination; AF, Animal Fluency test; LSF, Letter S Fluency test; AQT, A 
Quick Test of Cognitive Speed. 
 
5.4.2. Volumetric analyses 
Pairwise comparisons of volumes revealed the following significant differences 
between experimental groups (Table 5.2 and 5.3): the left caudate was significantly 
reduced in PDD compared to PD-CU (p = 0.009) and Controls (p < 0.001) with a 
large effect size (η2 = 0.177) (Figure 5.4A). The right caudate was significantly 
reduced in PDD compared to PD-CU (p = 0.021) and Controls (p = 0.001) also with a 
large effect size (η2 = 0.143) (Figure 5.4A). The left putamen was significantly 
reduced in PDD compared to PD-CU (p = 0.005) and Controls (p < 0.001) with a 
large effect size (η2 = 0.193) (Figure 5.4B). The right putamen was significantly 
reduced in PDD compared to Controls (p = 0.016) with a medium effect size (η2 = 
0.107) (Figure 5.4B). The left thalamus was significantly reduced in PDD compared 
to PD-CU (p = 0.011) and Controls (p = 0.037) with a medium effect size (η2 = 0.108) 
(Figure 5.4C). The right thalamus was significantly reduced in PDD compared to PD-
CU (p = 0.002) with a medium effect size (η2 = 0.136) (Figure 5.4C). 
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Table 5.2: Estimated volumes of caudate, putamen and thalamus 
 Controls 
(mm3) 
PD-CU 
(mm3) 
PD-MCI 
(mm3) 
PDD 
(mm3) 
Left caudate 3450.32  
± 1681.03 
3312.09 
± 1762.59 
3241.73 
± 1702.63 
2964.86 
± 1690.14 
Right caudate 3549.40  
± 1581.95 
3449.54  
± 1625.13 
3372.14 
± 1572.23 
3139.56 
± 1515.45 
Left putamen 4720.97  
± 410.388 
4541.24  
± 533.439 
4396.80 
± 547.57 
4065.27 
± 589.74 
Right putamen 4637.26  
± 494.10 
4511.64  
± 563.04 
4362.30 
± 582.08 
4199.70 
± 455.31 
Left thalamus 7312.49  
± 2181.14 
7360.32  
± 2285.64 
7231.95 
± 2287.58 
6814.29 
± 2159.28 
Right thalamus 7117.68  
± 1986.33 
7273.23 
± 2198.56 
7061.30 
± 2116.92 
6746.37 
± 2091.38 
Key: Volumetric data presented as mean ± standard deviation. All data corrected to two 
decimal places. 
 
Table 5.3: Pairwise comparisons of ROI volumes 
Structure Group 1 Group 2 
Difference  
[1-2] (mm3) p-value* η2 
Left caudate PD-CU PD-MCI 70.35 1.000 0.177 
  PDD 347.22 0.009*  
  Controls -138.24 0.797  
 PD-MCI PDD 276.87 0.098  
  Controls -208.59 0.243  
 PDD Controls -485.46 <0.001*  
Right caudate PD-CU PD-MCI 77.40 1.000 0.143 
  PDD 309.98 0.021*  
  Controls -99.86 1.000  
 PD-MCI PDD 232.58 0.221  
  Controls -177.27 0.432  
 PDD Controls -409.84 0.001*  
Left putamen PD-CU PD-MCI 144.44 1.000 0.193 
  PDD 475.96 0.005*  
  Controls -179.73 0.794  
 PD-MCI PDD 331.52 0.159  
  Controls -324.17 0.088  
 PDD Controls -655.69 <0.001*  
Right putamen PD-CU PD-MCI 149.35 1.000 0.107 
  PDD 311.94 0.146  
  Controls -215.62 1.000  
 PD-MCI PDD 162.59 1.000  
  Controls -274.97 0.210  
 PDD Controls -437.55 0.016*  
Left thalamus PD-CU PD-MCI 128.37 1.000 0.108 
  PDD 546.02 0.011*  
  Controls 47.83 1.000  
 PD-MCI PDD 417.66 0.143  
  Controls -80.54 1.000  
 PDD Controls -498.20 0.037*  
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Right thalamus PD-CU PD-MCI 211.94 0.561 0.136 
  PDD 526.87 0.002*  
  Controls 155.55 1.000  
 PD-MCI PDD 314.92 0.216  
  Controls -56.39 1.000  
 PDD Controls -371.32 0.071  
Key: Covariates appearing in the model are evaluated at the following values: Age = 
70.4008; ICV = 147.59; *, p-values < 0.05 (adjusted for multiple-comparisons using the 
Bonferroni method). 
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Figure 5.4: Pairwise comparison of volumes between PD subgroups and Controls. (A) 
Caudate (B) putamen and (C) thalamus. Volumes presented are estimated marginal mean 
values for each experimental group derived from MANCOVA models controlling for age and 
ICV. Abbreviations: *, indicates a pairwise comparison with a significant p-value < 0.05 
confidence interval correction: Bonferroni. PD-CU, cognitively unimpaired PD participants; 
PD-MCI, PD participants with mild cognitive impairment; PDD, PD participants with 
dementia. 
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5.4.3. SPHARM-PDM shape analyses 
SPHARM-PDM shape analysis of the caudate, putamen and thalamus found 
widespread deflation to the surface of these structures in PDD compared to PD-CU 
participants. Surface deflation can be observed at the bilateral rostral as well as 
dorsomedial surfaces areas of the caudate (Figure 5.5). Widespread deflation was also 
found on the surface of the left putamen, at the anterior, dorsal and posterior regions. 
Significant and widespread deflation was found across the medial surface of the 
bilateral thalami, potentially corresponding to surface regions of the anterior and 
mediodorsal thalamic nuclei. Surface deflation was also found across the posterior-
ventral surfaces of the thalami, potentially corresponding to the pulvinar as well as 
medial and lateral geniculate bodies. No FDR-corrected significant shape changes 
were found when comparing PD-CU to PD-MCI or PD-MCI to PDD. 
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Figure 5.5: SPHARM-PDM shape analysis of the caudate nucleus, putamen and 
thalamus in PDD compared to PD-CU. Neuroanatomical surface areas of FDR-corrected 
mean difference displacement maps. Displacement colour scale corresponds to the 
millimetres of inflation/deflation of the surface in that region in mm; warmer colours 
correspond to surface inflation in PDD while cooler colours correspond to surface deflation in 
PDD. The bilateral thalami sit medially, the caudate nuclei rostrally and the putamen are the 
most lateral of the three structures. Abbreviations: R, right hemisphere; FDR, false-
discovery rate; Left, looking at the structures from the left side of the brain; L, left 
hemisphere; Right, looking at the structures from the right side of the brain; R, right 
hemisphere. 
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5.4.4. Resting-state seed-based functional connectivity analyses 
5.4.4.1. PD-CU compared to Controls 
Dorsal caudate: Analysis of the dorsal caudate in PD-CU compared to Controls found 
clusters of increased functional connectivity with the right superior frontal gyrus 
(BA8), left frontal pole (BA10) and right middle frontal gyrus (BA8) (Figure 5.6A, 
Table 5.4). These clusters extended to include local maxima at the left postcentral 
gyrus (BA3), left precentral gyrus (BA6), left superior frontal gyrus (BA6), left 
paracingulate gyrus (BA32), right frontal pole (BA10), left anterior cingulate (BA24) 
and the left middle frontal gyrus (BA8) (Figure 5.6A; Appendix Table 7). We found 
clusters of decreased functional connectivity at the right lateral occipital cortex 
(BA19), left cerebellar crus I, left angular gyrus (BA39) and left cerebellar lobule VI 
(Figure 5.6A; Table 5.4). These clusters extended to include local maxima at the left 
supramarginal gyrus (BA39) and left cerebellar vermis VI (Figure 5.6A; Appendix 
Table 7). 
 
Anterior putamen: Analysis of the anterior putamen in PD-CU compared to Controls 
found clusters of increased functional connectivity at the bilateral middle frontal gyri 
(BA8, 9), left frontal pole (BA10), bilateral postcentral gyri (BA2, 3), left 
paracingulate gyrus (BA32) and right inferior frontal gyrus (BA44) (Figure 5.6B; 
Table 5.4). These clusters extended to include local maxima at the bilateral anterior 
cingulate cortex (BA24), right frontal pole (BA10), left superior frontal gyrus (BA9), 
bilateral precentral gyri (BA4, 6) and bilateral central operculum (BA42) (Figure 
5.6B; Appendix Table 8). We also found clusters of decreased functional connectivity 
at the left lateral occipital cortex (BA7) and right precuneus (BA7) (Figure 5.6B; 
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Table 5.4). These clusters extended to include a local maxima at the left precuneus 
(Figure 5.6B; Appendix Table 8). 
 
Mediodorsal thalamus: Analysis of the mediodorsal thalamus in PD-CU compared to 
Controls found clusters of increased functional connectivity at the left postcentral 
gyrus (BA1) and the right middle frontal gyrus (BA8) (Figure 5.6C; Table 5.4). These 
clusters extended to include local maxima at the left postcentral gyrus (BA3) and the 
left precentral gyrus (BA4, 6) (Figure 5.6C; Appendix Table 9). No significant 
clusters of decreased functional connectivity were found for the mediodorsal 
thalamus. 
 
5. Project three: Cognitive impairment 
 138 
 
Figure 5.6: Significant between-group differences in functional connectivity in PD-CU 
compared to Controls. Dorsal caudate (A), anterior putamen (B) and mediodorsal thalamus (C). 
Z-score statistic (Gaussianised) images thresholded non-parametrically using clusters determined 
by Z > 3.1 and a corrected cluster significance of p < 0.05, overlaid on MNI 152 T1 1mm standard 
axial brain image (Z = -26mm ascending to 64mm; 6mm interslice distance). Warm colours 
represent increased in functional connectivity in PD-CU, while shades of blue represent decreased 
functional connectivity in PD-CU. Abbreviations: Crus I, Crus I of cerebellum; Lobe VI, 
posterior cerebellar lobule VI; AG, angular gyrus; LOC, lateral occipital gyrus; A, anterior; R, 
right hemisphere; MFG, middle frontal gyrus; FP, frontal pole; SFG, superior frontal gyrus; PCG, 
paracingulate gyrus; FPM, frontal pole (medial); PostCG, postcentral gyrus. 
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Table 5.4: Functional connectivity differences in PD-CU compared to Controls 
Seed region # Brain region Direction Z 
MNI 
x y z 
Dorsal 
caudate 
1 R superior frontal gyrus (BA8) Ý 4.86 10 32 58 
2 L frontal pole (BA10) Ý 3.81 -28 56 2 
3 R middle frontal gyrus (BA8) Ý 4.39 34 16 38 
4 R lateral occipital cortex (BA19) ß 4.22 40 -76 28 
5 L cerebellar crus I ß 4.18 -24 -72 -26 
6 L angular gyrus (BA39) ß 4.36 -60 -54 28 
7 L cerebellar lobule VI ß 4.16 -6 -76 -20 
Anterior 
putamen 
8 R middle frontal gyrus (BA8) Ý 5.43 26 26 32 
9 L frontal pole (BA10) Ý 3.93 -2 56 20 
10 R postcentral gyrus (BA3) Ý 4.24 44 -22 58 
11 L postcentral gyrus (BA2) Ý 4.08 -54 -12 26 
12 L paracingulate gyrus (BA32) Ý 4.85 -12 32 28 
13 R postcentral gyrus (BA3) Ý 4.4 52 -16 44 
14 L middle frontal gyrus (BA9) Ý 4.42 -28 28 40 
15 R inferior frontal gyrus (BA44) Ý 3.79 48 29 18 
16 L lateral occipital cortex (BA19) ß 4.05 -26 -82 40 
17 R precuneus (BA7) ß 4.1 6 -62 42 
Mediodorsal 
thalamus 
18 L postcentral gyrus (BA1) Ý 4.94 -58 -10 26 
19 R middle frontal gyrus (BA8) Ý 3.97 24 24 32 
Key: Coordinates of peak Z-score voxel location for areas of significant functional connectivity 
differences in PD-CU compared to Controls (family-wise error corrected p < 0.05). 
Abbreviations: #, number of significant cluster; ß, decrease in functional connectivity; Ý, 
increase in functional connectivity; L, left hemisphere; R, right hemisphere; BA, Brodmann Area; 
Z, maximum Z-value for cluster; MNI, coordinates for location of maximum Z-value, in the 
Montreal Neurological Institute T1-standard space. 
 
5.4.4.2 PD-MCI compared to PD-CU 
Mediodorsal thalamus: Analysis of the mediodorsal thalamus in PD-MCI compared to 
PD-CU found one significant cluster of decreased functional connectivity at the right 
paracingulate gyrus (BA32) (Figure 5.7; Table 5.5). This cluster extended to include 
local maxima at the medial frontal gyrus (BA9) and right frontal pole (BA8) (Figure 
5.7; Appendix Table 10). No significant clusters of increased functional connectivity 
were found. There were no significant functional connectivity differences to the 
dorsal caudate or anterior putamen when comparing PD-MCI and PD-CU. 
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Figure 5.7: Significant between-group differences in functional connectivity of the 
mediodorsal thalamus in PD-MCI compared to PD-CU. Z-score statistic (Gaussianised) 
images thresholded non-parametrically using clusters determined by Z > 3.1 and a corrected 
cluster significance of p < 0.05, overlaid on MNI 152 T1 1mm axial standard brain image (Z = 
-30.5mm ascending to 45.5mm; 5mm interslice distance). Shades of blue show areas of 
decreased in functional connectivity in PD-MCI. Abbreviations: A, anterior; R, right 
hemisphere; PCG, paracingulate gyrus. 
 
Table 5.5: Functional connectivity differences in PD-MCI compared to PD-CU 
Seed region # Brain region Direction Z 
MNI 
x y z 
Dorsal 
caudate 
 - - - - - - 
Anterior 
putamen 
 - - - - - - 
Mediodorsal 
thalamus 
20 R paracingulate gyrus (BA32) ß 3.92 2 46 30 
Key: Coordinates of peak Z-score voxel location for areas of significant functional 
connectivity differences in PD-MCI compared to PD-CU (family-wise error corrected p < 
0.05). Abbreviations: #, number of significant cluster; FC, functional connectivity; ß, 
decrease in functional connectivity; Û, no significant functional connectivity changes; R, right 
hemisphere; BA, Brodmann Area; Z, maximum Z-value for cluster; MNI, coordinates for 
location of maximum Z-value, defined in the Montreal Neurological Institute T1 standard 
space. 
 
5.4.4.3. PDD compared to PD-CU 
There were no significant functional connectivity differences to the dorsal caudate, 
anterior putamen or mediodorsal thalamus when comparing PD-CU to PDD 
participants. 
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5.4.4.4 PDD compared to PD-MCI 
Mediodorsal thalamus: Analysis of the mediodorsal thalamus in PDD compared to 
PD-MCI found one cluster of decreased functional connectivity at the right posterior 
cingulate cortex (PCC) (BA23) (Figure 5.8; Table 5.6; Appendix Table 11). There 
were no significant functional connectivity differences of the dorsal caudate or 
anterior putamen when comparing PDD with PD-MCI. 
 
 
Figure 5.8: Significant between-group differences in functional connectivity of the 
mediodorsal thalamus in PDD compared to PD-MCI. Z-score statistic (Gaussianised) 
images thresholded non-parametrically using clusters determined by Z > 3.1 and a corrected 
cluster significance of p < 0.05, overlaid on MNI 152 T1 1mm axial standard brain image (Z 
= -3mm ascending to 57mm; 4mm interslice distance). Shades of blue show areas of 
decreased in functional connectivity in PDD. Abbreviations: PCC, Posterior cingulate 
cortex; R, right hemisphere; A, anterior. 
 
Table 5.6: Functional connectivity differences in PDD compared to PD-MCI 
Seed region # Brain region Direction Z 
MNI 
x y z 
Dorsal 
caudate 
- - - - - - - 
Anterior 
putamen 
- - - - - - - 
Mediodorsal 
thalamus 
21 R posterior cingulate cortex 
(BA23) 
ß 4.07 6 -38 26 
Key: Coordinates of peak Z-score voxel location for areas of significant functional 
connectivity differences in PDD compared to PD-MCI (family-wise error corrected p < 0.05). 
Abbreviations: #, number of significant cluster; FC, functional connectivity; ß, decrease in 
functional connectivity; Û, no significant functional connectivity changes; R, right 
hemisphere; BA, Brodmann Area; p, corrected p-value; Z, maximum Z-value for cluster; MNI, 
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coordinates for location of maximum Z-value, defined in the Montreal Neurological Institute 
T1 standard space.  
 
5.4.5. Correlation between functional connectivity and clinical variables 
When looking at the possible influences of clinical variables on the differences in 
functional connectivity in the PD-CU group compared to Controls, we looked at the 
correlation between average parameter estimate at the locations of clusters 1-7 within 
dorsal caudate statistic images, the average parameter estimate at the locations of 
clusters 8-17 within anterior putamen statistic images, and the average parameter 
estimate at the locations of clusters 18-19 within mediodorsal thalamus statistic 
images.  
 
When investigating functional connectivity with the dorsal caudate, we found PD-CU 
participants showed a negative correlation between average parameter estimate at the 
right middle frontal gyrus and MMSE scores (cluster #3, b = -0.420, p = 0.015). 
When investigating functional connectivity with the anterior putamen, PD-CU 
participants also showed a negative correlation between average parameter estimate at 
the right middle frontal gyrus (cluster #8, b = -0.354, p = 0.043), left paracingulate 
(cluster #12, b = -0.513, p = 0.002), left middle frontal gyrus (cluster #14, b = -0.445, 
p = 0.009) and MMSE scores. PD-CU participants also showed a positive correlation 
between average parameter estimate at the right postcentral gyrus (cluster #13, b = 
0.505, p = 0.006) and right inferior frontal gyrus (cluster #15, b = 0.521, p = 0.004) 
with LEDD levels. PD-CU participants also showed a negative correlation between 
average parameter estimate at the left lateral occipital cortex (cluster #16, b = -0.471, 
p = 0.012) and LEDD levels. Finally, when investigating functional connectivity with 
the mediodorsal thalamus, PD-CU participants showed a negative correlation between 
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average parameter estimate at the left postcentral gyrus (cluster #18, b = -0.348, p = 
0.047) and disease duration (Appendix Table 12). 
 
When looking at the possible influences of clinical variables on the differences in 
functional connectivity between the PD-CU and PD-MCI groups, we looked at the 
correlation between average parameter estimate at cluster #20 within the mediodorsal 
thalamus statistic images. PD-CU participants demonstrated a negative correlation 
between average parameter estimate at the paracingulate gyrus and LEDD scores 
(cluster #20, b = -0.486, p = 0.025) and a positive correlation with UPDRS-III scores 
(cluster #20, b = 0.424, p = 0.049) (Appendix Table 13). 
 
When looking at the possible influences of clinical variables on the differences in 
functional connectivity between PD-MCI and PDD groups, we looked at the 
correlation between average parameter estimate at cluster #21 within mediodorsal 
thalamus statistic images. PD-MCI participants demonstrated a positive correlation 
between average parameter estimate at the posterior cingulate and disease duration 
(cluster #21, b = 0.522, p = 0.013) (Appendix Table 14). 
 
While these results were all significant at the standard p < 0.05 level, after correcting 
the p-value using the Bonferroni method, none of these results remained significant 
(p-value required to reach significance, < 0.000272, based on performing 184 
regression analyses).  
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5.5. Discussion 
5.5.1. Findings 
This study investigates the pattern of caudate nucleus, putamen and thalamus 
functional connectivity and morphology alterations associated with cognitive 
impairment and dementia in PD. Our study contributes new knowledge by showing 
how important functional subdivisions of these structures are impacted across 
cognitive disease stages. Our results indicate that PD-CU participants display 
increased functional connectivity of the dorsal caudate, anterior putamen and 
mediodorsal thalamus with neuroanatomical areas across the frontal lobe, as well as 
reduced functional connectivity of the dorsal caudate with posterior cortical and 
cerebellar regions, compared to Controls. PD-MCI participants demonstrated reduced 
functional connectivity of the mediodorsal thalamus with midline structures within 
the executive control network while PDD participants demonstrated reduced 
functional connectivity of the mediodorsal thalamus with the posterior cingulate 
cortex, a key node within the default mode network. Significant volumetric and 
surface based changes to the caudate nucleus, putamen and thalamus were found 
exclusively in our PDD cohort, suggesting that functional connectivity changes in 
PD-CU and PD-MCI take place independently of observable morphological 
alterations. 
 
Our research found no evidence of morphological alterations to the caudate, putamen 
or thalamus in PD-CU participants compared to Controls, supporting the findings 
from a number of studies (Lee et al., 2014, Mak et al., 2014, Mckeown et al., 2008, 
Menke et al., 2014, Messina et al., 2011, Nemmi et al., 2015, Tinaz et al., 2011). We 
also found no evidence of atrophy to the caudate, putamen or thalamus in PD-MCI 
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compared to Controls, supporting work by Amboni et al. (2015). Our data indicate 
that PDD participants have reduced caudate volumes (bilaterally) in PDD compared 
to PD-CU and Controls. Left putamen and left thalamus volumes were reduced in 
PDD compared to PD-CU and Controls, while the right putamen and right thalamus 
was reduced in PDD compared to Controls and PD-CU, respectively. These results 
support studies showing reduced caudate, putamen and thalamic grey matter changes 
in PD participants with dementia compared to controls (Burton et al., 2004, Melzer et 
al., 2012, Summerfield et al., 2005). Shape analysis of these structures found 
widespread surface contraction in PDD compared to PD-CU, fine-tuning these 
volumetric results. Regarding the caudate, surface contraction was found primarily at 
the rostral and dorsomedial surfaces, areas with putative connectivity to the executive 
regions of the frontal lobe as well as the rostral motor regions (Tziortzi et al., 2014). 
Surface contraction was also found at the anterior, dorsal and posterior putamen 
surface regions areas with putative connectivity to the executive regions of the frontal 
lobe as well as caudal motor regions (Tziortzi et al., 2014). Widespread surface 
contraction was found primarily across the medial surface of the bilateral thalami, 
corresponding to surface regions of the anterior and mediodorsal thalamic nuclei with 
putative structural connections to the dorsolateral and prefrontal cortices (Behrens et 
al., 2003) as well as posterior cingulate, precuneus and hippocampal brain regions 
(Cunningham et al., 2017). No significant surface changes were found when 
comparing the other experimental groups. Our findings support the work of Mak et al. 
(2014) who found no significant difference between PD-MCI and cognitively 
unimpaired PD participants using a vertex-wise shape analysis method. Our 
morphological data on PD-CU participants are also consistent with previous studies 
which indicate that PD is not associated with localised surface based alterations (Lee 
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et al., 2014, Menke et al., 2014, Messina et al., 2011) however they contrast with the 
results of two groups who found localised surface contraction in PD (Garg et al., 
2015, Mckeown et al., 2008). Methodological inconsistencies between studies, 
including disease duration and symptom profiles, may be a significant factor behind 
these differences. 
 
Our findings of increased functional connectivity between the dorsal caudate, anterior 
putamen and mediodorsal thalamus with the pre- and postcentral gyri support a recent 
meta-analysis indicating that PD is associated with increased functional connectivity 
of these brain regions (Ji et al., 2018). After weighing the relative contributions of 
seed-ROIs, Ji et al. (2018) were able to demonstrate that seeds placed within the 
caudate, putamen and thalamus contributed most to this result. More specifically, our 
finding supports work by Gorges et al. (2015) who found increases in functional 
connectivity between a basal ganglia-thalamic network and areas of the prefrontal 
cortex and anterior/paracingulate gyri. These researchers argue that such hyper-
connectivity in cognitively unimpaired PD participants may be representative of the 
recruitment of additional resources in the brain to maintain cognitive performance 
(Gorges et al., 2015). Our results support our hypotheses, and may signal how 
resources can be recruited to maintain ‘normal’ cognitive functioning. These increases 
in functional connectivity may be indicative of compensatory changes taking place 
within the executive control network (ECN). This network is comprised of dorsal and 
ventrolateral prefrontal, frontoinsular, lateral parietal, middle prefrontal cortices, 
anterior and paracingulate gyri, as well as subcortical sites at the mediodorsal and 
anterior thalamic nuclei and the dorsal caudate (Beckmann et al., 2005, Seeley et al., 
2007). The ECN has been validated on a large scale and has shown that activity 
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within this network corresponds strongly with several paradigms of cognition in task-
based functional connectivity analyses (Smith et al., 2009).  
 
Our data also indicate that PD-CU is associated with a reduction in functional 
connectivity between the dorsal caudate and the cerebellum. This result supports the 
findings of Hacker et al. (2012) who demonstrated decreases in functional 
connectivity between the caudate nucleus and an ‘extended brainstem’ region 
encompassing the cerebellum. These findings are significant because loss of 
functional connectivity between the caudate and the cerebellum may serve as a viable 
candidate for PD related gait difficulties, postural instability and freezing, which can 
be linked to dysfunction in cerebellar circuitry (Hacker et al., 2012). Our data also 
indicate that PD-CU participants have decreased functional connectivity between the 
dorsal caudate/anterior putamen and the precuneus and angular gyrus. This finding 
supports the work of Amboni et al. (2015) who found decreases in functional 
connectivity between nodes in the default mode network (DMN), including lateral 
and medial parietal regions. 
 
While our results support a number of previous research findings, they contrast with 
similar work, necessitating explication. Bell et al. (2015) demonstrated no significant 
differences in functional connectivity of the anterior striatum in a PD cohort (when 
placed on medication) compared to Control participants. They also found no 
differences in functional connectivity of seed-ROIs in the thalamus with intrinsic 
connectivity networks. Similarly, our data contrast with the work of Agosta et al. 
(2014b) who found decreased functional connectivity between the caudate and 
putamen and brain regions across the frontal lobe, as well as hypo-connectivity of the 
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thalamus with insular cortices. There are a number of methodological considerations 
that may explain these discrepancies. The work of Bell and colleagues (2015) 
involved a younger PD cohort to the current study, which brings into question the 
impact of age related changes in functional connectivity (Fair et al., 2008), while the 
work of Agosta et al. (2014b) focussed on a PD cohort with unilateral disease 
presentation, studying functional connectivity of the ‘more affected’ and ‘less 
affected’ hemispheres. This approach increases the specificity of their analysis, 
however it makes comparisons with the present data difficult as we averaged 
functional connectivity signals from seeds within both hemispheres. 
 
PD-MCI participants showed decreased functional connectivity of the mediodorsal 
thalamus with the paracingulate gyrus, medial frontal gyrus and frontal pole 
compared to PD-CU participants. These findings support the work of Gorges et al. 
(2015) who showed that PD-MCI is associated with lower functional connectivity 
between a basal ganglia-thalamic intrinsic connectivity network and the 
anterior/paracingulate gyri compared to a cognitively unimpaired PD cohort. 
Decreased functional connectivity between the mediodorsal thalamus and medial 
prefrontal brain regions provides further evidence for the important link between 
midline nodes within the ECN and cognitive function. As outlined, structures within 
this intrinsic connectivity network are related to cognitive function (Beckmann et al., 
2005, Seeley et al., 2007), as they work together to provide bias signals to other areas 
of the brain to implement and maintain cognitive control processes (Miller and 
Cohen, 2001). While we have demonstrated increased functional connectivity of 
nodes within this network in cognitively unimpaired PD participants, here we 
demonstrate that PD-MCI subjects have a reduced functional connectivity between 
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the mediodorsal thalamus and paracingulate cortices. While traditionally thought to be 
subserve affective functions, the cingulate has emerged as an important structure 
associated with higher cognitive processes, and has been shown to be particularly 
vulnerable to disease processes where executive control is impaired (Carter et al., 
2000). Seeley et al. (2007) demonstrated that stronger functional connectivity 
between nodes of the ECN correlated positively with superior executive task 
performance of participants. If the corollary holds true, this would indicate that poorer 
cognitive performance, as our PD-MCI participants demonstrate, would be associated 
with reduced functional connectivity within this network, which our results show.  
 
PDD participants showed decreased functional connectivity of the mediodorsal 
thalamus with the PCC compared to PD-MCI participants, directly supporting recent 
graph theoretical research (Zhan et al., 2018). Decreases in functional connectivity 
between these regions is significant due to the crucial role played by the PCC in 
cognitive functioning as well as the role of the mediodorsal thalamus and PCC within 
the DMN. The functional role played by the PCC involves elements of memory 
consolidation, attention and the control required to balance internally and externally 
focussed thoughts (Leech and Sharp, 2014). The PCC is known to be crucial to the 
symptomology associated Alzheimer disease (Buckner et al., 2009, Greicius et al., 
2004, Mevel et al., 2011) and atrophy of the PCC has been demonstrated in PD 
participants with dementia (Melzer et al., 2012). The PCC has important structural 
and functional connectivity with the thalamus (Cunningham et al., 2017) and Greicius 
et al. (2003) suggested that the structure may play an important role balancing the 
interaction between brain regions in the prefrontal cortex that are involved cognitive 
processes and posterior nodes within the DMN. These researchers suggested that the 
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thalamus is uniquely positioned to act as an intermediary structure in the brain that 
balances the interaction between these regions due to its extensive cortico-cortical 
connectivity (Greicius et al., 2003). Our research supports this idea, highlighting how 
the functional connectivity between the mediodorsal thalamus and the PCC is 
impacted in PD participants with dementia. 
 
We found a number of interesting correlations between functional connectivity and 
clinical variables, however it is important to reiterate that these findings did not meet 
the highly conservative criteria for significance after controlling for multiple 
comparisons (p < 0.00027). Firstly, we found evidence that PD-CU participants with 
lower MMSE scores had increased functional connectivity of the dorsal caudate with 
the right middle frontal gyrus. We also found evidence that PD-CU participants with 
lower MMSE scores had increased functional connectivity of the anterior putamen 
with the right middle frontal, left paracingulate and left middle frontal gyri. These 
results are interesting as they suggest that PD-CU patients with lower global cognitive 
scores had increased functional connectivity with prefrontal regions of the brain, 
supporting our hypothesis that increases in functional connectivity may be evidence 
of a compensatory response to alleviate the impact of PD pathophysiology. We also 
found evidence that PD-CU participants with higher LEDD had increased functional 
connectivity of the anterior putamen with right postcentral and right inferior frontal 
gyri. These results support research which has demonstrated that dopaminergic 
medication can increase functional connectivity between the striatum and 
ventrolateral prefrontal cortices, while it can be associated with a decrease in 
functional connectivity with posterior cortical regions (Kelly et al., 2009). 
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Our findings provide partial support for our model regarding the relationship between 
functional connectivity and morphology across PD cognitive disease states. PD-CU 
participants showed no observable morphological changes compared to Controls, 
however they displayed significant increases in functional connectivity with 
prefrontal regions of the brain. At a number of sites in the brain, increased functional 
connectivity was associated with lower global cognitive scores. Taken together, these 
results may be evidence of compensatory mechanisms whereby the brain recruits 
additional neuronal resources to maintain normal cognitive function, due to impact of 
disease-related pathology. We hypothesised that neuronal resources that support this 
functional compensation would be diminished in PD-MCI and PDD, evidenced by 
morphological alterations to the caudate nucleus, putamen and thalamus with 
consequent reductions in functional connectivity. Whilst we found that PD-MCI 
participants showed reductions in functional connectivity compared to PD-CU 
participants, this was despite any observable morphological differences between the 
groups, which runs counter to our hypotheses. Supporting our hypothetical model, 
PDD participants displayed significant reductions in both surface morphology and 
seed-based functional connectivity. 
 
5.5.2. Limitations 
This research was performed in a cross-sectional manner, assuming a sequential 
temporal relationship between PD-CU, PD-MCI and PDD groupings, though we 
acknowledge that the progression of cognitive impairment from one stage to the next 
is not necessarily linear. Future research should follow a longitudinal design to better 
study how functional connectivity and morphology of basal ganglia-thalamocortical 
circuits are related to cognitive impairment in PD. This would have the added benefit 
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of reducing the influence of the significant disease heterogeneity in PD which has 
been shown to have a significant impact on the reproducibility of results in this field 
of research (Badea et al., 2017). Drawing conclusions about functional connectivity 
may also be limited by the influence of dopaminergic medication, which has been 
shown to be related to changes in functional connectivity in placebo-controlled 
healthy participants (Kelly et al., 2009) and also in research participants with PD (Bell 
et al., 2015). 
 
5.5.3. Conclusion 
This study demonstrated how the functional connectivity of subcortical hubs within 
basal ganglia-thalamocortical circuits are implicated in PD between cognitive disease 
stages. Functional connectivity changes are found in PD-CU participants, who display 
no morphological changes, while PD-MCI participants and PDD participants both 
display decreases in functional connectivity of the mediodorsal thalamus with the 
anterior and posterior cingulate cortices respectively. Our research highlights the 
importance of the caudate, putamen and thalamus as core structures within key 
intrinsic connectivity networks in the brain, and indicates that a breakdown in 
functional connectivity of the mediodorsal thalamus is tied to mild cognitive 
impairment and dementia in PD.  
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6. Project four: Corpus callosum 
This thesis has investigated subcortical structures of the caudate nucleus, putamen and 
thalamus and how their morphology and functional connectivity are impacted in PD. 
Each project focussed on a structure within basal ganglia-thalamocortical networks, 
with Project three investigating these variables from the vantage point of levels of 
cognitive impairment. For a more complete view of the neural circuit underpinnings 
associated with clinical dysfunction in PD, it is helpful to look orthogonally from the 
basal ganglia-thalamocortical circuit, which can be performed by analysing the 
structure of the corpus callosum. An analysis of the corpus callosum is warranted due 
to the important role played by the structure in facilitating interhemispheric neuronal 
activity. The structure is known to connect widescale networks, and demonstrates 
topographic connectivity between homologous cortical regions. This provides an 
opportunity to investigate thickness of the corpus callosum as a possible measure of 
cortical thickness, which could have potential as a biomarker in clinical contexts. 
Research for this chapter is based on a draft manuscript currently being prepared for 
publication. 
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Figure 6.1: Project four. The current project focusses on the corpus callosum as the major 
white matter tract, or ‘spoke’, connecting the two cerebral hemispheres, crucial to a range of 
higher-order processes in the brain. Thickness of the structure was thus investigated relative 
to levels of cognitive impairment, clinical function and cortical thicknesses. 
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6.1. Abstract 
People diagnosed with Parkinson disease (PD) can experience significant 
neuropsychiatric symptoms, including cognitive impairment and dementia, the 
neuroanatomical substrates of which are still not fully understood. The corpus 
callosum is the largest white matter tract in the brain, crucial to interhemispheric 
information transfer and thus critical to effective cognitive functioning. Symptoms 
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associated with cognitive impairment and dementia may relate to structural changes to 
the callosum via primary white matter pathology or as a secondary outcome due to 
cortical degeneration. The objective of this project was thus to investigate the 
thickness of the callosum and cortex in patients with PD with varying levels of 
cognitive impairment, and study how these two neuroimaging metrics are related. 
This project investigated the thickness of the callosum in the midsagittal plane using a 
semi-automated pipeline in cognitively unimpaired PD participants (n = 35), PD 
participants with mild cognitive impairment (n = 22), PD participants with dementia 
(n = 17) and a healthy control group (n = 27). Pairwise comparisons of midsagittal 
callosal thicknesses found thinning of the structure in PD-related dementia compared 
to PD-related mild cognitive impairment and cognitively unimpaired PD participants. 
Regression analyses investigating relationships between callosal thickness and 
cortical thickness found thickness of the left medial orbitofrontal cortex to be 
positively correlated with thickness of the anterior callosum in PD-related mild 
cognitive impairment, with all other analyses yielding non-significant results. 
Regression analyses investigating potential relationships between callosal thickness 
and clinical variables produced no significant results. This study suggests that a mid-
sagittal thickness model can uncover changes to the corpus callosum in PD-related 
dementia, however it has a limited usefulness in early disease stages, or as a potential 
biomarker of cortical thickness or clinical function. 
 
6.2. Introduction 
Parkinson disease (PD) is the second most common neurodegenerative disease in the 
world, directly affecting 2-3% of the population over the age of 65 (Poewe et al., 
2017). Longitudinal research has indicated that around 80% of PD patients develop 
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dementia across the disease course (Hely et al., 2005) which has significant impact on 
patients and caregivers. Mild cognitive impairment (MCI) in PD has emerged as an 
important clinical diagnosis and research focus, as it may represent an intermediate 
stage in the progression of the disease from cognitively unimpaired PD to PD-related 
dementia (Litvan et al., 2012). PD-related MCI identifies patients with impairment 
primarily affecting attention, working memory, executive function, language and 
visuospatial function (Litvan et al., 2012). While significant attention has been paid to 
grey matter changes associated with cognitive impairment, white matter damage may 
be an important pathological substrate of cognitive impairment, which may precede 
grey matter changes (Rektor et al., 2018). All domains of cognitive function require 
the integration of distributed neural activity via white matter connections (Van Den 
Heuvel and Sporns, 2013) and the corpus callosum is crucial in facilitating the 
interhemispheric processes associated with cognitive function (Doron and Gazzaniga, 
2008). The callosum is the largest white matter structure in the brain, comprising over 
one hundred million topographically arranged neurons (Schmahmann and Pandya, 
2009). Given that the majority of interhemispheric fibres from cortical regions 
traverse the callosum, the structure is seen as attractive target for research as regional 
cortical brain changes may be reflected in regional changes to the morphology of the 
callosum (Walterfang and Velakoulis, 2014). Information on the relationship between 
the structure of the callosum and clinical function can also be investigated, as it has 
been argued that the integrity and density of the callosal axons reflects the functional 
capacity of the brain regions they connect (Aboitiz et al., 1992).  
 
The callosum is an attractive candidate for structural brain imaging analysis due to its 
bright intensity and clear contrast on sagittal magnetic resonance imaging (MRI), 
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facilitating segmentation from surrounding tissue types. Accordingly, numerous 
schemes have been proposed to describe the morphology of the structure, including 
areal subdivision (Witelson, 1989), cortical endpoint (Hofer and Frahm, 2006), 
boundary tangent (Joshi et al., 2013) and cross-sectional thickness models (Adamson 
et al., 2011, Walterfang et al., 2009). Using a manual segmentation approach, early 
studies demonstrated no significant differences in the area of the total callosum, or in 
evenly spaced subdivisions of the structure, in PD or PD-dementia cohorts compared 
to controls (Wiltshire et al., 2005). More recent 3-dimensional volumetric analyses 
using semi-automated methods found no difference in total volume of the callosum in 
PD compared to controls, however analyses of callosal subdivisions found significant 
thinning in PD, driven by changes in PD-dementia participants (Goldman et al., 
2017). Goldman et al. (2017) were also able to demonstrate that changes in volumes 
of the callosum correlated with measures of clinical function (Goldman et al., 2017). 
Contrasting with this work, Lenka et al. (2017) utilised a volumetric approach and 
found no differences in total callosal volumes, or callosal subdivisions, in PD 
compared to controls, while Vasconcellos et al. (2018) found thinning of callosal 
subdivisions in PD, however they present no data on differences in callosal thickness 
between groups of PD patients based on levels of cognitive impairment. Our work 
attempts to advance this field of research by investigating the structure of the corpus 
callosum using a semi-automated computational tool that that models callosal 
morphology with thickness ‘streamlines’ placed at 100 points along the length of the 
structure at the mid-sagittal plane. Such a fine-grained approach may uncover greater 
detail about how the regional structure of the callosum is impacted in PD early in the 
disease course, when putative morphological alterations may be harder to detect with 
traditional volumetric approaches. This approach may also yield important 
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information on how the structure of the callosum informs on changes to the cerebral 
cortex, and measures of clinical function, opening up avenues for clinical translation 
tools. 
 
It was thus hypothesised that PD participants would demonstrate reduced thickness of 
the corpus callosum and cortex compared to controls. Research has shown that greater 
thickness of the callosum is linked to measures of general cognitive ability (Luders et 
al., 2007) and as there are increased structural changes to both grey and white matter 
structures in the brain with increasing levels of cognitive impairment, we 
hypothesised that changes in thickness of the corpus callosum would be more 
pronounced in MCI participants compared to cognitively unimpaired PD, and 
controls, while PD participants with dementia would have significant and widespread 
reductions in callosal thickness compared to PD with MCI and cognitively 
unimpaired PD participants. Due to the structural connectivity between the corpus 
callosum and cortex, it was also hypothesised that the thickness of the corpus 
callosum would correlate with thickness at particular cortical regions, highlighting a 
potential usefulness for corpus callosal thickness as a proxy measure of cortical 
degeneration in PD. This final hypothesis would be useful as the quantification of 
corpus callosal thickness has a potential for clinical translation and can be measured 
on an MRI scan, whereas quantifying changes to the cerebral cortex requires full 
processing of a scan which takes between 20 and 30 hours per individual 
(Gronenschild et al., 2012). 
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6.3. Methods  
6.3.1. Participants 
Participants in this research (n = 101) were from the Swedish BioFinder study 
(www.biofinder.se) and gave informed written consent. This research was performed 
in accordance with the World Medical Association’s Declaration of Helsinki and 
ethical approval was obtained through the Ethical Review Board of Lund, Sweden, 
and the Human Research Ethics Committee at the Australian National University, 
Canberra, Australia. 
 
6.3.2. PD disease groups: cognitive impairment 
Diagnosis of PD was made by a neurologist using the National Institute of 
Neurological and Stroke Diagnostic Criteria (Gelb et al., 1999). PD participants were 
divided into three cognitive impairment disease groups, the first group comprising 
cognitively unimpaired PD patients (PD-CU; n = 35); the second group comprising 
PD patients with MCI (PD-MCI; n = 22), with the diagnosis based on the Movement 
Disorder Society Task force guidelines (Litvan et al., 2012). This criterion is met 
when patients score at least 1 standard deviation below the normative mean in at least 
two cognitive tests, including executive function, attention, visuospatial, memory and 
language domains. The third subgroup consisted of PD participants with comorbid 
dementia (PDD; n = 17) (Emre et al., 2007). A healthy control group (Controls) was 
included for comparative purposes (n = 27). Exclusion criteria for this study included 
presence of a developmental disability, alcohol or substance abuse, poor knowledge 
of the Swedish language or the presence of a metabolic disorder. All participants 
underwent a cognitive and neurological examination by a medical doctor with 
extensive experience with movement disorders, while PD patients remained on their 
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usual medication regimes. Clinical functioning of participants was quantified using 
the Hoehn and Yahr staging, assessing the progression of the disorder, the Unified 
Parkinson’s Disease Rating Scale Part-III test (UPDRS-III), assessing the motor signs 
of PD (Fahn and Elton, 1987); the Mini Mental State Examination (MMSE), 
assessing cognitive mental state (Folstein et al., 1975); the A Quick Test of Cognitive 
Speed (AQT) assessing perceptual and cognitive speed (Jacobson et al., 2004) and the 
‘Letter S Fluency’ (LSF) and ‘Animal Fluency’ (AF) tests, assessing the verbal 
fluency aspect of executive function (Tombaugh et al., 1999). 
 
6.3.3. MRI acquisition 
MRI data was obtained on a 3T scanner (Trio, Siemens Magnetom, Erlangen, 
Germany) with a 20-channel head-coil. High resolution T1-weighted three-
dimensional anatomical brain images were acquired using a magnetization-prepared 
rapid acquisition technique with gradient-echo sequence (repetition time = 7 ms; echo 
time = 3 ms; flip angle = 90 degrees; voxel size = isotropic 1mm3). Image matrix size 
was 356 voxels in the coronal and sagittal planes and 176 voxels in the axial plane. 
 
6.3.4. Morphometry of the corpus callosum 
Morphometry of the corpus callosum was estimated using a semi-automated pipeline 
(https://github.com/chrisadamsonmcri/CCSegThickness), explained in detail in 
previously published works (Adamson et al., 2014, Adamson et al., 2011). Generally 
speaking, the pipeline involves the identification of the mid-sagittal plane in subjects 
T1-MRI data (Figure 6.2 A), followed by template guided segmentation of the corpus 
callosum, topological error fixing and the removal of pericallosal blood vessels 
(Adamson et al., 2014). After the structure has been segmented, thickness profile 
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generation is performed using the following steps: the callosum is split into left 
(posterior) and right (anterior) halves with an endpoint selected at the bottom-right 
and -left extrema. A midline equipotential contour is produced between these 
endpoints, as a solution to Laplace’s equation, maximising the length of the midline 
contour of the callosum, subdividing the outside boundary contour of the structure 
into superior and inferior contours. Streamlines are then generated at evenly spaced 
intervals along the centre contour, which are non-overlapping nominally parallel lines 
intersecting the superior and inferior contours orthogonally along an anterior-posterior 
trajectory (Figure 6.2B). 100 streamlines per subject were created for this study, 
modelled as callosal thickness during statistical analyses (Figure 6.2C). The first and 
last ten streamlines are removed during statistical analyses as the meaning of the 
MSP-thickness profile at the genu and splenium is still not yet fully characterised. 
 
 
Figure 6.2: Generation of mid-sagittal thickness streamlines. A) Shows a mid-
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sagittal callosal segmentation in an example subject; B) shows the non-overlapping 
cross-sectional contour lengths (streamlines) numbered from 0 at the intersection of 
the inferior and superior contours of the corpus callosum, moving anteriorly to node 
100 at the most rostral end of the corpus callosum; C) shows the lengths (thickness) of 
each streamline at the 100 nodes. 
 
6.3.5. Cortical grey matter thickness analysis 
Cortical reconstruction and segmentation of grey matter was performed with the 
FreeSurfer image analysis suite (version 6.00). Technical details of these procedures 
are described in published works (Dale et al., 1999, Fischl and Dale, 2000). Briefly, 
processing includes motion correction and averaging (Reuter et al., 2010) of multiple 
volumetric T1-weighted images, removal of non-brain tissue using a deformation 
procedure (Segonne et al., 2004), automated Talairach transformation, intensity 
normalization (Sled et al., 1998), tessellation of the grey matter-white matter 
boundary, automated topology correction (Fischl et al., 2001, Segonne et al., 2007), 
surface deformation along intensity gradients to optimally define cortical surface 
borders, registration to a spherical atlas using individual cortical folding patterns to 
align cortical anatomy between participants (Fischl et al., 1999), and finally, the 
parcellation of the cerebral cortex into units with respect to gyral and sulcal structure 
based on the Desikan-Killiany atlas (Desikan et al., 2006, Fischl et al., 2004). 
 
6.3.6. Statistical analyses 
Statistical analyses were performed using IBM SPSS Statistics for Macintosh, 
(Version 22.0). Multiple regression analyses were performed with scripts utilising the 
following Python packages: Pandas, Matplotlib, Numpy, Statsmodels and Seaborn. 
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6.3.6.1. Group differences in corpus callosum thickness 
To investigate group differences in the morphometry of the corpus callosum at the 80 
streamlines, we performed a series of multivariate analyses of covariance. Group 
membership was the fixed factor, with average callosal thickness for each group at 
each streamline serving as the dependent variable. Estimated total intracranial volume 
(eTIV), sex and age were entered as confounding variables. We controlled the false-
discovery rate (FDR) using the Benjamini-Hochberg procedure with a q = 5%. 
 
6.3.6.2. Group differences in cortical thickness 
Average cortical thicknesses for the 31 ROIs (per hemisphere) for each participant 
were used as dependent variables in a multivariate analysis of covariance, with 
experimental group as the fixed factor, and age and eTIV as confounding variables. 
We controlled the FDR using the Benjamini-Hochberg procedure with a q = 5%. 
 
6.3.6.3. Correlations between corpus callosal and cortical thickness 
To investigate the relationship between thickness of the callosum and cortical 
thickness at the 62 cortical ROIs, we ran a series of multiple regressions for each 
experimental group. These analyses controlled for age and eTIV, producing beta 
correlation coefficients indicating the magnitude and directionality of the relationship 
for each group and p-value n x m matries, where n = the number of callosal thickness 
measurements (n = 80) and m = the number of cortical thickness measurements (m = 
62), FDR corrected using the Benjamini-Hochberg procedure with a q = 5%. The 
Python scripts used for these analyses are available online in a Github repository 
(https://github.com/ConorOW/corpus_callosum/blob/master/CC_CT_correlations.py).  
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6.3.6.4. Correlations between corpus callosal thickness and clinical function 
To investigate the relationship between thickness of the callosum and measures of 
clinical function, we ran a series of multiple regressions for each experimental group. 
These analyses controlled for age and eTIV, producing beta correlation coefficients 
indicating the directionality of the relationship for each group and p-value n x m 
matries, where n = the number of callosal thickness measurements (n = 80) and m = 
the number of clinical function metrics (m = 6), FDR corrected q = 5%. The script 
used for these analyses are available online in a Github repository 
(https://github.com/ConorOW/corpus_callosum/blob/master/CC_function_correlation
s.py). 
 
6.4. Results 
6.4.1. Participant characteristics 
Participant characteristics in this research are displayed in Table 6.1. A Chi-square 
test for independence found no significant difference in sex between the groups [c2(3, 
n = 98) = 0.828, p = 0.843]. One-way analyses of variance found no significant 
difference in age [F(3, 97) = 2.166, p = 0.097], years of education [F(3, 82) = 1.159, p 
= 0.331] or eTIV [F(3, 97) = 0.036, p = 0.991] between experimental groups (Table 
6.1). There was a significant difference in disease duration between the PD cohorts 
[F(2, 71) = 10.299, p = <0.001], with post-hoc analyses of variance showing that the 
PDD cohort had a significantly longer duration than the PD and PD-MCI cohorts. As 
expected, there were significant differences in UPDRS-III [F(3,97) = 47.96, p < 
0.001], MMSE [F(3,97) = 4.049, p < 0.001], AF [F(3,96) = 17.28, p  <0.001], LSF 
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[F(3,94) = 11.37, p < 0.001] and AQT [F(3,94) = 18.59, p < 0.001] scores between 
experimental groups. 
 
Table 6.1: Participant characteristics 
Item Controls PD PD-MCI PDD p-value 
Number of 
participants 
27 35 22 17 - 
Female 
/Male 
12/15 17/18 12/10 7/10 0.843 
Average age 
in years 
69.47 
(6.09) 
69.45 
(6.18) 
70.53 
(5.38) 
73.70 
(6.67) 
0.097 
eTIV (cm3) 1572.64 
(157.37) 
1584.91 
(192.19) 
1570.74 
(179.15) 
1580.79 
(222.55) 
0.991 
Years of 
education 
12.54 
(3.47) 
11.68 
(5.35) 
9.66 
(6.807) 
11.5 
(4.52) 
0.331 
Years since 
diagnosis 
- 6.17 
(5.14) 
5.45 
(3.56) 
11.88 
(5.48) 
- 
H&Y - 1.73 
(0.72) 
2 
(0.72) 
2.85 
(0.77) 
- 
UPDRS-III 2.26 
(2.28) 
12.37 
(9.54) 
14.28 
(9.07) 
33 
(10.21) 
<0.001* 
MMSE 28.56 
(1.34) 
28.83 
(1.01) 
27.41 
(1.65) 
22.88 
(3.77) 
<0.001* 
AF 23.56 
(6.26) 
23.57 
(5.79) 
18.86 
(6.24) 
11.81 
(4.18) 
<0.001* 
LSF 18.56 
(6.26) 
16.15 
(5.33) 
12.5 
(5.62) 
9.31 
(4.24) 
<0.001* 
AQT 60.41 
(15.73) 
63.37 
(11.49) 
78.32 
(28.01) 
132.93 
(73.26) 
<0.001* 
Key: Participant data presented as mean (standard deviation). All data corrected to two 
decimal places. Abbreviations: eTIV, estimated total intracranial volume; H&Y, Hoehn and 
Yahr Scale; UPDRS-III, Unified Parkinson’s Disease Rating Scale part-III; MMSE, Mini 
Mental-state Examination; AF, Animal Fluency Test; LSF, Letter S Fluency Test; AQT, A 
Quick Test of Cognitive Speed. 
 
6.4.2 Corpus callosal thickness: pairwise analyses 
Estimated thicknesses of callosal streamlines are presented in Figure 6.3. 
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Figure 6.3: Estimated corpus callosum streamlines for all experimental groups. 
Streamline data represents the estimated averages for each group after controlling for head 
size and age. Abbreviations: PD-CU, cognitively unimpaired PD participants; PD-MCI, PD 
participants with mild cognitive impairment; PDD, PD participants with dementia. 
 
6.4.2.1. Controls and PD-CU 
We found no significant differences in callosal thickness when comparing Controls 
and PD participants (Figure 6.4).  
 
6.4.2.2. Controls and PD-MCI 
We found no significant differences in callosal thickness when comparing Controls 
and PD-MCI participants (Figure 6.4). 
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6.4.2.3. Controls and PDD 
Although this comparison is of less scientific interest, for full transparency we 
compared Controls and PDD groups and found no significant differences in callosal 
thickness when comparing Controls and PDD participants (Figure 6.4) 
 
6.4.2.4. PD and PD-MCI 
We found no differences in callosal thickness when comparing PD to PD-MCI 
participants (Figure 6.4). 
 
6.4.2.5. PD and PDD 
When comparing PD-CU and PDD participants, we found PDD subjects 
demonstrated reduced thickness at streamlines 42 (p = 0.023), 51 (p = 0.049) and 55 
(p = 0.032) (Figure 6.4). 
 
6.4.2.6. PD-MCI and PDD 
When comparing PD-MCI and PDD subjects, we found PDD subjects demonstrated  
reduced thickness at thickness at streamlines 42 (p = 0.039), 54 (p = 0.037), 55 (p = 
0.029) and 56 (p = 0.049) (Figure 6.4) 
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Figure 6.4. Group differences in midsagittal plane corpus callosum thickness. 
Areas of the corpus callosum where the thickness is reduced in one group compared 
to the other. Significant p-values (< 0.05) appear in light blue, becoming warmer in 
colour with lower values. Raw p-values are presented in the left column, with p-
values corrected for multiple comparisons using the Bonferroni method presented on 
the right. Positioning of streamlines are guided by the image at the top. The genu of 
the corpus callosum points to the right of the image, while the splenium faces left. 
Abbreviations: PD-CU, cognitively unimpaired PD participants; PD-MCI, PD participants 
with mild cognitive impairment; PDD, PD participants with dementia. 
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6.4.3. Cortical thickness profiles: pairwise analyses 
6.4.3.1. Controls and PD 
When comparing Controls and PD-CU groups, after controlling for multiple 
comparisons, we found no significant differences in thickness at any cortical region of 
interest (Appendix Table 15). 
 
6.4.3.2. Controls and PD-MCI 
When comparing Controls and PD-MCI groups, after controlling for multiple 
comparisons, we found no significant differences in thickness at any cortical region of 
interest (Appendix Table 16). 
 
6.4.3.3. Controls and PDD 
When comparing Controls and PDD groups, after contolling for multiple 
comparisons, we found that PDD subjects had significantly reduced cortical thickness 
at the left lateral orbitofrontal cortex (p = 0.028), left entorhinal cortex (p = 0.002), 
left fusiform gyrus (p < 0.001), left superior temporal gyrus (p = 0.014), left middle 
temporal gyrus (p = 0.044), left inferior temporal gyrus (p = 0.005), left insula cortex 
(p = 0.023), right lateral orbitofrontal cortex (p = 0.001), right pars triangularis (p = 
0.034), right fusiform gyrus (p < 0.001), right middle temporal gyrus (p = 0.009), 
right inferior temporal gyrus (p < 0.001), right supramarginal cortex (p = 0.011) and 
the right inferior parietal cortex (p = 0.014) (Appendix Table 17) 
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6.4.3.4. PD and PD-MCI 
When comparing PD-CU and PD-MCI groups, after controlling for multiple 
comparisons, we found no significant differences in thickness at any cortical region of 
interest (Appendix Table 18). 
 
6.4.3.5. PD and PDD 
When comparing PD-CU and PDD groups, we found that PDD subjects had reduced 
cortical thickness at the left fusiform gyrus (p = 0.005), left superior temporal gyrus 
(p = 0.0056), left middle temporal gyrus (p = 0.035), left insula  (p = 0.044), right 
lateral orbitofrontal cortex (p = 0.015), right pars triangularis (p = 0.004), right rostral 
middle frontal cortex (p = 0.006), right fusiform gyrus (p = 0.001), right middle 
temporal cortex (p = 0.008) and right inferior temporal cortex (p = 0.001) (Appendix 
Table 19). 
 
6.4.3.6. PD-MCI and PDD 
 When comparing PD-MCI and PDD groups, we found that PDD subjects had 
reduced cortical thickness at the left fusiform gyrus (p = 0.003), left superior temporal 
gyrus (p = 0.003), left transverse temporal gyrus (p = 0.026), left inferior temporal 
gyrus (p = 0.029), right lateral orbitofrontal cortex (p = 0.01), right fusiform gyrus (p 
= 0.004), right parahippocampal gyrus (p = 0.047), right middle temporal gyrus (p = 
0.048) and right inferior temporal gyrus (p = 0.006)  (Appendix Table 20). 
 
6.4.4. Correlation between thickness of the corpus callosum and cortex 
When correlating callosal and cortical thicknesses within each experimental group, 
we found that the thickness of the left medial orbitofrontal cortex, after controlling for 
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multiple comparisons, was significantly positively correlated with thickness of the 
corpus callosum at streamlines 78, 79 and 80 in the PD-MCI group (Figure 6.5). All 
other correlations were non-significant. 
 
 
Figure 6.5. Correlation between callosal thickness and cortical thickness. Beta 
correlation coefficients show the directionality of the relationship between callosal and 
cortical thicknesses. Corrected p-values show the significance for each of these 
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corresponding analyses. Only three relationships remained significant after FDR correction 
for testing, which can be seen in a small white region of the PD-MCI group at streamlines 
78, 79 and 80. Abbreviations: PO, pars orbitalis; MO, medial orbitofrontal cortex; LOR, 
lateral orbitofrontal cortex; PT, pars triangularis; POP, pars opercularis; RMF, rostral 
middle frontal cortex; CMF, caudal middle frontal cortex; SF, superior frontal cortex; PRE, 
precentral cortex; PARA, paracentral cortex; ENT, entorhinal cortex; FUS, fusiform gyrus; 
PH, parahippocampal gyrus; ST, superior temporal cortex; TT, transverse temporal cortex; 
MT, medial temporal cortex; IT, inferior temporal cortex; IN, insula; POS, postcentral 
cortex; SP, superior parietal cortex; SM, supramarginal cortex; IP, inferior parietal cortex; 
PC, precuneus; CUN, cuneus; PER, pericalcarine cortex; LIN, lingual cortex; LOC, lateral 
occipital cortex; RAN, rostral anterior cingulate; CAN, caudal anterior cingulate cortex; 
PCC, posterior cingulate cortex; IST, isthmus cingulate cortex; 
 
6.4.5. Correlation between thickness of the corpus callosum and clinical 
variables 
We found no significant correlations between thickness of the corpus callosum and 
clinical variables in any of the PD subgroups or Controls. 
 
6.5. Discussion 
6.5.1. Findings 
This study uses an advanced mid-sagittal corpus callosal morphology technique to 
investigate changes to the thickness of the structure in Parkinson disease patients with 
varying levels of cognitive impairment. This was followed by an analysis of the 
thickness of cortical regions of interest across these disease subgroups, and an 
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investigation of the usefulness of callosal thickness as a predictor of cortical 
thicknesses and clinical variables.  
 
This study demonstrated no significant differences in thickness of callosal streamlines 
in PD-CU subjects compared to Controls, supporting early 2-dimensional area-based 
findings (Wiltshire et al., 2005) as well as a recent 3-dimensional volumetric study 
(Lenka et al., 2017). Two studies showed volumes of callosal subdivisions are 
reduced in a total PD cohort comprising participants with and without cognitive 
impairment and also dementia (Goldman et al., 2017, Vasconcellos et al., 2018). 
Analyses between PD-disease subgroups in Goldman et al. (2017) indicate that their 
finding is likely due to significant changes in the PD participants diagnosed with 
dementia, and the results of the current study supports this finding. PDD participants 
in our study demonstrated reduced callosal thickness compared to PD-CU and PD-
MCI, predominantly around central and mid-posterior callosal regions. The work of 
Goldman et al. (2017) also found no differences in callosal volumes in a PD cohort 
with MCI compared to cognitively unimpaired PD participants, or a control group, 
supporting our findings. In this context, our study builds on previous research 
findings and indicates that the morphology of the corpus callosum is impacted in 
advanced PD stages, and that PD patients with mild or no cognitive impairment have 
observable structural alterations to the callosum. 
 
Considering possible pathophysiological mechanisms that may be responsible for 
structural changes observed in the callosum in PD dementia, it has been suggested 
that changes may be due to ‘Wallerian degeneration’ whereby atrophy of connected 
cortical regions is passed down neuronal axons causing a loss of synapses and 
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subsequent neurodegeneration of the structure (Coleman and Freeman, 2010). A 
second pathophysiological mechanism that may contribute to thinning of the corpus 
callosum in PD related dementia relates to the effects of primary white matter 
pathology. This has been hypothesised to drive atrophic callosal changes in 
Alzheimer disease (Di Paola et al., 2010) and diffusion weighted imaging research 
has demonstrated that microstructural white matter integrity is reduced in PD, and that 
these changes increase with levels of cognitive dysfunction (Agosta et al., 2014a, 
Bledsoe et al., 2018, Melzer et al., 2013). 
 
To investigate whether changes in the thickness of the corpus callosum are reflective 
of changes to connected cortical regions, this study investigated associations between 
these two metrics. Such an investigation was performed due to there being evidence 
that there are partially overlapping genetic loci involved in the thickness of both 
structures (Gozzo et al., 1979), while in people with corpus callosum agenesis, there 
are fewer cortical neurons in areas which are expected to receive input from the 
callosum (Abreu-Villaca et al., 2002). While we found a small relationship between 
left medial orbitofrontal cortical thickness and streamlines in the anterior corpus 
callosum in PD-MCI participants, the overwhelming majority of correlational 
analyses between thickness of the callosum and thickness of the cortex showed no 
significant relationships. Due to this lack of a clear relationship between callosal and 
cortical thickness, our chosen method of modelling callosal thickness via mid-sagittal 
non-overlapping streamlines is unable to be used as a proxy measure of changes to the 
cerebral cortex. 
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Cortical thickness changes were not the primary focus of this study, and have been 
documented both cross-sectionally (Mak et al., 2015, Melzer et al., 2012, Pereira et 
al., 2014, Segura et al., 2014, Tinaz et al., 2011, Wilson et al., 2019, Zarei et al., 
2013) and longitudinally (Hanganu and Monchi, 2016, Ibarretxe‐Bilbao et al., 2012, 
Mak et al., 2015), however they are worth mentioning at this stage as they can shed 
light on other results in this study. The present work found a lack of significant 
differences in cortical thickness between our PD-CU group and Controls, which is 
consistent with a number of previous studies (Ibarretxe‐Bilbao et al., 2012, Melzer et 
al., 2012, Zarei et al., 2013). However, a number of works have demonstrated reduced 
cortical thickness in cognitively unimpaired groups compared to control subjects 
(Pereira et al., 2014, Segura et al., 2014, Tinaz et al., 2011, Wilson et al., 2019). 
Changes in PD cohorts with MCI are more common (Mak et al., 2015, Melzer et al., 
2012), and our demonstration of reductions in cortical thickness in frontal and 
temporal cortices in PDD broadly support findings in the literature, with extensive 
grey matter changes commonly found in frontal, temporal and also parietal cortices 
(Burton et al., 2004, Zarei et al., 2013). While there are a number of similarities 
between the present work and previous studies, both in terms of changes to the corpus 
callosum and the cortex, there are also inconsistencies. Factors that may account for 
these discordant findings include variable disease staging and symptom profiles of PD 
cohorts, as well as variable methods used to assess structural brain changes, and the 
statistical methods used to analyse the results. 
 
6.5.2. Limitations 
Morphological analysis of brain structures can be performed with a number of shape 
descriptors, and thickness is just one way to sample this concept. The current work 
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models thickness of the callosum via the use of nominally-parallel non-overlapping 
thickness streamlines which are evenly placed along the midline of the structure, 
connecting orthogonally with the superior and inferior callosal edges. This method 
was developed to better model thickness of the structure without having to use a 
volumetric approach, which can be a difficult concept to reconcile given that lateral 
boundaries of the structure are hard to model in 3-dimensions due to a lack of clear 
anatomical boundaries (Walterfang and Velakoulis, 2014). While our chosen method 
samples thickness at very fine-grained level of detail, the approach may miss 
morphological alterations to the callosum that take place at other points along the 
sagittal plane. A second possible limitation involves the incompatibility of our chosen 
method for analysing the genu and splenium of the callosum. As shown in Figure 
6.2B, streamlines generated in these regions run in a curvilinear fashion, to maintain 
orthogonal connecting points with the superior and inferior boundaries of the 
structure. This makes the interpretation of their lengths difficult, which is important 
for the current work when we consider the callosal genu, as fibres from this region 
give rise to the white matter tract of the forceps minor that connects frontal cortices 
and is crucial to prefrontal cortical functioning (Goldstein and Mesfin, 2019).  
 
6.5.3. Conclusion 
This study demonstrates thinning of the callosum in PD participants with dementia 
compared to cognitively unimpaired PD participants and those with mild cognitive 
impairment. PD participants with dementia also demonstrated significant thinning of 
the cortex, primarily across the frontal and temporal lobes. Thickness of the corpus 
callosum was only correlated with thickness of the cortex in one very small region, 
while callosal thickness was also not significantly correlated with measures of clinical 
6. Project four: Corpus callosum 
 178 
function, limiting the applicability of this metric as a proxy for changes in these 
domains. The findings of this study suggest that the mid-sagittal thickness technique 
is able to detect the expected structural changes to the callosum in the advanced 
disease stage of PD-related dementia, however it is limited in usefulness when 
investigating PD participants with mild or no cognitive impairment. 
 
7. General discussion 
This thesis presents a search for neuroimaging biomarkers associated with clinical 
dysfunction in PD, focussing on the caudate nuclei, putamina, thalami, corpus 
callosum and cortex.  
 
This work was motivated by the fact that significant uncertainty still exists around the 
underlying pathophysiological mechanisms of the disorder and its clinical 
manifestations. The development of novel therapeutic interventions for 
neurodegenerative disorders requires a complete understanding of the in vivo 
neurobiology associated with each disorder, and accordingly the neural circuit basis 
of clinical dysfunction (Looi et al., 2014). A neural circuit-based framework was used  
as a number of the clinical features of the disorder are linked structural brain changes, 
while others are arise due to aberrant brain activity between brain regions (Mcgregor 
and Nelson, 2019). This General Discussion will now present a brief summary of the 
findings of each research project, followed by a consideration of the main 
neuroimaging changes found in this thesis, functional changes in early disease stages 
followed by structural changes in later disease stages. This chapter will then examine 
the main methodological considerations that warrant attention, limitations of the 
projects and possible future directions that may stem from this thesis. This chapter 
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will finish with concluding remarks about what this thesis has demonstrated about 
neuroimaging biomarkers associated with clinical dysfunction in PD. 
 
7.1. Brief Summary of Findings 
Project one of this thesis investigated the morphology and functional connectivity of 
caudate nucleus and putamen, and how morphological changes relate to clinical 
dysfunction in PD. This project demonstrated that volumes of the caudate nuclei and 
putamina are reduced in PD, with subgroup analyses revealing that this result is 
driven by significant atrophy in participants with PD-related dementia. PD 
participants demonstrated a significant correlation between caudate nuclei volumes 
and measures of general cognitive impairment and speed, while putamina volumes 
were correlated with general motor function. No significant surface-based shape 
changes were found in PD compared to Controls. Increased functional connectivity 
was found between the caudate nucleus and the anterior cingulate, medial prefrontal 
and superior frontal gyri, compared to Controls. Decreased functional connectivity 
was found between the caudate nucleus and the brainstem, thalamus, 
parahippocampal gyrus and precuneus. The PD group also showed decreased 
connectivity of the putamen with the cerebellum, inferior and superior parietal 
lobules. 
 
Project two investigated the morphology and functional connectivity of the important 
subdivisions of the thalamus, and how morphological changes relate to clinical 
dysfunction. This project found no evidence of significant volumetric or surface-
based changes to the thalamus in PD compared to Controls. Further, thalamic 
volumes were not correlated with measures of clinical function. Despite this, PD 
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participants demonstrated significant increases in functional connectivity between the 
VLp/VA thalamic nuclei and the supplementary motor area, and between the MD/A 
thalamus and widespread regions across anterior and dorsolateral prefrontal cortices, 
nuclei of the basal ganglia and anterior cingulate regions. 
 
Project three investigated the morphology and functional connectivity of the caudate 
nucleus, putamen and thalamus, but focussed on how these factors are impacted in PD 
relative to levels of cognitive impairment. This project demonstrated significant 
volumetric changes to the caudate nucleus, putamen and thalamus in PDD compared 
to PD-CU and Controls. Surface-based shape analyses of these structures found 
widespread surface deflation at the bilateral rostral as well as dorsomedial surface 
areas of the caudate. Deflation was found at the anterior, dorsal and posterior surface 
regions of the putamen, and significant and widespread deflation was found across the 
medial surface of the bilateral thalami. Significant increases in functional connectivity 
were found between the dorsal caudate nucleus, anterior putamen and mediodorsal 
thalamic subdivisions with areas across the frontal lobe, as well as reduced functional 
connectivity of the dorsal caudate with posterior parietal/lateral occipital and 
cerebellar regions. Compared to cognitively unimpaired participants, PD participants 
with MCI demonstrated reduced functional connectivity of the mediodorsal thalamus 
with midline nodes within the executive-control network. Compared to participants 
with MCI, participants with dementia demonstrated reduced functional connectivity 
of the mediodorsal thalamus with the posterior cingulate cortex, a key area within the 
default-mode network. While not meeting highly conservative multiple comparison-
corrected p-values, this project found evidence that PD participants with lower 
general cognitive scores on the MMSE had increased functional connectivity of the 
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caudate nucleus with the middle frontal gyrus, and between the anterior putamen and 
the middle frontal and paracingulate gyri. Project Three also demonstrated that PD 
participants on higher levodopa-equivalent daily dosages had increased functional 
connectivity of the anterior putamen with right postcentral and inferior frontal gyri. 
 
Project four investigated possible morphological alterations to the corpus callosum 
and cerebral cortex in PD participants relative to levels of cognitive impairment. This 
project also investigated how thickness of the corpus callosum related to the thickness 
of the cerebral cortex and levels of clinical function. This project demonstrated 
widespread thinning of the corpus callosum in PD-related dementia compared to PD- 
MCI and PD-CU participants. This was coupled with significant thinning of frontal, 
temporal and parietal cortices in PDD. Cognitively unimpaired and PD participants 
with MCI demonstrated minimal changes in corpus callosal and cortical thicknesses. 
When correlating the corpus callosal and cortical thicknesses, we found very little 
evidence of a relationship between these metrics, or between the corpus callosal 
thickness and clinical function, limiting the scope for corpus callosal thickness to be 
used as a proxy measure of cortical changes in PD. 
 
The four projects presented in this thesis were focussed on uncovering neuroimaging 
biomarkers associated clinical dysfunction in PD from individual vantage points. 
However, a number of consistent scientific and methodological concepts developed, 
warranting further discussion.  
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7.2. What neuroimaging biomarkers may reveal about the mechanisms 
underlying clinical dysfunction in Parkinson disease 
As outlined in section 1.9. of the Introduction, this thesis employed a network-based 
framework to investigate structural and functional changes to brain ‘hubs’ and 
‘spokes’ and how these changes are related to clinical dysfunction in PD. Using 
functional MRI, this thesis demonstrates that changes to brain ‘spokes’ are more 
pronounced in early disease stages, evidenced by both increases and decreases in 
connectivity of the caudate, putamen and thalamus, despite no significant 
morphological alterations to these structures. Alterations in functional connectivity 
may be indicative of adaptive or maladaptive changes in the brain in response to 
disease pathology. Using structural MRI, this thesis demonstrates that changes to the 
brain ‘hubs’, including the caudate, putamen, thalamus, corpus callosum and also 
cortex in PD are more pronounced at advanced disease stages. Structural changes may 
be due to transneuronal neurodegeneration or the consequences of Lewy pathology, 
both of which may spread via brain networks. This thesis will now unpack these two 
concepts to reveal more about possible pathophysiological mechanisms associated 
with clinical dysfunction in PD. 
 
7.2.1. Functional changes to brain networks in early disease stages 
This thesis showed that PD patients demonstrate decreased functional connectivity of 
striatal and thalamic nuclei with cingulate, lateral occipital and cerebellar brain 
regions. This hypo-connectivity associated with PD may be evidence of a 
‘connectional diaschisis’ which is a maladaptive brain mechanism associated with 
neural injury. Diaschisis was first defined by von Monakow as a temporary 
interruption of function in a particular brain region distal to an injured site in the brain 
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(Von Monakow, 1969). Originally thought to be a transient deafferentation of 
excitatory input most often tied to damage to brain regions following stroke (Fornito 
et al., 2015), the concept has been extended to include alterations in functional 
networks in the brain. This connectional diaschisis, whereby activity changes can be 
found in areas of the brain distal to the site of pathological insult (Carrera and Tononi, 
2014), can occur even if anatomical connectivity between damaged and undamaged 
brain regions remains intact (Van Meer et al., 2010). Results from this thesis suggest 
that such a connectional diaschisis may be useful in understanding network-based 
changes associated with clinical dysfunction in PD patients early in the disease. Such 
a model would suggest that loss of cells in the substantia nigra pars compacta causes 
changes in neural dynamics to the connected nuclei of the striatum, which has flow-
on consequences for brain regions distal to the substantia nigra. 
 
Hypo-connectivity of the striatum was found alongside increases in functional 
connectivity of both the striatum and thalamus with prefrontal regions of the brain. 
This may be evidence of a maladaptive process called ‘dedifferentiation,’ whereby 
typically specialised and segregated brain circuits undergo a non-specific recruitment 
of new brain areas (Rajah and D'esposito, 2005). Reconfiguration of networks in this 
way has been demonstrated experimentally, whereby PD patients shift toward a more 
integrated brain network topology, which is then reversed with the administration of 
dopaminergic medication (Shine et al., 2019). However, this increased integration of 
brain networks was inversely correlated with the symptoms of the disorder, 
suggesting that increased integration of networks may represent a potential 
compensatory mechanism. Compensatory mechanisms may also be tied to the hyper-
connectivity of brain circuits, shown to be a common response to neurological 
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disruption (Hillary et al., 2015). Such an adaptive change associated with neurological 
insult may represent an attempt to maintain homeostasis and performance after neural 
injury (Marder and Goaillard, 2006). 
 
As suggested in Projects one, two and three of this thesis, increases in functional 
connectivity of brain regions found in PD may be evidence of a compensatory 
mechanism whereby the brain attempts to preserve function following pathological 
insult (O'shea et al., 2007). Project three of this thesis presented evidence that the 
degree of cognitive impairment was inversely correlated with the strength of 
functional connectivity of the striatum with prefrontal regions in the brain, a concept 
that is supported by research showing that greater compensatory recruitment of brain 
areas is correlated with the extent and severity of neural damage (Bestmann et al., 
2010). However, persistent hyper-activation of brain regions may place neurons under 
high metabolic duress, making them susceptible to degeneration with progression of 
the disease. Such a process has been suggested to occur across the disease course in 
Alzheimer (Sheline and Raichle, 2013) and Huntington disease (Poudel et al., 2014) 
and our research, as well as work from Gorges et al. (2015) suggests a similar course 
may be involved in PD.  
 
Hyper-connectivity of brain regions as an adaptive response to pathology also relies 
on neuronal degeneracy and reserve. Neuronal degeneracy is the capacity of elements 
of a system to perform the same function (Tononi et al., 1999), meaning that elements 
of a brain network can make overlapping contributions. Such a capacity affords brain 
networks with the ability to adapt, while also making them more resistant to damage 
(Tononi et al., 1999). The loss of dopaminergic input to the striatum in PD may result 
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in basal ganglia-thalamocortical circuits using inherent degeneracy to alleviate the 
impact of this pathological insult. Functional compensation of brain networks using 
degeneracy in this way also require sufficient brain tissue that can facilitate this 
response. While it was hypothesised in Project three that the stage at which such a 
compensatory response would no longer viable, due to a loss of neural reserve, would 
be when patients demonstrated MCI, experimental support for this model could not be 
found. However it is clear that at advanced disease stages, significant losses of brain 
tissue in subcortical, corpus callosal and cortical brain regions is demonstrated, likely 
limiting any potential adaptive compensatory response due to the widespread loss of 
neuronal reserve. This thesis will now discuss some of the possible mechanisms that 
might be involved in the significant structural changes that were observed in PD 
patients with dementia. 
 
7.2.2. Structural changes to brain networks in advanced disease stages 
This thesis presents evidence of widespread structural changes to the brain in PD 
patients with dementia. Changes to the white matter of the corpus callosum were 
discussed in Project four, and will not be expanded upon here. The likely mechanisms 
that underlie structural changes to the grey matter of brain networks in PD dementia 
may be due to the consequences of abnormal patterns of neural activity causing 
transsynaptic neurodegeneration or to a ‘prion-like’ spread of a-synuclein causing 
neurodegeneration.  
 
Transneuronal neurodegeneration is a process whereby altered regulation of synaptic 
connections, due to synaptic depression or aberrant network synchronisation, 
interferes with the regulation of synapses (Palop and Mucke, 2010). Based on the 
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Hebbian notion regarding synaptic efficiency relying on the interaction between pre- 
and post-synaptic activity (Hebb, 2005), it is suggested that as activity can strengthen 
synaptic connections, so to does mismatched firing weaken these synapses resulting 
in neurodegeneration (Palop and Mucke, 2010). Such an activity-dependent 
neurodegeneration may proceed in the anterograde (damage to one neuron causes 
degeneration of the connected postsynaptic target) or retrograde direction (presynaptic 
neuron is damaged due to a lack of trophic support from postsynaptic target) (Cowan, 
1970).  
 
Structural brain changes in PD may also be due to the propagation of misfolded a-
synuclein, moving from cell-to-cell, causing a spread of neurodegeneration, in what is 
termed the ‘prion-hypothesis’. The build-up of aggregated proteins is a common 
denominator in most neurodegenerative disorders (Brundin et al., 2010), and evidence 
for the prion-hypothesis spread of these misfolded proteins in PD is extensive 
(Brundin and Melki, 2017). However, important questions still remain unanswered, 
such as how certain cell types in the brain are resistant to the spread of misfolded a-
synuclein while others are not (Surmeier et al., 2017). It has been suggested that 
highly connected hub structures such as the striatum and thalamus are vulnerable to 
neurodegeneration in this way as they form crucial nodes of functional networks, 
inherently vulnerable to this process in neurodegenerative diseases (Seeley et al., 
2009). Activity dependent transneuronal neurodegeneration and the prion-hypothesis 
are not mutually exclusive however, and it is possible that these two 
pathophysiological mechanisms represent elements of the same cycle (Palop and 
Mucke, 2010). 
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7.3. Methodological considerations, limitations and future directions 
The research in this thesis contains a number of important methodological 
characteristics that require more extensive discussion beyond what was provided in 
the preceding project chapters. These include the use of patients on medication, the 
cross-sectional nature of the study, the significant PD-symptomatic heterogeneity and 
the use of cluster-based thresholding. Future directions that may address these 
potential limitations are also suggested.  
 
7.3.1. Dopaminergic medication  
PD participants in the current thesis remained on their usual medication during the 
clinical assessment and MRI acquisition phases, which has some important scientific 
implications. In particular, this factor needs to be taken into account when considering 
functional connectivity results. Research has shown that dopaminergic medication can 
restore decreased functional connectivity (Bell et al., 2015), produce increases in 
functional connectivity (Esposito et al., 2013), or as mentioned previously, influence 
the functional integration between brain networks (Shine et al., 2019). While these 
results suggest a clear relationship between functional connectivity changes and 
dopaminergic medication, a meta regression analysis performed by Ji et al. (2018) 
found that the main finding of their work, increased functional connectivity of 
structures of the basal ganglia with post central gyri in PD, was not significantly 
affected by medication data. Project three of this thesis attempted to address the issue 
by controlling for LEDD when comparing functional connectivity between PD 
cohorts using linear regression. While using such an approach is common and found 
to be generally reliable in this field of research (Tomlinson et al., 2010), future 
investigations may benefit from being longitudinal in nature, incorporating a more 
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sophisticated approach that could take into account not only the particular LEDD of 
the participant on the day of clinical assessment or image acquisition, but the full 
complexity of the clinical medication regime that may change over time.  
 
Longitudinal research would also better characterise the progression of the disease. 
This thesis attempts to quantify disease progression in terms of years since diagnosis 
(Project one) and levels of cognitive impairment (Project three and four). While these 
two progression schemes are common in research, we cannot assume a linear 
progression of clinical dysfunction and disease processes according to these metrics. 
While there is strong evidence that PD-MCI does represent an intermediate cognitive 
disease stage between cognitively unimpaired PD and PDD (Litvan et al., 2012), a 
longitudinal approach would more accurately characterise the disease progression of 
participants. This would have the added benefit of more accurately characterising the 
significant clinical heterogeneity associated with PD. 
 
7.3.2. Disease heterogeneity 
A second important methodological consideration relates to disease heterogeneity in 
PD patients. Clinical features of the disorder can vary significantly between 
individuals, which has significant therapeutic and research implications (Greenland et 
al., 2019). This is such an important issue in PD, suggestions have been put forward 
arguing that the disorder be classified as a collection of distinct disease entities 
(Weiner, 2008) while other groups argue that PD is a clear disorder only with varying 
pathological kinetics (Barker and Williams-Gray, 2016).  
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Nonetheless, clinical and research observations have resulted in a clear subtyping of 
two distinct groups based on motor features of the disorder: a ‘tremor-dominant’ and 
a ‘postural instability/gait disturbance’ group (Jankovic et al., 1990). Patients with a 
tremor-dominant form of the disorder are more likely to have a mild disease 
phenotype and are slow to develop postural and gait disturbances. Conversely, those 
who present with predominant rigidity and bradykinesia are more likely to report 
impairments in mobility and postural stability, and are more likely to progress to 
advanced disease stages faster (Williams-Gray et al., 2013). However, while these 
two disease subtype profiles have clinical and research support, there is a significant 
overlap between these two motor phenotypes with the majority of patients 
experiencing some combination of features (Greenland et al., 2019). Alongside this 
motor subtyping, clinical and research evidence also suggests PD subtypes based on 
the type of cognitive impairment, that show links to these motor subtypes. 
 
Parsing the heterogeneous nature of cognitive impairment into ontologically 
meaningful groups has led to a theory of the ‘dual-syndrome hypothesis.’ This 
hypothesis suggests two broad syndromes based on type of cognitive impairment, 
linked to a tremor-dominant or postural instability/gait disturbance subtypes (Kehagia 
et al., 2013). The first group identifies a cohort of non-demented tremor-dominant PD 
patients with cognitive impairment who demonstrate deficits on tests of planning, 
working memory and executive function. These deficits are linked to fronto-striatal 
dysfunction, and the majority of their symptoms are amenable to dopaminergic 
medication. The second cohort is linked to the postural instability/gait disturbance 
subtype and generally identifies patients with pronounced deficits in visuospatial 
function and semantic fluency. These deficits are linked to posterior cortical and 
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temporal lobe function, the symptoms respond poorly to dopaminergic medication 
(cholinergic treatment shows more efficacy) and these patients can exhibit a more 
rapid cognitive decline to dementia (Kehagia et al., 2013). However, as with the 
tremor-dominant and postural instability/gait motor distinction, there is significant 
overlap between these syndromes, both in terms of clinical features and 
responsiveness to medication. Future research in this field may benefit from an 
increased specificity to any cognitive impairment diagnosis, which can group 
participants based on the types of dysfunction observed.  
 
7.3.3. Statistical approach to functional connectivity analyses 
As outlined in the Methodology 2.5.1.2 section of this thesis, there are a number of 
ways that functional MRI data can be analysed for statistical significance. The two 
main approaches used are parametric cluster-based and non-parametric permutation-
based thresholding. This thesis implemented both alternatives, however evidence is 
emerging that non-parametric permutation-based methods are more effective in 
minimising false-positive rates and they have a higher test-retest 
reliability/replicability (Chen et al., 2018). 
 
Cluster-based thresholding of statistic images in functional MRI makes use of the 
spatial neighbourhood information to assign probability values to clusters of voxels. 
Such an approach makes a number of assumptions about the data, and if violated, 
serve as limitations to this method. The first is the selection of an initial cluster-
forming threshold, which is set as a threshold above which values within a statistic 
image can be considered significant. Researchers in this field often select an arbitrary 
value, use the default option available in analysis software, or choose a value that is 
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commonly used in previously published articles. This is important as the choice of the 
cluster-forming threshold value has significant implications to the results of the 
research (Woo et al., 2014).  
 
Cluster-based thresholding also relies on data within the statistic image being 
normally distributed (Gaussian) and also can be impacted by the amount of spatial 
smoothing used on the data. Spatial smoothing (see Methodology 2.5.2) is a value 
that, similar to the cluster-forming threshold, is often arbitrarily selected (Smith and 
Nichols, 2009). When making inferences about significant results found using this 
method, cluster-based thresholding also only allows researchers to infer anatomical 
information based on significant regions that are within a cluster, but it is unable to 
provide high neuroanatomical specificity. If a significant cluster of functional 
connectivity is found that crosses neuroanatomical boundaries, cluster-based 
approaches are unable to accurately infer whether the significant result is driven by 
changes in one area to the next. Non-parametric permutation based approaches have 
been developed to address these issues, and the threshold-free cluster enhancement 
method in particular has shown significant promise as it does not require the selection 
of an arbitrary cluster-forming threshold value and can be applied to data that is non-
Gaussian (Smith and Nichols, 2009).  
 
The threshold-free cluster enhancement method with permutation testing uses the raw 
statistic image and creates an output that indicates how much cluster-like local 
support exists for each voxel within the image. This value is the sum of ‘scores’ or all 
‘supporting sections’ that exist underneath it, with the score being the height of the 
cluster multiplied by its spatial extent (Smith and Nichols, 2009). This new value 
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represents a weighted sum of the local cluster signal, able to detect both diffuse low-
amplitude brain activation in statistic images as well as sharp focal-activation.  
 
The ‘permutation’ element of the method works by adjusting the uncorrected p-values 
by permuting the participants in the study such that they do not correspond to their 
original group labels. Under the assumption that the null hypothesis is true (i.e. there 
is no difference in statistic images between the groups) the results would not change 
regardless of how participants were characterised. Each new permutation of the group 
labelling is run and the result varies as a result of the noise in the data. Once a 
sufficiently large number of permutations are run, values for each run are combined 
into an empirical null distribution at each voxel, which can then be compared with the 
original unpermuted statistic image and a p-value can be produced (Jenkinson and 
Chappell, 2018). Future research should consider the use of non-parametric 
approaches such as the threshold-free cluster enhancement method with permutation 
testing, which may partially address the significant replicability issues that cluster-
based approaches have caused in the field of functional neuroimaging (Eklund et al., 
2016). 
 
7.4. Conclusion 
This thesis demonstrates that PD is associated with significant morphological changes 
to structures in the brain in PD participants with dementia, that may be linked to 
transneuronal neurodegeneration or the spread of misfolded a-synuclein. Decreases in 
functional connectivity of striatal nuclei was found in PD participants, which may be 
evidence of maladaptive connectional diaschisis or dedifferentiation of brain 
networks. PD participants also demonstrated increased functional connectivity of 
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striatal and thalamic nuclei, potentially evidence of increased integration or an 
adaptive functional compensation of basal ganglia-thalamocortical brain networks. 
 
In conclusion, this thesis argues that alterations to the functional connectivity of basal 
ganglia-thalamocortical circuits may precede morphological alterations to the 
structures, which become impacted later in the disease course. These changes 
potentially represent structural and functional neuroimaging biomarkers associated 
with clinical dysfunction in Parkinson disease, revealing important insights about 
adaptive and maladaptive brain changes associated with the disorder. 
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8. Appendices 
Appendix 1: Tracing reliability of manual ROI segmentation 
Reliability of the manual segmentation of the bilateral caudate nucleus, putamen 
method and thalamus was quantified by the calculation of an inter-rater reliability 
coefficient, measuring the tracer’s agreement with an expert tracer and an intra-rater 
reliability coefficient, measuring the consistency of the rater over time. The inter-rater 
coefficient is the final correlation metric obtained after an extensive training period 
using an MRI example dataset of 20 ROIs of interest, re-traced in a blinded fashion 
until a satisfactory standard was reached. The intra-rater coefficient was obtained by 
re-tracing every ~10th participant’s MRI scan during the manual segmentation 
process, with obtained volumes at the first attempt correlated against the volumes 
obtained at the second attempt. The tracer for this task was COW, while the 
experienced rater for the inter-rater comparator group was FAW. Both the inter- and 
intra-rater reliability coefficient values relate to the conservative ‘absolute agreement’ 
definition. For the caudate nucleus and putamen, inter-rater reliability was r = 0.89 
and r = 0.83, respectively), while the intra-rater reliability (as an intra-class) 
coefficient was r = 0.98 for both structures. For the thalamus, the inter-rater reliability 
was 0.908 while the intra-rater score was r = 0.879 (Shrout and Fleiss, 1979). 
 
Appendix Table 1: Correlations between striatal volumes and clinical function - PD 
subgroups 
Group Nuclei 
Clinical 
measure 
R2 
change b p value 
Early PD BPV UPDRS-III 0.114 0.475 0.056 
Late PDD   0.132 0.436 0.060 
PDD   0.030 0.239 0.464 
Early PD RPV  0.129 0.484 0.042 
Late PDD   0.122 0.441 0.072 
PDD   0.092 0.478 0.187 
Early PD LPV  0.061 0.331 0.168 
Late PDD   0.097 0.347 0.113 
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PDD   0.006 0.095 0.743 
Early PD BCV MMSE 0.176 0.457 0.036 
Late PDD   0.028 -0.214 0.477 
PDD   0.202 0.670 0.191 
Early PD RCV  0.128 0.399 0.078 
Late PDD   0.011 0.520 0.657 
PDD   0.130 0.520 0.308 
Early PD LCV  0.216 0.494 0.019 
Late PDD   0.047 -0.292 0.352 
PDD   0.236 0.716 0.151 
Early PD BCV AQT 0.189 0.473 0.012 
Late PDD   0.016 0.163 0.602 
PDD   0.409 0.952 0.035 
Early PD RCV  0.133 0.407 0.040 
Late PDD   0.047 0.264 0.366 
PDD   0.338 0.839 0.075 
Early PD LCV  0.234 0.525 0.004 
Late PDD   0.002 0.058 0.860 
PDD   0.421 0.955 0.030 
Abbreviations: b, standardised beta values; BCV, bilateral caudate nucleus volume; RCV, 
right caudate nucleus volume; LCV, left caudate nucleus volume; BPV, bilateral putamen 
volume; RPV, right putamen volume; LPV, left putamen volume; UPDRS-III, Unified 
Parkinson’s Disease Rating Scale part III; TUG, Timed Up and Go; AF, Animal Fluency; 
LSF, Letter S Fluency; MMSE, Mini Mental-State Examination; AQT, A Quick Test of 
Cognitive Speed; ** significant at the Bonferroni corrected p < 0.0018; data correct to 3 
decimal places. 
 
Appendix Table 2: Pairwise ANOVA results comparing PD disease subgroups on 
demographic variables. 
Group 1 Group 2 Variable Difference (Group 1 - Group 2) p-value 
Control Early PD Age 0.057 1.00 
 Late PD  -0.517 0.992 
 PDD  -3.962 0.19 
Early PD Late PD  -0.575 0.987 
 PDD  -4.029 0.15 
Late PD PDD  -3.445 0.332 
Control Early PD UPDRS-III 3.655 0.052 
 Late PD  -0.071 1.00 
 PDD  1.229 0.899 
Early PD Late PD  -3.726 0.064 
 PDD  -2.426 0.504 
Late PD PDD  1.300 0.892 
Control Early PD AF 8.775* <0.001 
 Late PD  14.154* <0.001 
 PDD  30.091* <0.001 
Early PD Late PD  5.379 0.081 
 PDD  21.316* <0.001 
Late PD PDD  15.938* <0.001 
Control Early PD MMSE 1.767 0.075 
 Late PD  1.059 0.539 
 PDD  3.023* 0.019 
Early PD Late PD  -0.707 0.785 
 PDD  1.256 0.583 
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Late PD PDD  1.964 0.24 
Control Early PD Education 1.430 0.816 
 Late PD  2.885 0.382 
 PDD  11.951* <0.001 
Early PD Late PD  1.455 0.83 
 PDD  10.521* <0.001 
Late PD PDD  9.067* <0.001 
Control Early PD TUG 5.939* <0.001 
 Late PD  2.15 0.532 
 PDD  9.267* <0.001 
Early PD Late PD  -3.789 0.066 
 PDD  3.327 0.196 
Late PD PDD  7.117* 0.001 
Control Early PD LSF 0.48 0.781 
 Late PD  0.465 0.841 
 PDD  5.505* <0.001 
Early PD Late PD  -0.015 1.00 
 PDD  5.025* <0.001 
Late PD PDD  5.040* <0.001 
Control Early PD AQT 11.711 0.179 
 Late PD  7.741 0.613 
 PDD  56.385* <0.001 
Early PD Late PD  -3.97 0.911 
 PDD  44.674* <0.001 
Late PD PDD  48.643* <0.001 
Key: This table demonstrates the pairwise comparison of demographic data between PD 
disease subgroups and Controls showing the significant differences. *, indicates differences 
between groups that have a p-value of < 0.05. 
 
Appendix Table 3: Correlations between thalami volumes and clinical measures - PD 
and Controls 
Structure Group Clinical measure b p-value 
Right thalamus Controls Animal Fluency -0.008 0.973 
PD 0.257 0.058 
Left thalamus Controls -0.048 0.839 
PD 0.247 0.069 
Right thalamus Controls Letter S Fluency -0.236 0.317 
PD 0.086 0.542 
Left thalamus Controls -0.11 0.646 
PD -0.056 0.688 
Right thalamus Controls MMSE -0.143 0.547 
PD 0.274 0.043* 
Left thalamus Controls -0.205 0.387 
PD 0.225 0.099 
Right thalamus Controls AQT 0.164 0.489 
PD 0.260 0.060 
Left thalamus Controls -0.113 0.635 
PD 0.086 0.543 
Right thalamus Controls UPDRS-III -0.053 0.809 
PD 0.264 0.029* 
Left thalamus Controls 0.269 0.215 
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PD 0.316 0.009* 
Right thalamus Controls TUG -0.212 0.33 
PD 0.079 0.543 
Left thalamus Controls 0.041 0.851 
PD 0.190 0.143 
Abbreviations: UPDRS-III, Unified Parkinson’s Disease Rating Scale part III; MMSE, Mini 
Mental-State Examination; b, standardized beta coefficient indicating effect size. 
 
Appendix Table 4: Correlations between thalami volumes and clinical measures - PD 
subgroups 
Structure Group Clinical measure b p-value 
Right thalamus Early PD Animal Fluency 0.295 0.172 
 Late PD  0.027 0.921 
 PDD  -0.327 0.429 
Left thalamus Early PD  0.311 0.149 
 Late PD  0.248 0.355 
 PDD  -0.407 0.317 
Right thalamus Early PD Letter S Fluency 0.385 0.070 
 Late PD  -0.105 0.721 
 PDD  -0.685 0.061 
Left thalamus Early PD  0.264 0.224 
 Late PD  -0.194 0.506 
 PDD  -0.387 0.343 
Right thalamus Early PD MMSE 0.275 0.204 
 Late PD  0.445 0.084 
 PDD  0.135 0.750 
Left thalamus Early PD  0.229 0.293 
 Late PD  0.143 0.596 
 PDD  0.353 0.391 
Right thalamus Early PD AQT 0.129 0.557 
 Late PD  0.372 0.156 
 PDD  -0.254 0.627 
Left thalamus Early PD  0.117 0.595 
 Late PD  0.212 0.430 
 PDD  0.194 0.713 
Right thalamus Early PD UPDRS-III 0.122 0.520 
 Late PD  0.296 0.218 
 PDD  0.170 0.580 
Left thalamus Early PD  -0.149 0.432 
 Late PD  0.664 0.002* 
 PDD  -0.102 0.74 
Right thalamus Early PD TUG 0.313 0.098 
 Late PD  0.296 0.219 
 PDD  -0.050 0.915 
Left thalamus Early PD  -1.60 0.408 
 Late PD  0.662 0.002* 
 PDD  0.396 0.379 
8. Appendices 
 198 
Key: Family-wise error rate correction using the Bonferroni method stipulate a p < 0.0014 
required for significance (after running 36 analyses). Abbreviations: UPDRS-III, Unified 
Parkinson’s Disease Rating Scale part III; MMSE, Mini Mental-State Examination; b, 
standardized beta coefficient indicating effect size;  
 
Appendix Table 5: Local maxima of significant differences in functional connectivity of 
dorsal caudate in PD-CU compared to Controls 
FC Brain Region Z 
MNI Coordinate 
x y z 
Ý R superior frontal gyrus (BA8) 4.86 10 32 58 
 R postcentral gyrus (BA3) 4.56 44 -18 58 
 R precentral gyrus (BA6) 4.43 32 -4 54 
 R superior frontal gyrus (BA6) 4.4 2 14 54 
 R precentral gyrus (BA6) 4.35 46 -18 66 
 R paracingulate gyrus (BA32) 4.32 8 12 50 
 L frontal pole (BA10) 3.81 -28 56 2 
 L frontal pole (BA10) 3.8 -36 54 18 
 L frontal pole (BA10) 3.73 -32 40 18 
 L frontal pole (BA10) 3.72 -40 50 20 
 L frontal pole (BA10) 3.56 -30 52 18 
 L frontal pole (BA10) 3.53 -44 46 20 
 R middle frontal gyrus (BA8) 4.39 34 16 38 
 R middle frontal gyrus (BA8) 3.37 20 18 40 
ß R lateral occipital cortex (BA19) 4.22 40 -76 28 
 R lateral occipital cortex (BA19) 3.95 46 -74 28 
 R lateral occipital cortex (BA19) 3.9 36 -86 26 
 R lateral occipital cortex (BA19) 3.8 28 -88 30 
 R lateral occipital cortex (BA19) 3.22 32 -72 30 
 L cerebellar crus I 4.18 -24 -72 -26 
 L cerebellar crus I 3.74 -38 -70 -28 
 L cerebellar crus I 3.5 -34 -76 -28 
 L angular gyrus (BA39) 4.36 -60 -54 28 
 L angular gyrus (BA39) 4.23 -62 -56 24 
 L angular gyrus (BA39) 4.01 -60 -60 20 
 L supramarginal gyrus (BA40) 4.01 -62 -50 20 
 L cerebellar lobule VI 4.16 -6 -76 -20 
 L cerebellar vermis VI 3.69 -2 -70 -10 
 L cerebellar vermis VI 3.54 -2 -76 -30 
 L cerebellar vermis VI 3.39 -4 -70 -26 
Key: Brain regions and associated coordinates represent areas of significant functional 
connectivity differences with the dorsal caudate in PD-CU participants compared to Controls 
(family-wise error corrected p < 0.05). Abbreviations: FC, functional connectivity; ß, 
decrease in functional connectivity; Ý, increase in functional connectivity; n/a, coordinates 
fall outside brain tissue space; L, left hemisphere; R, right hemisphere; BA, Brodmann Area; 
Z, maximum Z-value for cluster; MNI, coordinates for location of maximum Z-value, in the 
Montreal Neurological Institute T1 standard space. 
 
Appendix Table 6: Local maxima of significant differences in functional connectivity of 
the anterior putamen in PD-CU compared to Controls 
FC Region Z 
MNI Coordinate 
x y z 
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Ý R middle frontal gyrus (BA8) 5.43 26 26 32 
 R middle frontal gyrus (BA8) 4.33 24 34 44 
 R anterior cingulate cortex (BA24) 4.14 12 24 20 
 R middle frontal gyrus (BA9) 4.06 32 30 20 
 L frontal pole (medial) (BA10) 3.93 -2 56 20 
 R frontal pole (BA10) 3.91 8 54 32 
 R frontal pole (BA10) 3.83 10 50 40 
 L superior frontal gyrus (BA9) 3.56 -2 56 30 
 L paracingulate gyrus (BA32) 3.51 -2 46 22 
 R postcentral gyrus (BA3) 4.24 44 -22 58 
 R precentral gyrus (BA4) 4.23 44 -12 56 
 R precentral gyrus (BA4) 4.1 40 -20 60 
 R precentral gyrus (BA4) 4.03 42 -8 60 
 R precentral gyrus (BA4) 3.83 42 -14 52 
 R postcentral gyrus (BA3) 3.83 46 -24 52 
 L postcentral gyrus (BA2) 4.08 -54 -12 26 
 L precentral gyrus (BA6) 3.78 -56 2 28 
 L postcentral gyrus (BA2) 3.73 -56 -10 20 
 L precentral gyrus (BA6) 3.58 -60 -4 28 
 L central operculum (BA42) 3.54 -50 -16 18 
 L precentral gyrus (BA6) 3.37 -50 -6 30 
 L paracingulate gyrus (BA32) 4.85 -12 32 28 
 L anterior cingulate gyrus (BA24) 4.56 -12 28 22 
 L paracingulate gyrus (BA32) 3.67 -4 36 20 
 L anterior cingulate gyrus (BA24) 3.49 -6 32 22 
 R postcentral gyrus (BA3) 4.4 52 -16 44 
 R precentral gyrus (BA4) 4.08 42 -8 34 
 R postcentral gyrus (BA3) 3.58 46 -12 32 
 R postcentral gyrus (BA3) 3.48 50 -14 36 
 L middle frontal gyrus (BA9) 4.42 -28 28 40 
 L middle frontal gyrus (BA8) 3.81 -32 22 40 
 L middle frontal gyrus (BA8) 3.71 -30 28 30 
 R inferior frontal gyrus (BA44) 3.79 48 20 18 
 R inferior frontal gyrus (BA44) 3.76 46 16 14 
 R inferior frontal gyrus (BA44) 3.67 48 16 10 
 R central operculum (BA42) 3.65 40 20 8 
 R inferior frontal gyrus (BA44) 3.46 54 22 12 
ß L lateral occipital cortex (BA19) 4.05 -26 -82 40 
 L lateral occipital cortex (BA19) 3.79 -28 -76 40 
 L lateral occipital cortex (BA19) 3.76 -34 -88 32 
 L lateral occipital cortex (BA19) 3.73 -42 -80 32 
 L lateral occipital cortex (BA19) 3.72 -18 -84 38 
 L lateral occipital cortex (BA19) 3.69 -28 -82 34 
 R precuneus (BA7) 4.1 6 -62 42 
 Precuneus (BA7) 4.08 0 -68 46 
 L precuneus (BA7) 3.56 -2 -54 38 
Key: Brain regions and associated coordinates represent areas of significant functional 
connectivity changes with the anterior putamen in PD-CU participants compared to Controls 
(family-wise error corrected p < 0.05). Abbreviations: FC, functional connectivity; ß, 
decrease in functional connectivity; Ý, increase in functional connectivity; n/a, coordinates 
fall outside brain tissue space; L, left hemisphere; R, right hemisphere; BA, Brodmann Area; 
p, corrected p-value; Z, maximum Z-value for cluster; MNI, coordinates for location of 
maximum Z-value, in the Montreal Neurological Institute T1 standard space. 
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Appendix Table 7: Local maxima of significant differences in functional connectivity of 
the mediodorsal thalamus in PD-CU participants compared to Controls 
FC Region Z 
MNI Coordinate 
x y z 
Ý L postcentral gyrus (BA1) 4.94 -58 -10 26 
 L precentral gyrus (BA6) 4.45 -60 -2 32 
 L postcentral gyrus (BA3) 4.37 -58 -12 42 
 L precentral gyrus (BA6) 4.09 -56 4 20 
 L precentral gyrus (BA4) 4.01 -54 -12 40 
 L postcentral gyrus (BA3) 3.95 -54 -12 32 
 R middle frontal gyrus (BA8) 3.97 24 24 32 
 R middle frontal gyrus (BA8) 3.63 24 20 38 
Key: Brain regions and associated coordinates represent areas of significant functional 
connectivity changes with the mediodorsal thalamus in PD-CU participants compared to 
Controls (family-wise error corrected p < 0.05). Abbreviations: FC, functional connectivity; 
Ý, increase in functional connectivity; n/a, coordinates fall outside brain tissue space; L, left 
hemisphere; R, right hemisphere; BA, Brodmann Area; p, corrected p-value; Z, maximum Z-
value for cluster; MNI, coordinates for location of maximum Z-value, in the Montreal 
Neurological Institute T1 standard space. 
 
Appendix Table 8: Local maxima of significant differences in functional connectivity of 
the mediodorsal thalamus in PD-MCI participants compared to PD-CU 
FC Region Z 
MNI Coordinate 
x y z 
ß R paracingulate gyrus (BA32) 3.92 2 46 30 
 Paracingulate gyrus (BA32) 3.76 0 42 24 
 Medial frontal gyrus (BA9) 3.75 0 46 24 
 R frontal pole (BA8) 3.67 8 48 38 
 R frontal pole (BA8) 3.63 10 52 36 
 R frontal pole (BA8) 3.52 10 52 32 
Key: Brain regions and associated coordinates represent areas of significant functional 
connectivity changes with the mediodorsal thalamus in PD-MCI participants compared to 
Controls (family-wise error corrected p < 0.05). Abbreviations: FC, functional connectivity; 
ß, decrease in functional connectivity; L, left hemisphere; R, right hemisphere; BA, 
Brodmann Area; Z, maximum Z-value for cluster; MNI, coordinates for location of maximum 
Z-value, in the Montreal Neurological Institute T1 standard space. 
 
Appendix Table 9: Local maxima of significant differences in functional connectivity of 
the mediodorsal thalamus in PDD participants compared to PD-MCI 
FC Region Z 
MNI Coordinate 
x y z 
ß R posterior cingulate cortex (BA23) 4.07 6 -38 26 
 R posterior cingulate cortex (BA23) 3.97 4 -42 30 
 Posterior cingulate cortex (BA23) 3.93 0 -34 26 
Key: Brain regions and associated coordinates represent areas of significant functional 
connectivity changes with the mediodorsal thalamus in PDD participants compared to PD-
MCI participants (family-wise error corrected p < 0.05). Abbreviations: FC, functional 
connectivity; ß, decrease in functional connectivity; n/a, coordinates fall outside brain tissue 
space; L, left hemisphere; R, right hemisphere; BA, Brodmann Area; p, corrected p-value; Z, 
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maximum Z-value for cluster; MNI, coordinates for location of maximum Z-value, in the 
Montreal Neurological Institute T1 standard space. 
 
Appendix Table 10: Correlations between average parameter estimate clinical variables - 
PD participants compared to Controls 
Cluster Result LEDD UPDRS AF LSF MMSE AQT DD 
#1 Ý in PD 0.243 
(0.213) 
0.055 
(0.76) 
0.048 
(0.789) 
0.017 
(0.928) 
-0.157 
(0.382) 
-0.028 
(0.876) 
0.241 
(0.177) 
#2 Ý in PD -0.041 
(0.834) 
0.08 
(0.658) 
0.189 
(0.293) 
0.121 
(0.518) 
-0.306 
(0.083) 
0.16 
(0.374) 
-0.02 
(0.913) 
#3 Ý in PD 0.358 
(0.062) 
-0.073 
(0.688) 
0.044 
(0.806) 
0.057 
(0.761) 
-.420* 
(0.015) 
0.278 
(0.118) 
0.34 
(0.053) 
#4 ß in PD -0.14 
(0.476) 
0.017 
(0.925) 
-0.331 
(0.06) 
-0.211 
(0.255) 
0.246 
(0.168) 
-0.245 
(0.17) 
-0.108 
(0.548) 
#5 ß in PD -0.264 
(0.175) 
0.091 
(0.616) 
0.044 
(0.808) 
-0.274 
(0.136) 
0.284 
(0.109) 
-0.131 
(0.468) 
-0.271 
(0.126) 
#6 ß in PD -0.334 
(0.082) 
0.316 
(0.073) 
0.166 
(0.357) 
-0.076 
(0.685) 
0.165 
(0.359) 
0.024 
(0.897) 
-0.284 
(0.109) 
#7 ß in PD -0.14 
(0.476) 
-0.01 
(0.957) 
-0.209 
(0.244) 
-0.208 
(0.262) 
0.302 
(0.087) 
-0.191 
(0.286) 
-0.084 
(0.641) 
#8 Ý in PD 0.327 
(0.09) 
-0.046 
(0.801) 
-0.044 
(0.809) 
0.207 
(0.263) 
-.354* 
(0.043) 
0.206 
(0.251) 
0.222 
(0.214) 
#9 Ý in PD 0.144 
(0.464) 
-0.196 
(0.274) 
0.258 
(0.147) 
0.33 
(0.07) 
-0.319 
(0.07) 
0.033 
(0.856) 
0.008 
(0.964) 
#10 Ý in PD 0.073 
(0.712) 
0.015 
(0.935) 
-0.095 
(0.599) 
-0.106 
(0.57) 
-0.272 
(0.126) 
0.033 
(0.857) 
0.147 
(0.415) 
#11 Ý in PD 0.106 
(0.593) 
0.193 
(0.281) 
-0.193 
(0.282) 
-0.192 
(0.302) 
-0.001 
(0.994) 
0.029 
(0.875) 
0.075 
(0.679) 
#12 Ý in PD 0.139 
(0.481) 
0.024 
(0.893) 
0.044 
(0.806) 
0.171 
(0.358) 
-.513* 
(0.002) 
0.059 
(0.743) 
0.086 
(0.635) 
#13 Ý in PD .505* 
(0.006) 
-0.245 
(0.17) 
-0.197 
(0.272) 
0.073 
(0.697) 
-0.325 
(0.065) 
-0.074 
(0.682) 
0.324 
(0.066) 
#14 Ý in PD 0.17 
(0.386) 
-0.076 
(0.676) 
0.04 
(0.823) 
0.193 
(0.298) 
-.445* 
(0.009) 
0.091 
(0.614) 
0.222 
(0.214) 
#15 Ý in PD .521* 
(0.004) 
-0.191 
(0.287) 
-0.115 
(0.526) 
0.185 
(0.319) 
-0.197 
(0.273) 
0.177 
(0.325) 
0.321 
(0.069) 
#16 ß in PD -.471* 
(0.012) 
-0.043 
(0.812) 
0.045 
(0.803) 
-0.077 
(0.682) 
0.233 
(0.192) 
-0.148 
(0.411) 
-0.295 
(0.095) 
#17 ß in PD -0.1 
(0.613) 
0.009 
(0.961) 
0.102 
(0.573) 
0.043 
(0.818) 
-0.063 
(0.728) 
-0.131 
(0.467) 
0.096 
(0.593) 
#18 Ý in PD -0.074 
(0.71) 
0.039 
(0.831) 
-0.224 
(0.21) 
-0.251 
(0.174) 
0.26 
(0.144) 
0.081 
(0.653) 
-.348 
(0.047) 
#19 Ý in PD 0.109 
(0.581) 
-0.097 
(0.592) 
-0.017 
(0.924) 
0.24 
(0.193) 
0.11 
(0.541) 
0.136 
(0.452) 
0.201 
(0.261) 
Key: Beta correlation coefficients showing direction of correlation between average parameter 
estimate at each cluster location and measures of clinical function, with associated p-value 
shown in brackets. Correlations are performed within each PD disease group that had a 
significant difference in FC at that location. Abbreviations: ß, decrease in functional 
connectivity; Ý, increase in functional connectivity; LEDD, levodopa-equivalent daily dosage; 
UPDRS, Unified Parkinson Disease Rating Scale Part-III; AF, Animal Fluency test; LSF, 
Letter S Fluency Test; MMSE, Mini Mental State Examination; AQT, A Quick Test of 
Cognitive Speed; DD, disease duration. 
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Appendix Table 11: Correlations between average parameter estimate clinical variables - 
PD compared to PD-MCI 
Cluster Result LEDD UPDRS AF LSF MMSE AQT DD 
#20 Ý in PD -.486* 
(0.025) 
.424* 
(0.049) 
0.13 
(0.565) 
0.293 
(0.185) 
-0.386 
(0.076) 
-0.105 
(0.642) 
-0.352 
(0.108) 
#20 ß in PD-MCI -0.259 
(0.183) 
-0.034 
(0.85) 
0.197 
(0.271) 
0.061 
(0.744) 
0.001 
(0.995) 
0.098 
(0.588) 
-0.269 
(0.13) 
Key: Beta correlation coefficients showing direction of correlation between average parameter 
estimate at each cluster location and measures of clinical function, with associated p-value 
shown in brackets. Correlations are performed within each PD disease group that had a 
significant difference in FC at that location. Clusters are repeated as the significant difference 
in FC found at cluster #20 could be due to increases in PD or decreases in PD-MCI. 
Abbreviations: ß, decrease in functional connectivity; Ý, increase in functional connectivity; 
LEDD, levodopa-equivalent daily dosage; UPDRS, Unified Parkinson Disease Rating Scale 
Part-III; AF, Animal Fluency test; LSF, Letter S Fluency Test; MMSE, Mini Mental State 
Examination; AQT, A Quick Test of Cognitive Speed; DD, disease duration. 
 
Appendix Table 12: Correlations between average parameter estimate clinical variables - 
PD-MCI compared to PDD 
Cluster Result LEDD UPDRS AF LSF MMSE AQT DD 
#21 Ý in PD-MCI 0.367 
(0.102) 
-0.279 
(0.209) 
-0.396 
(0.068) 
-0.099 
(0.662) 
0.238 
(0.287) 
-0.009 
(0.969) 
.522* 
(0.013) 
#21 ß  in PDD 0.391 
(0.135) 
-0.04 
(0.88) 
0.045 
(0.868) 
0.271 
(0.311) 
0.268 
(0.299) 
0.283 
(0.327) 
0.235 
(0.365) 
Key: Beta correlation coefficients showing direction of correlation between average parameter 
estimate at each cluster location and measures of clinical function, with associated p-value 
shown in brackets. Correlations are performed within each PD disease group that had a 
significant difference in FC at that location. Clusters are repeated as the significant difference 
in FC found at cluster #21 could be due to increases in PD-MCI or decreases in PDD.  
Abbreviations: ß, decrease in functional connectivity; Ý, increase in functional connectivity; 
LEDD, levodopa-equivalent daily dosage; UPDRS, Unified Parkinson Disease Rating Scale 
Part-III; AF, Animal Fluency test; LSF, Letter S Fluency Test; MMSE, Mini Mental State 
Examination; AQT, A Quick Test of Cognitive Speed; DD, disease duration. 
 
Appendix Table 13: Estimated corpus callosal streamline thicknesses and corresponding corrected 
p-values for pairwise comparisons - Controls and PD-CU 
Node 
Controls 
(mm) 
PD-CU 
(mm) p-value Node 
Controls 
(mm) 
PD-CU 
(mm) p-value 
11 9.451 9.883 1 51 5.099 5.198 1 
12 9.009 9.35 1 52 5.026 5.116 1 
13 8.607 8.924 1 53 5.06 5.111 1 
14 8.244 8.448 1 54 5.09 5.091 1 
15 7.879 8.071 1 55 5.042 5.159 1 
16 7.552 7.731 1 56 5.033 5.184 1 
17 7.184 7.345 1 57 5.008 5.202 1 
18 6.896 7.036 1 58 4.978 5.09 1 
19 6.611 6.704 1 59 4.954 5.042 1 
20 6.219 6.342 1 60 4.92 5.012 1 
21 5.925 6.033 1 61 4.875 5.015 1 
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22 5.67 5.647 1 62 4.82 4.922 1 
23 5.351 5.381 1 63 4.823 4.897 1 
24 5.049 5.058 1 64 4.855 4.872 1 
25 4.752 4.855 1 65 4.769 4.928 1 
26 4.544 4.631 1 66 4.708 4.958 1 
27 4.356 4.373 1 67 4.761 4.928 1 
28 4.132 4.186 1 68 4.752 4.905 1 
29 4.031 4.038 1 69 4.69 4.946 1 
30 3.968 4.031 1 70 4.683 4.972 1 
31 3.949 4.017 1 71 4.769 5 1 
32 3.944 4.038 1 72 4.885 5.014 1 
33 3.975 4.076 1 73 4.921 5.087 1 
34 4.04 4.096 1 74 5.082 5.145 1 
35 4.154 4.182 1 75 5.179 5.202 1 
36 4.214 4.278 1 76 5.226 5.275 1 
37 4.297 4.447 1 77 5.343 5.389 1 
38 4.314 4.588 1 78 5.449 5.52 1 
39 4.429 4.654 1 79 5.539 5.695 1 
40 4.562 4.729 1 80 5.633 5.79 1 
41 4.632 4.915 1 81 5.696 5.97 1 
42 4.762 5.04 1 82 5.909 6.219 1 
43 4.885 5.108 1 83 6.181 6.558 1 
44 4.868 5.098 1 84 6.605 6.968 1 
45 4.977 5.12 1 85 7.067 7.462 1 
46 5.033 5.195 1 86 7.72 8.113 1 
47 5.084 5.247 1 87 8.512 8.844 1 
48 5.095 5.259 1 88 9.066 9.36 1 
49 5.164 5.206 1 89 8.67 9.174 1 
50 5.127 5.135 1 90 7.393 7.954 0.831 
Key: Estimated corpus callosal streamlines and associated pairwise comparison p-values, adjusted 
using the Bonferroni method. Covariates in the model are evaluated at the following values: age = 
70.407, eTIV = 1577849.18 mm3. 
 
Appendix Table 14: Estimated corpus callosal streamline thicknesses and corresponding corrected 
p-values for pairwise comparisons - Controls and PD-MCI 
Node 
Controls 
(mm) 
PD-MCI 
(mm) p-value Node 
Controls 
(mm) 
PD-MCI 
(mm) p-value 
11 9.451 9.891 1 51 5.099 5.141 1 
12 9.009 9.413 1 52 5.026 5.181 1 
13 8.607 8.975 1 53 5.06 5.166 1 
14 8.244 8.523 1 54 5.09 5.236 1 
15 7.879 8.023 1 55 5.042 5.223 1 
16 7.552 7.642 1 56 5.033 5.314 1 
17 7.184 7.319 1 57 5.008 5.221 1 
18 6.896 6.99 1 58 4.978 5.293 1 
19 6.611 6.655 1 59 4.954 5.227 1 
20 6.219 6.393 1 60 4.92 5.252 1 
21 5.925 6.067 1 61 4.875 5.219 0.947 
22 5.67 5.748 1 62 4.82 5.258 0.508 
23 5.351 5.408 1 63 4.823 5.185 1 
24 5.049 5.101 1 64 4.855 5.207 1 
25 4.752 4.876 1 65 4.769 5.187 0.774 
26 4.544 4.616 1 66 4.708 5.26 0.274 
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27 4.356 4.408 1 67 4.761 5.206 0.694 
28 4.132 4.322 1 68 4.752 5.131 1 
29 4.031 4.258 1 69 4.69 5.109 0.996 
30 3.968 4.135 1 70 4.683 5.125 0.759 
31 3.949 4.154 1 71 4.769 5.197 0.822 
32 3.944 4.245 1 72 4.885 5.177 1 
33 3.975 4.23 1 73 4.921 5.259 1 
34 4.04 4.288 1 74 5.082 5.279 1 
35 4.154 4.471 1 75 5.179 5.271 1 
36 4.214 4.535 1 76 5.226 5.364 1 
37 4.297 4.585 1 77 5.343 5.494 1 
38 4.314 4.761 0.418 78 5.449 5.651 1 
39 4.429 4.843 0.624 79 5.539 5.814 1 
40 4.562 4.912 1 80 5.633 5.951 1 
41 4.632 4.933 1 81 5.696 6.158 0.92 
42 4.762 5.048 1 82 5.909 6.455 0.477 
43 4.885 5.084 1 83 6.181 6.855 0.18 
44 4.868 5.081 1 84 6.605 7.214 0.443 
45 4.977 5.108 1 85 7.067 7.63 0.698 
46 5.033 5.109 1 86 7.72 8.226 1 
47 5.084 5.061 1 87 8.512 9.186 0.877 
48 5.095 5.082 1 88 9.066 9.795 1 
49 5.164 5.058 1 89 8.67 9.579 0.546 
50 5.127 5.113 1 90 7.393 8.387 0.122 
Key: Estimated corpus callosal streamlines and associated pairwise comparison p-values, adjusted 
using the Bonferroni method. Covariates in the model are evaluated at the following values: age = 
70.407, eTIV = 1577849.18 mm3. 
 
Appendix Table 15: Estimated corpus callosal streamline thicknesses and corresponding corrected 
p-values for pairwise comparisons - Controls and PDD 
Node 
Controls 
(mm) 
PDD 
(mm) p-value Node 
Controls 
(mm) 
PDD 
(mm) p-value 
11 9.451 8.613 1 51 5.099 4.569 0.189 
12 9.009 8.224 1 52 5.026 4.529 0.274 
13 8.607 8.013 1 53 5.06 4.509 0.234 
14 8.244 7.698 1 54 5.09 4.463 0.128 
15 7.879 7.388 1 55 5.042 4.43 0.144 
16 7.552 7.086 1 56 5.033 4.557 0.5 
17 7.184 6.646 1 57 5.008 4.568 0.689 
18 6.896 6.271 1 58 4.978 4.606 1 
19 6.611 5.984 1 59 4.954 4.598 1 
20 6.219 5.702 1 60 4.92 4.584 1 
21 5.925 5.467 1 61 4.875 4.599 1 
22 5.67 5.204 1 62 4.82 4.577 1 
23 5.351 5.014 1 63 4.823 4.676 1 
24 5.049 4.907 1 64 4.855 4.731 1 
25 4.752 4.74 1 65 4.769 4.734 1 
26 4.544 4.479 1 66 4.708 4.665 1 
27 4.356 4.29 1 67 4.761 4.627 1 
28 4.132 4.171 1 68 4.752 4.67 1 
29 4.031 4.007 1 69 4.69 4.734 1 
30 3.968 3.861 1 70 4.683 4.759 1 
31 3.949 3.725 1 71 4.769 4.715 1 
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32 3.944 3.649 1 72 4.885 4.675 1 
33 3.975 3.696 1 73 4.921 4.618 1 
34 4.04 3.734 1 74 5.082 4.622 0.951 
35 4.154 3.765 0.991 75 5.179 4.683 0.845 
36 4.214 3.925 1 76 5.226 4.824 1 
37 4.297 4.065 1 77 5.343 4.946 1 
38 4.314 4.078 1 78 5.449 5.032 1 
39 4.429 4.079 1 79 5.539 5.243 1 
40 4.562 4.153 0.879 80 5.633 5.465 1 
41 4.632 4.286 1 81 5.696 5.864 1 
42 4.762 4.286 0.461 82 5.909 6.127 1 
43 4.885 4.417 0.587 83 6.181 6.424 1 
44 4.868 4.591 1 84 6.605 6.782 1 
45 4.977 4.662 1 85 7.067 7.249 1 
46 5.033 4.695 1 86 7.72 7.891 1 
47 5.084 4.735 1 87 8.512 8.32 1 
48 5.095 4.769 1 88 9.066 8.584 1 
49 5.164 4.658 0.433 89 8.67 8.49 1 
50 5.127 4.607 0.277 90 7.393 7.747 1 
Key: Estimated corpus callosal streamlines and associated pairwise comparison p-values, adjusted 
using the Bonferroni method. Covariates in the model are evaluated at the following values: age = 
70.407, eTIV = 1577849.18 mm3. 
 
Appendix Table 16: Estimated corpus callosal streamline thicknesses and corresponding corrected 
p-values for pairwise comparisons - PD-CU and PDD 
Node 
PD-CU 
(mm) 
PDD 
(mm) p-value Node 
PD-CU 
(mm) 
PDD 
(mm) p-value 
11 9.883 8.613 0.305 51 5.198 4.569 0.049* 
12 9.35 8.224 0.442 52 5.116 4.529 0.085 
13 8.924 8.013 0.784 53 5.111 4.509 0.114 
14 8.448 7.698 1 54 5.091 4.463 0.097 
15 8.071 7.388 1 55 5.159 4.43 0.032* 
16 7.731 7.086 1 56 5.184 4.557 0.108 
17 7.345 6.646 1 57 5.202 4.568 0.112 
18 7.036 6.271 0.778 58 5.09 4.606 0.443 
19 6.704 5.984 0.808 59 5.042 4.598 0.512 
20 6.342 5.702 0.921 60 5.012 4.584 0.583 
21 6.033 5.467 1 61 5.015 4.599 0.643 
22 5.647 5.204 1 62 4.922 4.577 1 
23 5.381 5.014 1 63 4.897 4.676 1 
24 5.058 4.907 1 64 4.872 4.731 1 
25 4.855 4.74 1 65 4.928 4.734 1 
26 4.631 4.479 1 66 4.958 4.665 1 
27 4.373 4.29 1 67 4.928 4.627 1 
28 4.186 4.171 1 68 4.905 4.67 1 
29 4.038 4.007 1 69 4.946 4.734 1 
30 4.031 3.861 1 70 4.972 4.759 1 
31 4.017 3.725 1 71 5 4.715 1 
32 4.038 3.649 0.677 72 5.014 4.675 1 
33 4.076 3.696 0.719 73 5.087 4.618 0.762 
34 4.096 3.734 0.913 74 5.145 4.622 0.57 
35 4.182 3.765 0.724 75 5.202 4.683 0.647 
36 4.278 3.925 1 76 5.275 4.824 1 
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37 4.447 4.065 0.873 77 5.389 4.946 1 
38 4.588 4.078 0.302 78 5.52 5.032 0.788 
39 4.654 4.079 0.202 79 5.695 5.243 0.904 
40 4.729 4.153 0.202 80 5.79 5.465 1 
41 4.915 4.286 0.11 81 5.97 5.864 1 
42 5.04 4.286 0.023* 82 6.219 6.127 1 
43 5.108 4.417 0.069 83 6.558 6.424 1 
44 5.098 4.591 0.354 84 6.968 6.782 1 
45 5.12 4.662 0.538 85 7.462 7.249 1 
46 5.195 4.695 0.422 86 8.113 7.891 1 
47 5.247 4.735 0.411 87 8.844 8.32 1 
48 5.259 4.769 0.46 88 9.36 8.584 1 
49 5.206 4.658 0.255 89 9.174 8.49 1 
50 5.135 4.607 0.208 90 7.954 7.747 1 
Key: Estimated corpus callosal streamlines and associated pairwise comparison p-values, adjusted 
using the Bonferroni method. Covariates in the model are evaluated at the following values: age = 
70.407, eTIV = 1577849.18 mm3. *, significant difference at the p < 0.05 level. 
 
Appendix Table 17: Estimated corpus callosal streamline thicknesses and corresponding corrected 
p-values for pairwise comparisons: PD-MCI and PDD 
Node 
PD-MCI 
(mm) 
PDD 
(mm) p-value Node 
PD-MCI 
(mm) 
PDD 
(mm) p-value 
11 9.891 8.613 0.405 51 5.141 4.569 0.146 
12 9.413 8.224 0.475 52 5.181 4.529 0.069 
13 8.975 8.013 0.828 53 5.166 4.509 0.105 
14 8.523 7.698 1 54 5.236 4.463 0.037* 
15 8.023 7.388 1 55 5.223 4.43 0.029* 
16 7.642 7.086 1 56 5.314 4.557 0.049* 
17 7.319 6.646 1 57 5.221 4.568 0.146 
18 6.99 6.271 1 58 5.293 4.606 0.115 
19 6.655 5.984 1 59 5.227 4.598 0.147 
20 6.393 5.702 0.913 60 5.252 4.584 0.102 
21 6.067 5.467 1 61 5.219 4.599 0.159 
22 5.748 5.204 1 62 5.258 4.577 0.115 
23 5.408 5.014 1 63 5.185 4.676 0.541 
24 5.101 4.907 1 64 5.207 4.731 0.765 
25 4.876 4.74 1 65 5.187 4.734 0.886 
26 4.616 4.479 1 66 5.26 4.665 0.348 
27 4.408 4.29 1 67 5.206 4.627 0.432 
28 4.322 4.171 1 68 5.131 4.67 0.932 
29 4.258 4.007 1 69 5.109 4.734 1 
30 4.135 3.861 1 70 5.125 4.759 1 
31 4.154 3.725 0.785 71 5.197 4.715 0.849 
32 4.245 3.649 0.149 72 5.177 4.675 0.77 
33 4.23 3.696 0.26 73 5.259 4.618 0.321 
34 4.288 3.734 0.257 74 5.279 4.622 0.311 
35 4.471 3.765 0.094 75 5.271 4.683 0.544 
36 4.535 3.925 0.181 76 5.364 4.824 0.806 
37 4.585 4.065 0.397 77 5.494 4.946 0.738 
38 4.761 4.078 0.092 78 5.651 5.032 0.458 
39 4.843 4.079 0.055 79 5.814 5.243 0.556 
40 4.912 4.153 0.059 80 5.951 5.465 0.994 
41 4.933 4.286 0.145 81 6.158 5.864 1 
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42 5.048 4.286 0.039* 82 6.455 6.127 1 
43 5.084 4.417 0.137 83 6.855 6.424 1 
44 5.081 4.591 0.535 84 7.214 6.782 1 
45 5.108 4.662 0.744 85 7.63 7.249 1 
46 5.109 4.695 0.974 86 8.226 7.891 1 
47 5.061 4.735 1 87 9.186 8.32 0.606 
48 5.082 4.769 1 88 9.795 8.584 0.369 
49 5.058 4.658 0.999 89 9.579 8.49 0.451 
50 5.113 4.607 0.356 90 8.387 7.747 1 
Key: Estimated corpus callosal streamlines and associated pairwise comparison p-values, adjusted 
using the Bonferroni method. Covariates in the model are evaluated at the following values: age = 
70.407, eTIV = 1577849.18 mm3. *, significant difference at the p < 0.05 level. 
 
Appendix Table 18: Cortical thicknesses and corresponding corrected p-values for pairwise 
comparisons: Controls and PD-CU 
Lobe Cortical region 
Hemisphere 
Left Right 
Ctrls 
(mm) 
PD-CU 
(mm) p-value 
Ctrls 
(mm) 
PD-CU 
(mm) p-value 
Frontal Pars orbitalis 2.571 2.518 1 2.629 2.605 1 
 Medial orbitofrontal 2.356 2.335 1 2.384 2.394 1 
 Lateral orbitofrontal 2.626 2.598 1 2.646 2.603 1 
 Pars triangularis 2.358 2.338 1 2.366 2.389 1 
 Pars opercularis 2.497 2.451 1 2.474 2.453 1 
 Rostral middle frontal 2.4 2.427 1 2.375 2.399 1 
 Caudal middle frontal 2.523 2.481 1 2.497 2.465 1 
 Superior frontal 2.621 2.618 1 2.58 2.603 1 
 Precentral 2.549 2.517 1 2.508 2.475 1 
 Paracentral 2.385 2.392 1 2.354 2.353 1 
Temporal Entorhinal 3.298 3.217 1 3.42 3.317 1 
 Fusiform 2.688 2.636 1 2.754 2.677 0.332 
 Parahippocampal 2.767 2.706 1 2.685 2.648 1 
 Superior temporal 2.732 2.738 1 2.785 2.765 1 
 Transverse temporal 2.297 2.248 1 2.314 2.271 1 
 Middle temporal 2.744 2.718 1 2.819 2.814 1 
 Inferior temporal 2.868 2.827 1 2.892 2.851 1 
 Insula 2.959 2.937 1 2.947 2.898 1 
Parietal Postcentral 2.104 2.092 1 2.055 2.073 1 
 Superior parietal 2.227 2.211 1 2.184 2.205 1 
 Supramarginal 2.489 2.432 0.948 2.49 2.451 1 
 Inferior parietal 2.462 2.416 1 2.482 2.441 1 
 Precuneus 2.335 2.315 1 2.336 2.308 1 
 Cuneus 1.889 1.863 1 1.883 1.869 1 
 Pericalcarine 1.547 1.561 1 1.551 1.584 1 
 Lingual thickness 1.982 1.93 0.641 2.002 1.977 1 
 Lateral occipital 2.275 2.241 1 2.326 2.25 0.146 
Cingulate Rostral anterior 2.696 2.679 1 2.79 2.758 1 
 Caudal anterior 2.638 2.617 1 2.497 2.49 1 
 Posterior 2.355 2.376 1 2.414 2.388 1 
 Isthmus 2.329 2.263 1 2.362 2.29 1 
Key: Cortical thicknesses estimated using a multivariate analysis of covariance model, with 
covariates evaluated at the following values: age = 70.407, eTIV = 1577849.18 mm3. p-values were 
adjusted using the Bonferroni method. Ctrls, Controls. 
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Appendix Table 19: Cortical thicknesses and corresponding corrected p-values for pairwise 
comparisons: Controls and PD-MCI 
Lobe Cortical region 
Hemisphere 
Left Right 
Ctrls 
(mm) 
PD-
MCI 
(mm) p-value 
Ctrls 
(mm) 
PD-
MCI 
(mm) p-value 
Frontal Pars orbitalis 2.571 2.498 1 2.629 2.568 1 
 Medial orbitofrontal 2.356 2.303 1 2.384 2.403 1 
 Lateral orbitofrontal 2.626 2.591 1 2.646 2.614 1 
 Pars triangularis 2.358 2.299 0.925 2.366 2.295 0.56 
 Pars opercularis 2.497 2.436 1 2.474 2.427 1 
 Rostral middle frontal 2.4 2.399 1 2.375 2.373 1 
 Caudal middle frontal 2.523 2.512 1 2.497 2.464 1 
 Superior frontal 2.621 2.612 1 2.58 2.61 1 
 Precentral 2.549 2.52 1 2.508 2.436 1 
 Paracentral 2.385 2.367 1 2.354 2.374 1 
Temporal Entorhinal 3.298 3.154 0.733 3.42 3.272 0.768 
 Fusiform 2.688 2.657 1 2.754 2.666 0.304 
 Parahippocampal 2.767 2.697 1 2.685 2.707 1 
 Superior temporal 2.732 2.761 1 2.785 2.795 1 
 Transverse temporal 2.297 2.395 1 2.314 2.341 1 
 Middle temporal 2.744 2.736 1 2.819 2.797 1 
 Inferior temporal 2.868 2.848 1 2.892 2.838 1 
 Insula 2.959 2.928 1 2.947 2.888 1 
Parietal Postcentral 2.104 2.139 1 2.055 2.068 1 
 Superior parietal 2.227 2.257 1 2.184 2.206 1 
 Supramarginal 2.489 2.465 1 2.49 2.429 0.926 
 Inferior parietal 2.462 2.448 1 2.482 2.448 1 
 Precuneus 2.335 2.318 1 2.336 2.305 1 
 Cuneus 1.889 1.911 1 1.883 1.884 1 
 Pericalcarine 1.547 1.577 1 1.551 1.571 1 
 Lingual thickness 1.982 1.941 1 2.002 1.971 1 
 Lateral occipital 2.275 2.257 1 2.326 2.304 1 
Cingulate Rostral anterior 2.696 2.711 1 2.79 2.784 1 
 Caudal anterior 2.638 2.591 1 2.497 2.446 1 
 Posterior 2.355 2.339 1 2.414 2.415 1 
 Isthmus 2.329 2.311 1 2.362 2.308 1 
Key: Cortical thicknesses estimated using a multivariate analysis of covariance model, with 
covariates evaluated at the following values: age = 70.407, eTIV = 1577849.18 mm3. p-values were 
adjusted using the Bonferroni method. Ctrls, Controls. 
 
Appendix Table 20: Cortical thicknesses and corresponding corrected p-values for pairwise 
comparisons: Controls and PDD 
Lobe Cortical region 
Hemisphere 
Left Right 
Ctrls 
(mm) 
PDD 
(mm) p-value 
Ctrls 
(mm) 
PDD 
(mm) p-value 
Frontal Pars orbitalis 2.571 2.492 1 2.629 2.507 0.212 
 Medial orbitofrontal 2.356 2.24 0.164 2.384 2.293 0.566 
 Lateral orbitofrontal 2.626 2.507 0.028* 2.646 2.464 0.001* 
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 Pars triangularis 2.358 2.32 1 2.366 2.235 0.034* 
 Pars opercularis 2.497 2.405 0.526 2.474 2.367 0.196 
 Rostral middle frontal 2.4 2.336 0.815 2.375 2.276 0.061 
 Caudal middle frontal 2.523 2.45 0.961 2.497 2.411 0.602 
 Superior frontal 2.621 2.544 0.67 2.58 2.495 0.388 
 Precentral 2.549 2.412 0.095 2.508 2.402 0.48 
 Paracentral 2.385 2.319 1 2.354 2.304 1 
Temporal Entorhinal 3.298 2.913 0.002* 3.42 3.142 0.063 
 Fusiform 2.688 2.459 <0.001* 2.754 2.487 <0.001* 
 Parahippocampal 2.767 2.541 0.169 2.685 2.474 0.077 
 Superior temporal 2.732 2.568 0.014* 2.785 2.662 0.118 
 Transverse temporal 2.297 2.148 0.439 2.314 2.213 1 
 Middle temporal 2.744 2.606 0.044* 2.819 2.671 0.009* 
 Inferior temporal 2.868 2.684 0.005* 2.892 2.659 <0.001* 
 Insula 2.959 2.77 0.023* 2.947 2.81 0.184 
Parietal Postcentral 2.104 2.087 1 2.055 2.034 1 
 Superior parietal 2.227 2.173 1 2.184 2.119 1 
 Supramarginal 2.489 2.372 0.132 2.49 2.341 0.011* 
 Inferior parietal 2.462 2.371 0.317 2.482 2.332 0.014* 
 Precuneus 2.335 2.216 0.163 2.336 2.262 0.741 
 Cuneus 1.889 1.889 1 1.883 1.89 1 
 Pericalcarine 1.547 1.601 1 1.551 1.561 1 
 Lingual thickness 1.982 1.928 1 2.002 1.966 1 
 Lateral occipital 2.275 2.201 0.43 2.326 2.266 0.897 
Cingulate Rostral anterior 2.696 2.688 1 2.79 2.751 1 
 Caudal anterior 2.638 2.546 0.742 2.497 2.459 1 
 Posterior 2.355 2.358 1 2.414 2.36 1 
 Isthmus  2.329 2.292 1 2.362 2.323 1 
Key: Cortical thicknesses estimated using a multivariate analysis of covariance model, with 
covariates evaluated at the following values: age = 70.407, eTIV = 1577849.18 mm3. p-values were 
adjusted using the Bonferroni method. Ctrls, Controls; *, significant difference at the p < 0.05 level. 
 
Appendix Table 21: Cortical thicknesses and corresponding corrected p-values for pairwise 
comparisons: PD-CU and PD-MCI 
Lobe Cortical region 
Hemisphere 
Left Right 
PD-
CU 
(mm) 
PD-
MCI 
(mm) p-value 
PD-
CU 
(mm) 
PD-
MCI 
(mm) p-value 
Frontal Pars orbitalis 2.518 2.498 1 2.605 2.568 1 
 Medial orbitofrontal 2.335 2.303 1 2.394 2.403 1 
 Lateral orbitofrontal 2.598 2.591 1 2.603 2.614 1 
 Pars triangularis 2.338 2.299 1 2.389 2.295 0.118 
 Pars opercularis 2.451 2.436 1 2.453 2.427 1 
 Rostral middle frontal 2.427 2.399 1 2.399 2.373 1 
 Caudal middle frontal 2.481 2.512 1 2.465 2.464 1 
 Superior frontal 2.618 2.612 1 2.603 2.61 1 
 Precentral 2.517 2.52 1 2.475 2.436 1 
 Paracentral 2.392 2.367 1 2.353 2.374 1 
Temporal Entorhinal 3.217 3.154 1 3.317 3.272 1 
 Fusiform 2.636 2.657 1 2.677 2.666 1 
 Parahippocampal 2.706 2.697 1 2.648 2.707 1 
 Superior temporal 2.738 2.761 1 2.765 2.795 1 
8. Appendices 
 210 
 Transverse temporal 2.248 2.395 0.234 2.271 2.341 1 
 Middle temporal 2.718 2.736 1 2.814 2.797 1 
 Inferior temporal 2.827 2.848 1 2.851 2.838 1 
 Insula 2.937 2.928 1 2.898 2.888 1 
Parietal Postcentral 2.092 2.139 1 2.073 2.068 1 
 Superior parietal 2.211 2.257 1 2.205 2.206 1 
 Supramarginal 2.432 2.465 1 2.451 2.429 1 
 Inferior parietal 2.416 2.448 1 2.441 2.448 1 
 Precuneus 2.315 2.318 1 2.308 2.305 1 
 Cuneus 1.863 1.911 1 1.869 1.884 1 
 Pericalcarine 1.561 1.577 1 1.584 1.571 1 
 Lingual thickness 1.93 1.941 1 1.977 1.971 1 
 Lateral occipital 2.241 2.257 1 2.25 2.304 0.777 
Cingulate Rostral anterior 2.679 2.711 1 2.758 2.784 1 
 Caudal anterior 2.617 2.591 1 2.49 2.446 1 
 Posterior 2.376 2.339 1 2.388 2.415 1 
 Isthmus 2.263 2.311 1 2.29 2.308 1 
Key: Cortical thicknesses estimated using a multivariate analysis of covariance model, with 
covariates evaluated at the following values: age = 70.407, eTIV = 1577849.18 mm3. p-values were 
adjusted using the Bonferroni method. 
 
Appendix Table 22: Cortical thicknesses and corresponding corrected p-values for pairwise 
comparisons: PD-CU and PDD 
Lobe Cortical region 
Hemisphere 
Left Right 
PD-CU 
(mm) 
PDD 
(mm) p-value 
PD-CU 
(mm) 
PDD 
(mm) p-value 
Frontal Pars orbitalis 2.518 2.492 1 2.605 2.507 0.468 
 Medial orbitofrontal 2.335 2.24 0.352 2.394 2.293 0.306 
 Lateral orbitofrontal 2.598 2.507 0.136 2.603 2.464 0.015* 
 Pars triangularis 2.338 2.32 1 2.389 2.235 0.004* 
 Pars opercularis 2.451 2.405 1 2.453 2.367 0.42 
 Rostral middle frontal 2.427 2.336 0.176 2.399 2.276 0.006* 
 Caudal middle frontal 2.481 2.45 1 2.465 2.411 1 
 Superior frontal 2.618 2.544 0.665 2.603 2.495 0.086 
 Precentral 2.517 2.412 0.316 2.475 2.402 1 
 Paracentral 2.392 2.319 1 2.353 2.304 1 
Temporal Entorhinal 3.217 2.913 0.014 3.317 3.142 0.54 
 Fusiform 2.636 2.459 0.005* 2.677 2.487 0.001* 
 Parahippocampal 2.706 2.541 0.552 2.648 2.474 0.189 
 Superior temporal 2.738 2.568 0.006* 2.765 2.662 0.236 
 Transverse temporal 2.248 2.148 1 2.271 2.213 1 
 Middle temporal 2.718 2.606 0.132 2.814 2.671 0.008* 
 Inferior temporal 2.827 2.684 0.035* 2.851 2.659 0.001* 
 Insula 2.937 2.77 0.044* 2.898 2.81 0.858 
Parietal Postcentral 2.092 2.087 1 2.073 2.034 1 
 Superior parietal 2.211 2.173 1 2.205 2.119 0.447 
 Supramarginal 2.432 2.372 1 2.451 2.341 0.09 
 Inferior parietal 2.416 2.371 1 2.441 2.332 0.116 
 Precuneus 2.315 2.216 0.317 2.308 2.262 1 
 Cuneus 1.863 1.889 1 1.869 1.89 1 
 Pericalcarine 1.561 1.601 1 1.584 1.561 1 
 Lingual thickness 1.93 1.928 1 1.977 1.966 1 
8. Appendices 
 211 
 Lateral occipital 2.241 2.201 1 2.25 2.266 1 
Cingulate Rostral anterior  2.679 2.688 1 2.758 2.751 1 
 Caudal anterior  2.617 2.546 1 2.49 2.459 1 
 Posterior  2.376 2.358 1 2.388 2.36 1 
 Isthmus  2.263 2.292 1 2.29 2.323 1 
Key: Cortical thicknesses estimated using a multivariate analysis of covariance model, with 
covariates evaluated at the following values: age = 70.407, eTIV = 1577849.18 mm3. p-values were 
adjusted using the Bonferroni method. *, significant difference at the p < 0.05 level. 
 
Appendix Table 23: Cortical thicknesses and corresponding corrected p-values for pairwise 
comparisons: PD-MCI and PDD 
Lobe Cortical region 
Hemisphere 
Left Right 
PD-
MCI PDD p-value 
PD-
MCI PDD p-value 
Frontal Pars orbitalis 2.498 2.492 1 2.568 2.507 1 
 Medial orbitofrontal 2.303 2.24 1 2.403 2.293 0.289 
 Lateral orbitofrontal 2.591 2.507 0.305 2.614 2.464 0.014* 
 Pars triangularis 2.299 2.32 1 2.295 2.235 1 
 Pars opercularis 2.436 2.405 1 2.427 2.367 1 
 Rostral middle frontal 2.399 2.336 0.951 2.373 2.276 0.085 
 Caudal middle frontal 2.512 2.45 1 2.464 2.411 1 
 Superior frontal 2.612 2.544 1 2.61 2.495 0.091 
 Precentral 2.52 2.412 0.382 2.436 2.402 1 
 Paracentral 2.367 2.319 1 2.374 2.304 1 
Temporal Entorhinal 3.154 2.913 0.14 3.272 3.142 1 
 Fusiform 2.657 2.459 0.003* 2.666 2.487 0.004* 
 Parahippocampal 2.697 2.541 0.831 2.707 2.474 0.047* 
 Superior temporal 2.761 2.568 0.003* 2.795 2.662 0.088 
 Transverse temporal 2.395 2.148 0.026* 2.341 2.213 0.983 
 Middle temporal 2.736 2.606 0.085 2.797 2.671 0.048* 
 Inferior temporal 2.848 2.684 0.021* 2.838 2.659 0.006* 
 Insula 2.928 2.77 0.107 2.888 2.81 1 
Parietal Postcentral 2.139 2.087 1 2.068 2.034 1 
 Superior parietal 2.257 2.173 0.523 2.206 2.119 0.568 
 Supramarginal 2.465 2.372 0.456 2.429 2.341 0.406 
 Inferior parietal 2.448 2.371 0.669 2.448 2.332 0.127 
 Precuneus 2.318 2.216 0.381 2.305 2.262 1 
 Cuneus 1.911 1.889 1 1.884 1.89 1 
 Pericalcarine 1.577 1.601 1 1.571 1.561 1 
 Lingual thickness 1.941 1.928 1 1.971 1.966 1 
 Lateral occipital 2.257 2.201 1 2.304 2.266 1 
Cingulate Rostral anterior  2.711 2.688 1 2.784 2.751 1 
 Caudal anterior  2.591 2.546 1 2.446 2.459 1 
 Posterior  2.339 2.358 1 2.415 2.36 1 
 Isthmus  2.311 2.292 1 2.308 2.323 1 
Key: Cortical thicknesses estimated using a multivariate analysis of covariance model, with 
covariates evaluated at the following values: age = 70.407, eTIV = 1577849.18 mm3. p-values were 
adjusted using the Bonferroni method. *, significant difference at the p < 0.05 level. 
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